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SUMMARY
Thyroid cancer is the commonest endocrine malignancy. Several of the 
initiating genetic events in thyroid tumorigenesis have been identified, although 
the exact molecular mechanisms are unclear. Our thyrocyte model has 
demonstrated that p16INK4A is up-regulated in RAS-induced colonies which 
resemble follicular adenomas. Affymetrix microarrays revealed that many 
interferon-stimulated genes (ISGs) are also up-regulated in these colonies. I 
hypothesised that p16 expression would be induced in follicular adenomas and 
lost in follicular cancers, consistent with their escape from growth control, and 
that ISG expression (HLA-DR, PKR, MxA) would be induced in follicular 
adenomas. I tested these hypotheses using immunohistochemistry, and 
correlated p16 expression with cyclin D1 and p21 expression to further 
investigate growth control.
My original research demonstrates that p16 is expressed in adenomas, and 
surprisingly up-regulated in well-differentiated cancers. Loss of expression was 
only seen in poorly-differentiated carcinomas. Cyclin D1 expression increased 
during the transition from a benign to a malignant tumour, whereas p21 protein 
was expressed at a lower level in both adenomas and carcinomas. 
Unexpectedly, ISGS were not up-regulated in either the adenomas or 
carcinomas, but were expressed in some papillary carcinomas. PKR 
expression was positively correlated with p16 expression.
I speculate that there must be two or more growth inhibitory pathways involved 
in thyroid tumorigenesis, one of which involves p16, and both must be 
inactivated for progression to a more aggressive phenotype. The cyclin D1 
result is explained as a result of growth stimulation during tumorigenesis, 
whereas the basis and implication of p21 expression is uncertain. Thyroid 
cancers are unusual because the majority are slow-growing yet potentially fatal 
despite continued p16 expression. Further work is needed to elucidate the 
nature of the additional pathways controlling tumour growth, which will improve 
our understanding of thyroid tumorigenesis, and may potentially lead to the 
development of novel treatment strategies.
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1Chapter 1
INTRODUCTION
Thyroid cancer is the commonest endocrine malignancy (Aldred et al., 2004), 
and is within the top twenty most common cancers for women in the United 
Kingdom. However it is rare in comparison to other tumours, and accounts for 
less than 1 % of all cancers. Each year there are approximately 1,200 female 
and 390 male cases diagnosed each year, therefore thyroid cancer is three 
times more common in women. The age-standardised incidence rates for 
thyroid cancer are around two cases per 100,000 population, although the 
annual incidence has increased by 50% in the United States over the last 25 
years (Hundahl et al., 1998). Thyroid cancer accounts for about 300 deaths 
per year and 64% of endocrine cancer deaths per year (Mallick and 
Charalambous, 2004), with a five-year survival rate in the United Kingdom of 
65-75%. The ten-year survival rate in the United States is better by 20% (85- 
93%) (Kendall-Taylor, 2002). Thyroid cancer can affect all ages, but the 
highest incidence occurs in people aged between 20 and 55 years. This is 
different from most other malignancies, which become more prevalent with 
advancing age.
There is a geographic variation in thyroid cancer prevalence, with the Kuwaiti, 
Vietnamese and Filipino populations having a much higher incidence than that 
in the UK and America (Farid et al., 1994). There is an increased prevalence 
of follicular thyroid cancer in areas of iodine deficiency or a high incidence of
2endemic goitre (Franceschi et al., 1991), whereas papillary carcinoma is more 
prevalent in iodine-sufficient regions. There is also a strong link between 
thyroid cancer and external radiation, for example from X-rays of the neck. 
Papillary carcinoma is associated with radiation exposure due to a nuclear fall­
out, as seen in the survivors of the atomic bombs at Nagasaki, and the 
Chernobyl nuclear accident (Nikiforov, 2006).
There is also a genetic component to the development of follicular cancer, 
because a positive family history of thyroid cancer increases the risk of 
developing thyroid cancer by 3.2 -  6.2-fold (Hemminki et al., 2005). Finally, 
there are several tumour syndromes that predispose to thyroid carcinoma, 
including familial polyposis coli, Cowden syndrome (Sogol et al., 1983) and 
Gardner’s syndrome (Thompson et al., 1983), the scope of which will not be 
covered in this work.
1.1 The thyroid gland
Embryologically, the thyroid forms from an invagination in the floor of the 
pharynx between the first and second pharyngeal pouches, and this tissue 
migrates inferiorly to reach the final position in the neck, being dragged by the 
developing heart. The midline thyroid tissue fuses with tissues derived from 
the fourth and fifth branchial clefts, which combine to form the lateral lobes. 
These clefts bring neuroendocrine cells from the ultimobranchial body that 
form parafollicular (C) cells.
3The thyroid gland is the largest human endocrine organ, and it regulates 
metabolism through the production of thyroid hormones. The thyroid gland 
consists of two lobes which lay either side of the trachea, and are joined by an 
isthmus. The lobes extend superiorly and inferiorly from the isthmus, with a 
butterfly appearance. Each lobe is covered by a fibrous capsule that sends 
septae into the gland, dividing it into lobules, and each lobule is further divided 
into 30-40 follicles. The follicle is a structural and a functional unit, consisting 
of a single layer of cells arranged around a gelatinous core of colloid, a 
proteinaceaous material. The follicular thyroid cells are cuboidal, and their 
apex has a microvillous structure which interdigitates with the colloid, to 
facilitate the passage of molecules between the cell and the colloid.
The main constituent of the colloid is thyroglobulin, a 660kDa protein that is 
synthesised in the follicular cells and secreted into the colloid together with 
iodine. The cells absorb thyroglobulin back from the colloid and secrete the 
thyroid hormones tri-iodothyronine and thyroxine directly into the bloodstream. 
These hormones are involved in the regulation of the basal metabolic rate and 
their secretion is adjusted in response to alterations in the body’s energy need, 
caloric supply and thermal environment. Each follicle is surrounded by a 
basement membrane, between which are the neuroendocrine parafollicular 
cells (C-cells) that secrete calcitonin, a peptide hormone necessary for calcium 
metabolism.
The thyroid gland epithelium is a “conditional renewal” epithelium. It normally 
has a very low proliferative rate, and on average a thyroid cell will turn over no 
more than five times throughout adulthood. However, the epithelium is
4capable of a great increase in proliferation in response to an appropriate 
stimulus.
1.2 The pathology of thyroid cancer
The vast majority of thyroid cancers are derived from the follicular cells, and 
can be broadly divided into two categories, benign (follicular and atypical) 
adenomas and malignant (follicular, papillary, insular and anaplastic) 
carcinomas, representing a multi-stage model of epithelial tumorigenesis with a 
low frequency of malignant progression (Williams, 1979; Lemoine et al., 1989). 
The remainder of the thyroid tumours are derived from the neuroendocrine C- 
cells, producing medullary thyroid cancers, which will not be covered in this 
work.
1.2.1 Follicular adenoma 
A follicular adenoma is an encapsulated, solitary benign thyroid neoplasm 
derived from the follicular cells. It lacks the characteristic invasiveness of 
follicular carcinomas, and the typical nuclear features of papillary carcinomas 
(Hedinger et al., 1989). By definition, capsular and vascular invasion are 
absent. The neoplastic cells are demarcated from the adjacent parenchyma 
by a well-defined, intact capsule, and the centre of the adenoma may show 
areas of haemorrhage and cystic changes. Thyroid adenomas can be divided 
on the basis of their microscopic appearance into two major groups: 
microfollicular adenomas which have very compact follicles and very little 
colloid, and macrofollicular adenomas, but these sub-divisions have little 
clinical significance.
51.2.2 Atypical adenoma
In 1950, Zimmerman et al., (1950) used the term 'malignant adenoma' to 
describe thyroid tumours that exhibited cellular pleomorphism and mitoses 
without vascular or capsular invasion. Hazard and Kenyon in 1954 used the 
term 'atypical adenoma* to describe thyroid adenomas with a more solid 
architecture than follicular adenomas, and with no evidence of invasion of the 
surrounding capsule or blood vessels. Atypical adenomas resemble thyroid 
carcinomas but do not have the invasive signs characteristic of follicular 
carcinoma or the clear overlapping nuclei characteristic of papillary carcinoma 
(Lang et al., 1980), and this suggests that they can precede either tumour type 
(Vasko et al., 2004a). The nature of these adenomas is unclear; however 
Tzen et al., (2003) suggested that atypical adenomas may represent a pre- 
invasive malignancy of the thyroid, as a precursor of anaplastic carcinoma.
1.2.3 Papillary carcinoma
This is the commonest thyroid tumour and has a peak incidence in the third 
and fourth decades. It occurs three times more frequently in women and 
accounts for 60-70% of all thyroid cancers in adults. There is an increased 
incidence in iodine-rich areas and previous neck irradiation, particularly in 
young people, may predispose to papillary thyroid cancer. This is an indolent, 
slow-growing tumour with a good prognosis. Papillary tumours usually present 
as a solitary thyroid nodule, although they are often bilateral and multi-focal. 
The tumours range phenotypically from well- to poorly-differentiated and the 
cancers tend to be infiltrative and primarily metastasise to lymph nodes. 
Encapsulation is rare. Micro-papillary carcinomas are papillary tumours that 
are less than one centimetre in size, and although they are not clinically
6obvious, they have the ability to metastasise to regional lymph nodes. They 
are extremely common, and occur in up to 30% of autopsies (Fink et al., 1996).
Microscopically, there is typically a mixture of papillary projections and follicular 
structures. They are characterised by a complex branching structure in which 
neoplastic cells cover the surfaces of the papillary cores. The cuboidal cells 
have pale abundant cytoplasm and intranuclear cytoplasmic inclusions, 
nuclear overlapping and grooves (Orphan Annie cells), and these features are 
diagnostic of papillary carcinoma. Areas of lymphocytic infiltration and even 
extensive lymphocytic thyroiditis are common. Furthermore, chronic 
lymphocytic thyroiditis may be a potential precursor for thyroid cancer 
(Gasbarri et al., 2004). This suggests that immunological factors might be 
involved in thyroid tumour progression (Kondo et al., 2006).
1.2.4 Follicular carcinoma 
This thyroid tumour is also three times as common in women, is rare in 
children and has a peak incidence in the fifth decade. It accounts for 25% of 
all thyroid cancers in adults. It is a slow-growing tumour and usually presents 
as a solitary thyroid nodule. Follicular thyroid cancers tend to invade locally 
and metastasise distantly via the blood stream. Lymphatic spread is usually a 
late phenomenon. There is a higher incidence in iodine-deficient areas, and it 
can also be induced by previous irradiation.
Most tumours are composed of fairly uniform cells forming small follicles, 
although this differentiation may be less apparent in the more aggressive 
stages. They are defined as malignant epithelial tumours with evidence of
7follicular cell differentiation but lacking the diagnostic nuclear features of 
papillary thyroid cancer. Invasion of blood vessels or the capsule, apart from 
metastasis, is the only reliable criterion of malignancy, and the only 
distinguishing feature between a follicular adenoma and a follicular carcinoma. 
However, this invasion may be limited to microscopic foci and therefore 
extensive histological sampling is required for a diagnosis in less clear cut 
cases. Follicular cancers that are widely invasive have a significant morbidity 
and mortality. Since follicular adenoma is distinguished from follicular 
carcinoma by the absence of clear-cut capsular or vascular invasion, by 
definition, lesions intermediate between adenoma and carcinoma do not exist. 
However pre-invasive malignancy of the thyroid should exist from a biological 
standpoint.
1.2.5 Insular carcinoma 
Thyroid carcinomas derived from follicular cells have traditionally been 
classified into a well-differentiated, prognostically favourable group (the 
papillary and follicular carcinomas) and an undifferentiated, prognostically 
unfavourable group (anaplastic carcinomas) (Fadare and Sinard, 2002). 
Carcangiu et al., (1984), firmly established the category of poorly-differentiated 
‘insular’ thyroid carcinomas, previously described by Sakamoto et al., (1983), 
which were believed to be intermediate in biology and morphology between the 
well-differentiated follicular and papillary cancers, and the undifferentiated 
anaplastic cancers. To date, more than 150 patients with insular thyroid 
cancer have been described in the literature (Carcangiu et al., 1984; Flynn et 
al., 1988; Papotti et al., 1993; Pilotti et al., 1997). The overall incidence of 
insular carcinoma is around 3%.
8These insular tumours were characterised histologically by the formation of 
solid clusters of small, uniform cells arranged in small follicles with variable 
mitotic activity and frequent necrotic foci (Lam et al., 2000). In the currently 
accepted model of non-medullary thyroid carcinogenesis a morphologic and 
biologic spectrum connects the well-, poorly- and undifferentiated tumours and 
the insular and anaplastic carcinomas are believed to arise from their well- 
differentiated follicular and papillary counterparts. Concomitant areas of 
follicular and papillary thyroid carcinomas have been noted in both insular and 
anaplastic tumours, strengthening the theory that the well-differentiated 
carcinomas can progress to insular and then to anaplastic carcinoma by de­
differentiation (Ito et al., 1992; Ito et al., 1993).
1.2.6 Anaplastic carcinoma 
Anaplastic carcinoma is one of the most aggressive human neoplasms and 
accounts for 2-5% of all thyroid cancers. It occurs predominantly in the frail, 
elderly population with a peak incidence at 60-70 years of age. The tumour is 
slightly more common in women and has a higher incidence in endemic goitre 
areas. The tumour presents as a bulky mass in the neck that rapidly infiltrates 
local structures and metastasises via both the blood stream and lymphatic 
system. Foci of either papillary or follicular differentiation may be present, 
suggesting an origin from a previously unrecognised or un-treated well- 
differentiated tumour (Harada et al., 1977), and this is most frequently papillary 
thyroid carcinoma (Wiseman et al., 2003).
Microscopically the tumour contains bizarre giant multi-nucleated cells, spindle 
cells or squamous cells, with evidence of epithelial differentiation. The
9prognosis is very poor due to rapid local invasion of structures such as the 
trachea, producing respiratory obstruction, and there is no effective treatment 
(Lo et al., 1999). By the time diagnosis is made, the disease has spread in 
most patients beyond the area that can be attacked surgically, and most 
patients die within six months from diagnosis.
1.3 Diagnosis and treatment of thyroid cancer
The majority of thyroid tumours present clinically as a thyroid nodule, which 
may be picked up incidentally during a routine clinical examination, or the 
patient complains of a growing lump in the neck. Rarely the patient complains 
of hoarseness in the neck or difficulty in breathing and swallowing, because of 
local invasion of the recurrent laryngeal nerve, the trachea or the oesophagus. 
Thyroid tumours are diagnosed with careful clinical assessment and fine 
needle aspiration cytology (FNAC), which was first used in the early 1950s 
(Soderstrom, 1952). In experienced hands, this technique can accurately 
diagnose colloid nodules, thyroiditis, papillary, medullary and anaplastic 
carcinoma, and lymphoma. However this technique cannot differentiate 
between benign and malignant follicular lesions (Lowhagen et al., 1979), since 
this distinction depends on the histological criteria of vascular and capsular 
invasion. Because of this limitation of FNAC, all suspicious follicular lesions 
are excised, and subsequently 80-90% of patients will have unnecessary 
surgery for a benign tumour.
The treatment objectives of thyroid carcinoma are to remove the primary 
tumour, reduce the incidence of local or distant recurrence, and treat
10
metastatic deposits. Papillary carcinomas are divided into low- and high-risk 
groups in terms of long-term survival and recurrence. The vast majority of 
patients have a total thyroidectomy, because papillary carcinoma is 
predominantly multifocal, and local tumour recurrence carries a high risk of 
death. A total thyroidectomy also removes the risk of anaplastic 
transformation. Patients presenting with a suspicious follicular lesion are 
initially treated with a thyroid lobectomy. If the lesion is an invasive carcinoma, 
then the patient proceeds to a completion thyroidectomy. For patients 
presenting with anaplastic carcinoma, there is no effective treatment and most 
will die within six months of the diagnosis.
Despite the development of a multimodality approach for treating thyroid 
cancer, combining surgery with radio-iodine (I131) therapy, chemotherapy, 
radiotherapy and thyroid hormone suppression, the survival rates of thyroid 
cancer have not significantly improved (Spitzweg and Morris, 2004). The 
identification of potential markers that could indicate invasive or aggressive 
behaviour, metastasis or a worse clinical prognosis will greatly benefit patients.
Thyroid carcinomas encompass a broad spectrum of clinical behaviour, and 
the diagnosis and treatment options are not always clear-cut. An improved 
understanding of the potential for an indolent follicular or papillary carcinoma to 
transform into a poorly- or undifferentiated phenotype may lead to a better use 
of our clinical resources, and improved treatment options for patients. This 
information can partly be gained through analysis of the molecular biology of 
multi-step thyroid tumorigenesis, and relating this data to tumour behaviour 
and patient survival. This may eventually lead to the development of better
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strategies and treatments (surgical, genetic or pharmacological), to help 
combat thyroid cancer.
1.4 Tumorigenesis
It is widely accepted that tumours develop by a step-wise accumulation of 
genetic events which eventually result in a population of tumour cells that 
exhibit uncontrolled proliferation. Several pre-malignant lesions, such as 
dysplasia and hyperplasia have been detected in many human organs prior to 
the development of a fully invasive cancer. These lesions can either be 
caused by genetic or environmental factors, and subsequent genetic 
alterations in these cells may eventually lead to the development of an invasive 
tumour. These genetic events can be an accumulation of inherited and / or 
somatic mutations involving the genes controlling cellular differentiation and 
growth.
Hanahan and Weinberg in 2000 proposed a biological basis for tumorigenesis, 
and outlined “six essential alterations in cell physiology that collectively dictate 
malignant growth”. These six changes that a cell must acquire were;
(i) Self-sufficiency in growth signals
(ii) Insensitivity to growth inhibitory signals
(iii) Evasion of programmed cell death
(iv) Unlimited replicative potential
(v) Sustained angiogenesis
(vi) Tissue invasion and metastasis
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The alterations can be divided into two broad categories, those resulting from 
activation of oncogenes, and those resulting from inactivation of tumour 
suppressor genes. At any given time a cell has three options, to remain static, 
to divide or to apoptose. Oncogenes and tumour suppressor genes generate 
and interpret these intra- and extra-cellular signals to ensure a cell makes the 
right choice.
In a normal cell, proto-oncogenes encode for proteins which have a role in the 
regulation of cell differentiation and growth. These genes, which are normally 
silent, can be activated by chromosomal translocations or mutations, and this 
leads to uncontrolled growth and neoplasia. Oncogenes can be classified 
according to their function into the following groups -  growth factors, growth 
factor receptors, transducers and nuclear factors (Wynford-Thomas, 1991). 
Generally the activation of one oncogene is not sufficient to produce malignant 
transformation, and a step-wise approach is needed, with the accumulation of 
further mutations of oncogenes involved in cellular growth pathways.
In addition to these positive genetic factors, tumorigenesis frequently involves 
the inactivation of tumour suppressor genes. The first tumour suppressor gene 
demonstrated was the Rb gene, which is implicated in the development of the 
hereditary retinoblastoma tumour. Children with bilateral tumours fitted with a 
one-mutation model, and children with a unilateral tumour fitted with a two- 
mutation model, implying that those children with bilateral tumours had already 
inherited a mutation in one of the Rb alleles (Knudson, 1971). The Rb gene 
has a fundamental role in cell cycle progression and will be reviewed later. 
The roles of tumour suppressor genes can be divided into two broad groups,
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the “gatekeepers” and the “caretakers” (Kinzler and Vogelstein, 1997). Loss of 
a gatekeeper gene (Rb) causes deregulation of the cell cycle and uncontrolled 
cell proliferation, whilst loss of a caretaker gene (p53) leads to genetic 
instability and the acquisition of genetic mutations. Tumour suppressor genes 
can be altered by deletions (either homozygous or hemizygous), mutations (for 
example non-sense and frame-shift) and by methylation of CpG islands at 
promoter sequences.
Thyroid tumours represent an ideal model in which to study the molecular 
mechanism of tumorigenesis, as they comprise a broad spectrum of well- 
defined phenotypes. These include microscopic papillary carcinomas that are 
discovered incidentally, benign follicular adenomas, slow-growing and non­
metastatic follicular and papillary carcinomas, which can also give rise to local 
and distant metastases with increased de-differentiation, and finally the very 
aggressive undifferentiated anaplastic carcinomas. Furthermore, most thyroid 
tumours are clonal, arising from a single precursor cell that has somehow 
gained a growth advantage over the other thyroid cells through genetic 
mutations (Namba et al., 1990a).
The genetic events that have been previously identified in thyroid carcinomas 
indicate that there are several cumulative alterations involved in the initiation, 
progression and de-differentiation of these tumours. The follicular adenomas 
and carcinomas have a high prevalence of loss of heterozygosity involving 
multiple chromosomal regions, and are frequently aneuploidal tumours. This 
contrasts with papillary carcinomas, which show less frequent loss of 
heterozygosity, and are diploid or near-diploid, and implies that the two types
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of follicular-cell derived tumours arise from different molecular pathways. 
These genetic alterations can be sub-divided in several ways, either as 
alterations in oncogenes and tumour suppressor genes, or on the basis of the 
pathways affected by the genetic alterations. I will now review the major 
genetic alterations known to occur in thyroid cancer affecting the 
RET/RAS/BRAF/MAPK pathway, the PI3/AKT pathway, the control of the cell 
cycle via the pRb pathway, and alternative cellular pathways.
1.5 RET/RAS/BRAF/MAPK pathway
The molecular events involved in the tumorigenesis of follicular and papillary 
cancer are still incompletely understood despite several recent advancements, 
as reviewed by Moretti et al., 2000, Bongarzone and Pierotti, 2003, and Segev 
et al., 2003. However, activating mutations of several genes in the 
RET/RAS/BRAF/mitogen-activated kinase (MAPK) / extracellular signal- 
regulated kinase (ERK) signal transduction pathway have been identified in 
both follicular and papillary carcinomas (Xing et al., 2005).
The RET/RAS/BRAF/MAPK pathway regulates cell proliferation, survival and 
differentiation in response to changing environmental conditions. The pathway 
is activated when peptide growth factors interact with receptor tyrosine kinases 
in the cell membrane, bringing about a series of events that lead to activation 
of several intracellular signalling pathways (Pawson, 2002). Stimulated 
receptor kinases activate RAS, a small G protein embedded in the inner leaflet 
of the plasma membrane. Activated RAS recruits the protein kinase RAF to 
the plasma membrane. RAF in turn activates the protein kinase MEK, which
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activates the protein kinase ERK. ERK translocates to the nucleus and 
regulates gene expression and cellular metabolism by the phosphorylation of 
proteins such as transcription factors. The MAPK cascade is vital to the 
control of cellular responses to mitogens, and affects growth through the 
nuclear transcriptional regulation and via cytoskeletal processes. ERK can 
activate the synthesis of cyclin D1 and its assembly with cdk4, which has a 
major role to play in cell cycle progression. Therefore MAPK can control some 
of the checkpoints in the cell cycle in response to extra-cellular growth signals.
1.5.1 RAS
The RAS proteins are signal transducers that share properties with the G 
proteins. There are three different RAS genes (H-RAS, K-RAS and N-RAS) 
that synthesize a family of 21kDa proteins. RAS proteins are bound to the 
inner part of the cytoplasmic membrane, and function as GTPases. They have 
two forms, an inactive form linked to GDP, and an active form which is able to 
bind and subsequently hydrolyse GTP (as reviewed by Fagin, 1992 and Tallini,
2002). The function of RAS proteins is to convey signals that originate from 
tyrosine-kinase receptors in the cytoplasmic membrane to a cascade of 
mitogen-activated phosphokinases (MAPKs). This activates the transcription 
of target genes and results in cellular proliferation. RAS proteins are also 
involved in the pathways controlling cell survival and apoptosis. Oncogenic 
mutations of the RAS gene affect the GTP-binding domain and maintain the 
RAS protein in an active form, and these mutations play a major role in human 
tumorigenesis. They represent one of the commonest mutated oncogenes in 
human cancer development (Bos, 1989).
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There is evidence to suggest that RAS mutations may have a role to play in 
the initiation of thyroid tumorigenesis, with the thyroid-specific expression of 
mutant K-RAS in transgenic mice being associated with the development of 
follicular thyroid cancer (Santelli et al., 1993). In vitro transfer experiments 
have also provided compelling evidence for the initiating role of RAS in thyroid 
tumorigenesis. Normal cultured thyrocytes proliferate slowly and stop dividing 
after a few passages in vitro (Bond et al., 1999). The infection of thyrocyte 
colonies in a monolayer culture with replication-defective retroviral vectors 
encoding H-Ras V12 results in a dramatic stimulation of proliferation. This is 
sustained for up to 20-25 population doublings (Jones et al., 2000).
The expression of mutant RAS in these follicular cells does not inhibit the 
differentiation of thyroid epithelial cells, and this is consistent with the 
phenotype of an early follicular adenoma (Lemoine et al., 1989; Lemoine et al., 
1990; Suarez et al., 1990; Wynford-Thomas, 1993a; Bond et al., 1994; Gire 
and Wynford-Thomas, 2000). However, the expression of mutant RAS is not 
sufficient alone for complete malignant transformation (Bond et al., 1994; 
Monaco et al., 1995), and RAS may exert its effects by increasing cellular 
chromosomal instability and therefore predisposing cells to accumulate further 
genetic alterations (Nikiforov, 2004). Ultimately this RAS-induced proliferation 
ceases in vitro, and this suggests the need for subsequent mutations either 
downstream in the RAS/RAF/MAPK pathway, or in separate pathways 
involved in the control of cell proliferation, for further malignant progression to 
occur.
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Mutations in ail three families of RAS oncogenes have been detected in both 
benign and malignant thyroid tumours (Suarez et al., 1988; Lemoine et al., 
1989; Wright et al., 1989; Namba et al., 1990a; Namba et al., 1990b; Basolo et 
al., 2000; Nikiforova et al., 2003a). Mutations have been noted in up to 0-85% 
of follicular adenomas (Shi, Y.F. et al., 1991a), 14-82% of follicular carcinomas 
(Lemoine et al., 1988), up to 0-50% of papillary carcinomas (Naito et al., 1998) 
and in up to 60% of undifferentiated carcinomas (Garcia-Rostan et al., 2003), 
as reviewed by Vasko et al., (2003). Generally, oncogenic RAS mutations are 
more common in follicular than papillary carcinomas (Manenti et al., 1994). 
The majority of mutations have been found at codon 61 of H- and N-RAS 
genes. There are variations in the prevalence of RAS mutations among the 
different series, and this may be related to the differences in differentiation of 
the thyroid tumours analysed, as well as varying genetic mutations that were 
not investigated in the studies.
The prevalence of RAS mutations in 50% follicular adenomas (Lemoine et al., 
1989; Namba et al., 1990b) continues to implicate this as an early event in 
thyroid tumorigenesis, and it may even be the founder event, particularly for 
follicular thyroid cancer. However several studies have implicated N-RAS 
mutations to be involved with tumour progression and an aggressive clinical 
behaviour (Basolo et al., 2000; Motoi et al., 2000). In accordance with this, 
over-expression of RAS in papillary carcinomas has been associated with a 
worse clinical prognosis (Basolo et al., 1994). A recent case report of an 
anaplastic carcinoma with areas of well-differentiated follicular cancer found 
RAS mutations in both tumour types, whereas p53 mutation was only observed 
in the anaplastic tumour (Asakawa and Kobayashi, 2002). This suggests that
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the continued expression of RAS is important for tumour progression and 
metastasis (Tallini, 2002), and that oncogenic RAS may act as a mutator gene 
(Fagin, 2002), predisposing the cell to further genetic change.
1.5.2 BRAF
The RAF proteins are serine/threonine kinases that are intracellular effectors of 
the RAS/RAF/MAPK pathway, and they have a critical role in cell 
differentiation, proliferation and apoptosis. There are three isoforms in 
mammalian cells: A-RAF, B-RAF and C-RAF. B-RAF is the predominant 
isoform in thyroid follicular cells (B-type RAF kinase) and is the most potent 
RAF kinase activator of the MAPK pathway. Growth factors bind to cell 
membrane receptor tyrosine kinases, which then activate RAS. RAS then 
recruits RAF proteins to the membrane where they are activated, and this 
triggers the phosphorylation cascade of the MAPK pathway via the activation 
of MAPK/ERK kinase, which in turn activates ERK (Trovisco et al., 2006). 
Most oncogenic B-RAF mutations allow the formation of new interactions that 
fold the kinase enzyme into a catalytically competent structure. BRAF was first 
implicated in tumorigenesis by Davies, H. et al., 2002 who reported point 
mutations in colorectal carcinomas and malignant melanomas.
Although the aetiology of papillary thyroid cancer is not completely understood, 
activating mutations of three genes in the RET/RAS/BRAF/MAPK signal 
transduction pathway have been identified in the majority of papillary tumours. 
These three genetic alterations (RAS mutation, BRAF mutation, RET/PTC 
rearrangement) are mutually exclusive (Kimura et al., 2003; Soares et al.,
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2003). Genetic changes in either one of these genes are believed to be one of 
the earliest initiating events in papillary carcinogenesis (Giordano et al., 2005).
BRAF mutations are unique to papillary tumorigenesis, and the BRAF mutation 
is the most prevalent of the three oncogenic mutations in papillary thyroid 
cancer. The mutation is almost exclusively the T1799A transversion mutation 
in exon 15. The high specificity and frequency of this mutation suggest that it 
plays a fundamental role in the development of papillary thyroid cancer. This 
is supported by the presence of BRAF mutations in 20-52% of micro-papillary 
carcinomas (Sedliarou et al., 2004; Kim, T.Y. et al., 2005). The mutation has 
been demonstrated in 29-83% papillary carcinomas (Kimura et al., 2003; 
Soares et al., 2003; Namba et al., 2003; Nikiforova et al., 2003b). Papillary 
carcinomas that have a BRAF mutation have been shown to have a more 
aggressive clinical course (Nikiforova et al., 2003b), a higher incidence of 
extra-thyroidal invasion and distant metastases (Namba et al., 2003). A larger 
study by Xing et al., (2005) demonstrated a significant association between 
BRAF mutations and a more aggressive papillary cancer, with a greater 
incidence of metastasis, invasion and recurrence in these patients.
BRAF mutations have also been detected in 0-13% poorly differentiated 
papillary carcinomas (Nikiforova et al., 2003b; Soares et al., 2004) and in 0- 
63% undifferentiated, anaplastic carcinomas (Nikiforova et al., 2003b; Soares 
et al., 2004). It has been demonstrated that BRAF mutations are much more 
prevalent in anaplastic tumours that have papillary cancer components. The 
presence of BRAF mutations in these undifferentiated, aggressive tumours 
suggests that continued BRAF expression has as a role to play in the
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malignant disease progression of papillary tumorigenesis. However it cannot 
be the only driving force for anaplastic transformation as many anaplastic 
cancers do not harbour this mutation (Soares et al., 2004).
1.5.3 RET
The RET (RE-arranged during T-ransfection) gene was first identified in 1985 
(Takahashi et al., 1985). It is located at 10q21 and encodes a tyrosine kinase 
receptor protein consisting of an extracellular domain with a ligand binding site, 
a transmembrane domain and an intracellular tyrosine kinase domain (Myers 
et al., 1995), whose ligands belong to the glial cell line-derived neurotropic 
factor family (Tallini, 2002). It operates as an intracellular signal transducer, 
and is expressed in human cells of neural crest origin. In a normal thyroid 
gland, RET is expressed in the parafollicular C-cells, and is not normally 
expressed in thyroid follicular cells. Ligand binding results in initiation of the 
signalling cascade, and by stimulating RAS activation, can directly stimulate 
the MAPK pathway. RET plays a critical role in the development and 
maturation of the peripheral nervous system (DeLellis, 2006).
A RET/PTC chromosomal rearrangement unique to papillary thyroid carcinoma 
links the N-terminal and promoter domains of unrelated genes to the C- 
terminal fragment of RET to produce a chimeric form of the protein that is 
constitutively active (Santoro et al., 2002). These fusion proteins are 
inappropriately expressed in papillary thyroid cancer and stimulate constitutive 
signalling, thus bypassing the need for receptor activation by growth signalling 
and therefore the cell is continually stimulated to proliferate. More than fifteen 
forms of RET rearrangement have been identified, with RET/PTC1 and
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RET/PTC3 being the most common. RET/PTC1 is formed by a paracentric 
inversion of the long arm of chromosome 10, resulting in fusion with the H4 
(D10S170) gene. RET/PTC3 is formed by fusion with the RFG/ELE1 gene 
(Fagin, 2004).
Activated RET/PTC is tumorigenic, and has been shown to induce proliferation 
in thyrocytes in vitro (Bond et al., 1994). The introduction of activated RET into 
thyroid follicular cells results in outgrowth of the proliferating thyrocyte 
colonies, which show phenotypical differences with the mutant RAS-induced 
colonies, including a migratory pattern of growth and the formation of 
papilliform structures. This suggests that the initial oncogenic event (either 
RAS or RET) may determine whether the resulting tumour has a follicular or a 
papillary phenotype (Wynford-Thomas, 1997).
There is a high frequency of RET/PRC rearrangements in papillary micro­
carcinomas, which lends evidence to the in vitro work suggesting that the 
RET/PTC rearrangement is an early event in papillary thyroid tumorigenesis 
(Viglietto et al., 1995; Sugg et al., 1998). RET/PTC rearrangements are 
prevalent in 13-43% of papillary carcinomas (Bongarzone et al., 1989; Grieco 
et al., 1990; Fagin, 1992; Soares et al., 2003), and are the second commonest 
genetic abnormality found in papillary carcinomas. The wide variation in 
prevalence of RET/PTC rearrangements may be partly due to geographic 
variability, and the use of different methods to detect these rearrangements, as 
RET/PTC has been found in only a small fraction of papillary tumour cells, as 
well as almost all of a papillary cancer (Zhu et al., 2006).
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In contrast, there is a low prevalence of these rearrangements in poorly- and 
undifferentiated thyroid carcinoma and a recent study demonstrated that 
papillary tumours with the RET/PTC rearrangement do not progress to become 
anaplastic carcinomas (Tallini et al., 1998). This suggests that the RET/PTC 
fusion proteins may only have a small role in the further development of thyroid 
tumorigenesis (Santoro et al., 2002), although this loss of expression in the 
aggressive cancers may be an epiphenomenon related to the cell de­
differentiation in these tumours (Kondo et al., 2006).
Therefore the activation of the linear signalling RET/RAS/RAF/MAPK pathway 
has an initiating role in the development of papillary thyroid tumorigenesis, 
although the mutations and rearrangements of the RAS, RAF and RET genes 
are not sufficient alone to induce continued proliferation, tissue invasion and 
metastasis. These alterations will result in continuous stimulation of the cell to 
divide, however the cell must also bypass the tumour suppressor genes that 
control the cell cycle checkpoints, and develop the ability to induce 
angiogenesis and local and distant tissue invasion.
1.6 PAX8-PPARY
PAX8 encodes a thyroid cell-transcription factor that is essential for the 
genesis and differentiation of thyroid follicular cell lineages and regulation of 
thyroid-specific gene expression such as thyroglobulin and thyroperoxidase 
(Tallini, 2002). Peroxisome proliferator-activator receptor-y (PPARy) is a 
member of the steroid nuclear-hormone-receptor super-family that forms 
heterodimers with retinoid receptors. It is best known for its differentiation
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effects on adipocytes and insulin-mediated metabolic functions (Desvergne 
and Wahli, 1999), and it stimulates lipogenesis, inhibits growth, and induces 
terminal differentiation of cancer cell lines. Kroll et al., (2000) first identified a 
unique and interesting rearrangement in follicular thyroid carcinomas. This 
involves the translocation t(2;3)(q13;p25) that generates a chimeric gene 
encoding for the DNA-binding domain of PAX8 and the A-F domains of 
PPARy. The PAX8-PPARy rearrangement has a dominant-negative effect on 
the transcriptional activity of wild-type PPARy and contributes to thyroid 
tumorigenesis with an oncogenic role by targeting several cellular pathways 
(Kondo et al., 2006).
PAX8-PPARy rearrangements are seen in both follicular adenomas and 
follicular carcinomas; however the adenomas have a lower prevalence (0-31%) 
than the carcinomas (25-63%) (Marques et al., 2002; Cheung et al., 2003). 
The follicular cancers with the PAX8-PPARy rearrangement are more likely to 
be overtly invasive (Nikiforova et al., 2003a). To date, the rearrangement has 
not been demonstrated in either poorly-differentiated follicular carcinoma or 
anaplastic carcinoma (Nikiforov et al., 2004), although the number of analysed 
cases is too small to reach a definitive conclusion. In a comparative study of 
RAS mutations and PPARy rearrangements, 49% follicular cancers had RAS 
mutations, 35% had the PAX8-PPARy rearrangement and only 3% of cases 
had both genetic alterations (Nikiforova et al., 2003a). Interestingly, 12% of 
the follicular cancers were negative for both, which implies that follicular 
cancers may develop through at least two separate pathways, including 
separately both the RAS/RAF/MAPK and the PPARy pathway.
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1.7 MET
The c-MET oncogene (7q13) encodes for a trans-membrane tyrosine kinase 
protein identified as the receptor for a polypeptide known as hepatocyte growth 
factor (HGF) (Bottaro et al., 1991). HGF is a potent mitogen for epithelial cells 
and HGF-MET signalling regulates cell proliferation and differentiation in a 
normal embryonic development. MET is not over-expressed in normal thyroid 
tissue; however HGF is present in the connective tissue stroma of the thyroid 
(Trovato et al., 1998).
Di Renzo et al., (1992) investigated MET expression in thyroid cancers with 
Western blot analysis, and reported that MET was over-expressed in 70% 
papillary cancers, and was negligible in follicular adenomas and carcinomas, 
and anaplastic carcinomas. HGF induces a significant increase in the 
invasiveness of thyroid tumour cells in vitro (Scarpino et al., 1999). HGF-MET 
signalling in papillary carcinomas has been shown to modulate the motility of 
the cancer cells and therefore promote invasion, metastasis and angiogenesis 
(Ruco et al., 2001; Scarpino et al., 2003). Scarpino et al., (2003) also 
discovered evidence that HGF-MET signalling plays a role in the recruitment of 
inflammatory cells to a tumour via the induction of cytokine release by the 
neoplastic cells. Whereas some studies have demonstrated an association 
between MET over-expression and a poor prognosis (Chen et al., 1999), other 
data has correlated a loss of MET expression with the development of 
aggressive, undifferentiated tumours.
This up-regulation of MET by papillary cancer cells is believed to partly sustain 
their continued growth through the paracrine stimulation of HGF, which is
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found in thyroid stromal cells. Thyrocyte in vitro work has demonstrated a 
relationship between RAS and RET activation and MET over-expression in 
human thyroid follicular cells (Ivan et al., 1997), and this group suggested that 
the advantage gained from the activation of RAS and RET oncogenes could 
be due to sensitisation of the tumour epithelium to the paracrine secretion of 
HGF from the stroma. These results all suggest that MET over-expression 
may have a role to play in thyroid papillary tumorigenesis.
1.8 P I3K I AKT pathway
The PI3-kinase / AKT pathway is involved in the control of cell growth and the 
inhibition of apoptosis, and its effects are mediated by the phosphorylation of 
downstream effectors by AKT, a serine threonine tyrosine kinase (Tallini, 
2002). The PI3K/AKT pathway is negatively regulated by PTEN (phosphate 
and tensin homologue), and is activated by tyrosine kinases and RAS. There 
are three isoforms of AKT, AKT-1, AKT-2 and AKT-3, and all three isoforms 
are expressed in human thyroid tissue, although AKT-1 and AKT-2 are the 
predominant isoforms at both the mRNA and protein levels (Ringel et al., 
2001). Downstream targets of AKT regulate cell cycle progression, apoptosis, 
proliferation, cytoskeletal motility and stability and energy metabolism (Brazil et 
al., 2004; Kada et al., 2004). The PI3K/AKT pathway may have a crucial role 
to play in the progression of thyroid cancer, since the oncogenic activation of 
RAS and tyrosine kinases such as RET/PTC have been shown to be initiating 
events in thyroid tumorigenesis.
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The importance of the PI3K/AKT pathway was first highlighted when loss of 
PTEN expression was identified as the genetic cause for Cowden syndrome, 
mentioned earlier. Ten percent of patients with this disease develop thyroid 
cancer, in the form of a follicular adenoma or follicular carcinoma (Longy and 
Lacombe, 1996). However, PTEN mutations have also been described in up 
to 25% of sporadically occurring follicular adenomas and carcinomas, and less 
frequently in papillary carcinomas (Dahia et al., 1997; Halachmi et al., 1998; 
Bruni et al., 2000).
Ringel et al., 2001, demonstrated that follicular carcinomas have an increased 
expression of AKT-1 and AKT-2 isoforms, and increased levels of total AKT 
activity when compared to normal human thyroid tissue. This increase in AKT 
activity was also reported by Vasko et al., 2004b, and this increase in activity 
correlated with either activating mutations of RAS, or the PAX8-PPARy 
rearrangement. Furthermore, loss of PTEN expression has also been 
described in follicular carcinomas (Halachmi et al., 1998; Bruni et al., 2000). 
This data indicates that activation of the PI3K/AKT pathway is an early event in 
follicular thyroid tumorigenesis, and occurs in both sporadic and inherited 
forms of the disease.
Papillary carcinomas can be divided into those tumours with a BRAF mutation, 
and those with a RET/PTC rearrangement or a RAS mutation. The PI3K/AKT 
pathway has only been shown to be activated in those cancers harbouring a 
RET/PTC rearrangement or RAS mutation, and BRAF mutations do not appear 
to activate the pathway (Vasko et al., 2004b).
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The activation of AKT signalling in several human malignancies has been 
shown to be associated with an advanced tumour stage and tumour 
progression (Kim, D. et al., 2005). There is an association between increased 
thyroid tumour size and invasion, and increased AKT activity, for both follicular 
carcinomas and those papillary carcinomas with a RET/PTC rearrangement or 
RAS mutation (Shin et al., 2004; Vasko et al., 2004b). Therefore the PI3/AKT 
pathway is not only important in the early development of thyroid carcinoma, 
but also has a role to play in the progression of the disease.
1.9 The cell cycle
When a cell is stimulated to divide, it begins a tightly regulated sequence of 
events known as the cell cycle. The purpose of the cell cycle is to replicate 
DNA, after allowing for repair of DNA damage, and to segregate the duplicated 
DNA into two daughter cells (Sherr, 2000). Quiescent cells remain in the 
resting Go phase of the cell cycle. This can be a temporary phase, and cells 
can re-enter the cycle at the G1 phase if stimulated by mitogens. Alternatively, 
the quiescence can be permanent, as seen in terminally differentiated cells.
The cell cycle has several checkpoints to ensure that a cell does not replicate 
with damaged DNA, and the primary “restriction point” controls the transition 
from G1 (Gap 1) to S (synthesis) phase (Pardee, 1989). At this stage a cell 
must determine whether to continue through the cell cycle, to become 
quiescent or to undergo apoptosis if the damage is irreparable. If a cell was to 
continue through the cell cycle, the continued accumulation of genetic defects 
and instability could lead to malignant transformation. Once a cell has
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committed to the division process, it is committed to entering S phase, during 
which DNA synthesis begins, and the genome is duplicated. A second 
checkpoint occurs at the transition from G2 (Gap 2) to M (Mitosis) phase. If a 
cell successfully passes this restriction point, the replicated chromosomes are 
condensed and sister chromatids separate to form two nuclei, and the 
cytoplasm splits to form two daughter cells, marking the end of the cell cycle.
The transition from G1 to S phase is controlled by cyclin - cyclin dependent 
kinase (cyclin-cdk) complexes. The cdk subunit has a catalytic action and the 
cyclin subunit has a regulatory action. There are two families of enzymes, the 
cyclin D-dependent and the cyclin E-dependent kinases. Cyclins D1, D2 and 
D4 interact with cdk4 and cdk6. The D-type cyclins are inherently unstable, 
and their expression and function depends upon persistent growth factor 
signalling. Cyclin D has a short half-life, and after a cell has passed the G1/S 
phase checkpoint, it is degraded. Because the cdk4 and cdk6 enzymes are 
only active when cyclin D is bound, the expression of cyclin D is a rate-limiting 
step for entry into S-phase. The active cyclin D -  cdk4/6 complexes are 
required to inactivate Rb protein, the major ‘gatekeeper’ of the cell cycle and 
the Rb pathway. This then allows the cell to progress to S phase.
During G1 phase, the Rb protein is initially active in a hypophosphorylated 
form. In this state it sequesters the E2F family of transcription factors (E2F 1, 
2, 3). When cyclin D binds to cdk4/6 during G1 phase, this enzyme complex 
phosphorlyates and subsequently inactivates Rb, which causes the release of 
E2F proteins and cancelling the growth-suppressive actions of Rb (Kato et al., 
1993). The E2F factors are only active when they are released from Rb, and
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they are essential for S phase transition. They up-regulate S-phase genes 
such as cyclins A and E, and promote progression of a cell through the G1/S 
phase checkpoint (reviewed by Nevins, 2001).
Formation of the cyclin D — cdk 4/6 complexes is followed by the up-regulation 
of cyclin E which itself forms complexes with cdk2 in late G1 phase, and further 
phosphorylates Rb (Koff et al., 1992; Lundberg and Weinberg, 1998). The 
cyclin E-cdk2 complex is not dependent on mitogenic stimulation, and 
therefore the cell is no longer dependent on extra-cellular growth factors at this 
stage of the cell cycle. Cyclin E-cdk2 activity reaches a peak at the G1-S 
phase transition point and is then degraded, when it is replaced by cyclin A 
expression during late G1 phase through to the M phase of the cell cycle. The 
formation of cyclin A -  cdk2 complexes is an essential requirement for the S- 
phase of the cell cycle.
The thyroid cell turns over on average no more than 5 times through adulthood 
and there is a higher rate of turnover in early infancy and adolescence. Mature 
adult thyroid cells have a very low rate of both cell proliferation and cell death. 
However if the cells are exposed to an appropriate extrinsic or intrinsic 
mitogenic stimulus, they can mount a significant proliferative response 
(Wynford-Thomas, 1997). It is assumed that cycles of cell division are more 
frequent in benign or malignant thyroid tumours. Well-differentiated thyroid 
tumours (follicular adenomas and follicular and papillary carcinomas) have a 
low proliferative rate when compared with poorly- and undifferentiated thyroid 
tumours, as defined by the MIB-1 index. This has been reported as being 1- 
3% in well-differentiated cancers, 6-7% in poorly-differentiated cancers and 14-
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52% in undifferentiated anaplastic thyroid cancers (Katoh et al., 1995; Basolo 
et al., 1997; Yoshida et al., 1999; Kjellman et al., 2003). Altered expression of 
both positive (e.g. cyclin D1, cdk4, cdk6, E2F) and negative (p16, p21, pRb, 
p53) cell cycle regulators govern these differences in tumour growth activity.
1.9.1 p16
There are two main inhibitors of the cell cycle during the G1/S phase restriction 
point; the INK4 and the Cip/Kip families of cyclin-dependent kinase inhibitors. 
The INK proteins (inhibit cdk4) specifically target and inhibit cyclin D- 
dependent kinases (reviewed by Sherr and Roberts, 1995), and there are 4 
members, p16INK4A, p16INK4B, p18INK4C and p19,NK4D.
The p16INK4A protein is a 148 amino acid protein encoded by exons 1a, 2 and 3 
in open reading frames of 125, 307 and 12 base pairs respectively, on the 
short arm of chromosome 9 (Kamb et al., 1994) at the CDKN2A locus. It was 
first isolated as cdk4-binding protein in a yeast two-hybrid system (Serrano et 
al., 1993). One molecule of p16 binds to each molecule of cdk4 or cdk6, and 
prevents cyclin D1 binding by competing for the cyclin D binding site, thus 
rendering this enzyme complex inactive, and therefore Rb remains in an 
active, hypophosphorylated state and the cell is unable to pass the G1/S 
phase checkpoint. There is evidence to suggest that the Rb pathway acts as a 
single target in tumorigenesis. Inactivation of the Rb and p16 genes is 
mutually exclusive in lung cancer (Shapiro et al., 1995) and bladder cancer 
(Benedict et al., 1999).
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In order for p16 to exert its action, the cell must have a functional Rb protein 
(Guan et al., 1994; Lukas et al., 1995). When p16 expression is forced in cells 
with functional Rb in vitro, a reversible arrest of the cell cycle occurs (Lukas et 
al., 1999). Therefore the inactivation of both proteins would be of no 
advantage to a developing tumour and therefore would not be selected for.
Levels of p16 are regulated at the transcriptional level. Expression of p16 
mRNA is very low in most tissues and it is also a very stable mRNA (Hara et 
al., 1996). We currently do not have a clear understanding of the signals that 
regulate p16 expression. However, tissue culture work using human dermal 
fibroblasts has shown that the p16 promoter is activated by the expression of 
Ets transcription factors. Oncogenic RAS has the ability to promote expression 
of the Ets factors, which are downstream targets of the RAS/RAF/MAPK 
signalling pathway (Ohtani et al., 2001).
The p16 gene is one of the most frequently altered genes involved in cell cycle 
regulation in human cancers (Sherr, 1996). The gene can be inactivated by 
point mutation, promoter methylation or deletion. Complete inactivation of the 
gene occurs when both alleles are deleted, or one allele is deleted (loss of 
heterozygosity) and the other allele is inactivated by promoter methylation or 
mutation, or if methylation and mutation occur on separate alleles. Partial 
inactivation by deletion, methylation or mutation of only one allele can also 
occur, causing haplo-insufficiency. However, it is the level of protein 
expression and not the genetic copy number that may exert a genotype -  
phenotype influence, and the protein expression may not directly relate to the
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gene copy number if the p16 protein has been modified by post-transcriptional 
events.
Loss of p16 activity by gene deletion, mutation or transcriptional inactivation 
has been demonstrated in a wide range of human cancers (Nobori et al., 1994; 
Hirama and Koeffler, 1995; Sherr, 1996; Ruas and Peters, 1998). The loss of 
p16 expression is expected to lead to inappropriate progression through the 
cell cycle and uncontrolled proliferation of a tumour.
Thyroid tumour cell lines have been shown to have deletions, point mutations 
and structural alterations of the p16 gene in both follicular- and papillary- 
derived cancer cell lines (Calabro et al., 1996; Jones et al., 1996) and cell lines 
from undifferentiated thyroid cancers (Elisei et al., 1998). This data suggests 
that p16 may have an important role to play in both follicular and papillary 
thyroid tumorigenesis.
In contrast, p16 genetic alterations are rare in thyroid tumours in vivo. Loss of 
heterozygosity and hypermethylation are more common than point mutations, 
but they are not as common as the cell studies would indicate (Calabro et al., 
1996; Tung et al., 1996; Yane et al., 1996; Elisei et al., 1998). Our 
understanding of the frequency of the epigenetic and genetic events as a 
cause for p16 mutation in thyroid cancer is complicated by that fact that not 
every study analyses every possible mode of p16 gene inactivation in the 
same tumour panel.
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Therefore we have to put together an overall view with results from different 
laboratories in different thyroid tumour panels from different geographic 
backgrounds. This may partly explain the different results seen by individual 
researchers. It is also possible for one tumour to have two or more co-existing 
modes of gene inactivation, such as methylation and point mutation. Thus a 
study that concentrates on just one mode could potentially give an inaccurate 
representation of the gene status for the tumour group. Furthermore, 
variations in the population of patients from which the thyroid tumours were 
obtained, such as differing geographical locations which have a higher or lower 
incidence of thyroid cancer, may be of relevance where the mode of gene 
inactivation can be influenced by environmental factors such as ionising 
radiation.
1.9.2 p21
The p21 protein belongs to the Cip/Kip family of cyclin-dependent kinase 
inhibitors (p21, p27, p57), and was the first cyclin-dependent kinase inhibitor to 
be identified (Harper et al., 1993). It inhibits cdk2, and is involved in the 
assembly of cyclin D-cdk4/6 complexes when a cell enters the cell cycle after a 
period of quiescence in response to mitogenic signals (Sherr, 2000). At low 
cellular concentrations, p21 facilitates the formation of cyclin D -  cdk4/6 
complexes and subsequent progression through the cell cycle. At higher 
concentrations, p21 inhibits the formation of both cyclin D-cdk4/6 and cyclin E- 
cdk2 complexes (Harper et al., 1995) and prevents the cell entering S phase. 
When p16 is expressed, it binds to cdk4/6, and liberates the bound p21 
proteins. This increase in circulating p21 leads to an increase in cyclin E-cdk2 
complex inhibition, thus ensuring cell cycle arrest (Sherr and Roberts, 1999).
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p21 exerts it effects via p53-dependent pathways p21, as a direct 
transcriptional target of p53 (el-Deiry et al., 1994). However it is also activated 
through p53-independent pathways, and has a role to play in cellular 
differentiation and apoptosis.
Thyroid carcinomas in vivo demonstrate an up-regulation in follicular 
adenomas when compared to normal thyroid tissue, and a further up- 
regulation is seen in both follicular and papillary carcinomas (Ito et al., 1996; 
Zedenius et al., 1996; Pickett et al., 2005). There is some discordance with 
regards to the level of p21 protein expression in undifferentiated carcinomas, 
with both an increase (Okayasu et al., 1998) and a decrease in expression 
(Brzezinski et al., 2005) having been reported. In summary, both p16 and p21 
appear to have a role to play in the development of thyroid tumours. However 
there must be other pathways controlling the cell cycle that are involved in 
thyroid tumorigenesis, because follicular and papillary carcinomas continue to 
proliferate in the face of both p16 and p21 expression.
1.10 p53 pathway
The majority of mutations described so far involving the RET/RAS/RAF/MAPK 
are prevalent in well-differentiated thyroid cancers. Some of them appear to 
predispose to the progression of these tumours to a poorly- and 
undifferentiated tumour, although they are not sufficient alone to instigate this 
process, and additional mutations have to occur for this to happen. One of the 
candidates for this additional mutation is the tumour suppressor gene p53.
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The p53 gene maps to chromosome 17p13 and encodes a nuclear 
phosphoprotein that, as a tetramer, acts as a transcription factor and has a 
central role in the regulation of the cell cycle. It is a key component in the 
cellular emergency response mechanism and converts both intra- and extra­
cellular stress signals (such as DNA damage, activation of dominant 
oncogenes) into either growth arrest or apoptosis.
When DNA is damaged, p53 arrests the cell at the G1-S checkpoint of the cell 
cycle, which allows DNA repair mechanisms to correct the damage. It exerts 
these functions by activating the expression of several genes, such as p21, 
which can induce G1 arrest by inhibiting cyclin-cdk complexes. If the damage 
cannot be repaired, p53 promotes apoptosis, therefore avoiding the replication 
of abnormal clones of cells (Gottlieb and Oren, 1996). The function of p53 is 
altered in cancer cells either by point mutations (typically in exons 5-8), or by 
deletions, and this results in the accumulation of genetic damage, with the 
resulting cells having a selective advantage for clonal expansion. These 
alterations of the p53 tumour suppressor gene represent the most frequent 
genetic change in human cancer, and usually occur at a late stage in 
tumorigenesis (Tallini, 2002).
In thyroid tumorigenesis, point mutations of p53 have been demonstrated in a 
significant proportion of anaplastic (63.6-75%) and poorly-differentiated 
cancers (5-52.6%), and are rarely seen in the well-differentiated follicular and 
papillary cancers (Donghi et al., 1993; Fagin et al., 1993; Ito et al., 1993; 
Dobashi et al., 1994; Takeuchi et al., 1999). The differences in prevalence of 
p53 mutation in the series of poorly-differentiated thyroid carcinomas are
36
thought to be due to the differences in histological diagnostic criteria in 
identifying insular carcinomas. p53 mutations have also been reported in the 
metastatic counterparts of differentiated thyroid carcinomas (Sapi et al., 1995; 
Zedenius et al., 1996). Furthermore, Tzen et al., (2003), reported that p53 
mutations are present in the atypical cells seen in thyroid atypical adenomas, 
and speculated therefore that atypical adenomas may represent an 
intermediate lesion between follicular and anaplastic carcinomas. There have 
also been several reports that when a tumour contains areas of both well- 
differentiated and undifferentiated tumour, p53 mutations are restricted to the 
undifferentiated areas (Nakamura et al., 1992; Matias-Guiu et al., 1996; 
Asakawa and Kobayashi, 2002).
The recovery of p53 function in cultured thyrocytes derived from human thyroid 
tumours is accompanied by a reduction in both tumorigenic activity and 
proliferation, and a return to a more differentiated phenotype (Fagin et al., 
1996; Moretti et al., 1997). These data indicate that the mutational inactivation 
of the p53 gene is likely to play a key role in thyroid cancer de-differentiation 
and the progression from a differentiated to an undifferentiated tumour.
1.11 p-Catenin
p-catenin is a cytoplasmic protein, encoded by the CTNNB1 gene on 
chromosome 3p22-21.3, which plays an important role in E-cadherin-mediated 
cell-cell adhesion by binding the cytoplasmic tail of cadherin proteins. It is also 
a downstream effector of the Wingless/Wnt signalling pathway, which targets 
cyclin D1, and is critical in regulating cell fate and differentiation during
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embryogenesis (reviewed by Dierick and Bejsovec, 1999). Normal thyroid 
follicular cells express p-catenin.
For tumorigenesis to occur, epithelial cells must alter their adhesion properties 
to allow invasion and metastasis to occur. In the absence of Wnt signalling, p- 
catenin is located on the cell membrane and is present at a low level in the 
cytoplasm, where it is rapidly degraded by the adenomatous polyposis coli 
(APC) multi-protein complex. In the presence of Wnt, p-catenin is stabilised, 
translocates to the nucleus and up-regulates the transcriptional activity of 
genes such as cyclin D1 (Nikiforov, 2004). Point mutations in exon 3 of the 
gene stabilize the protein, bypassing Wnt, resulting in constitutive activation of 
target gene expression.
Point mutations in exon 3 have been reported in 25% poorly-differentiated 
thyroid tumours and in 66% anaplastic cancers, but are not present in well- 
differentiated thyroid cancers (Garcia-Rostan et al., 2001; Miyake et al., 2001). 
This data suggests that P-catenin mutations play a direct role in the de­
differentiation of thyroid carcinomas, particularly in those follicular and papillary 
tumours that transform into anaplastic cancers.
1.12 Overview of thyroid tumorigenesis
Thyroid tumorigenesis is the result of a step-wise progression of genetic 
changes, including activating mutations of oncogenes such as BRAF and 
RET/PTC, and genetic and epigenetic silencing of tumour suppressor genes 
such as p53, as previously described. Studies of allelic imbalances in well-
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differentiated and poorly-differentiated thyroid cancer give further evidence for 
this stepwise progression. In many human neoplasms, there is a widespread 
loss and / or duplication of chromosomal regions and entire chromosomes in 
the late, poorly-differentiated stages and this reflects the destabilisation of the 
cancer’s genome.
In thyroid tumorigenesis, both follicular and anaplastic thyroid cancers have a 
high rate of allelic losses and gains. In contrast, papillary cancers have only a 
mild degree or a lack of chromosomal instability (Ward et al., 1998; Hemmer et 
al., 1999; Kitamura et al., 2000; Kleer et al., 2000; Hunt et al., 2003; Nikiforov, 
2004). The loss of identical chromosomal regions in both follicular and 
anaplastic carcinomas, and in both the well-differentiated and undifferentiated 
components of an individual thyroid tumour indicates that there is a connection 
between these two tumour phenotypes (Hunt et al., 2003). Wreesmann et al., 
2002, analysed the chromosomal abnormalities in well-differentiated, poorly- 
differentiated and undifferentiated thyroid cancer with comparative genomic 
hybridization. They observed that the chromosomal abnormalities fell into 
three groups. All three thyroid cancers had gains of 5p15, 5q11-13, 8q23, 19p 
and 19q, and deletions of 8p and 22q. Secondly, the poorly- and 
undifferentiated cancers had gains of 1q34-36, 6p21, 9q34, 17q25 and 20q, 
and deletions of 1 p11-31, 2q32-33, 4q11-13, 6q21 and 13q21-31. Finally, the 
anaplastic carcinomas had gains of 3p13-14 and 11q13, and loss of 5q 11-31. 
The gains or losses of identical chromosomal regions in well-, poorly- and 
undifferentiated thyroid carcinoma indicate that there is a common genetic 
pathway linking these tumour phenotypes. Furthermore, there were no
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chromosomal abnormalities that were unique to the mid-stage of thyroid 
tumorigenesis, the poorly-differentiated thyroid cancers.
During thyroid tumorigenesis, a single transformed cell appears to gain a 
growth advantage due to loss of proliferative regulation (Heaney et al., 2001). 
The ensuing genomic instability renders the cell prone to large scale 
chromosomal aberrations, amplifications, deletions and translocations, as 
described above. Thyroid neoplasms are quite unique, because a single 
normal follicular cell can give rise to two tumours with distinctly different 
histological characteristics, namely follicular and papillary carcinomas.
These tumours have different biological characteristics, and metastasise via 
two different pathways (papillary cancers invade via the lymphatic system and 
follicular cancers invade via the blood stream), yet both tumours have the 
potential to transform into an undifferentiated anaplastic carcinoma. Evidence 
for differing initiating events in the early tumorigenesis of these two cancers 
has already been described, such as RAS and PAX8-PPARy mutations which 
predominate in follicular adenomas and malignant follicular carcinomas, and 
RET/PTC mutations which are unique to papillary thyroid carcinomas. 
However, the exact molecular mechanisms involved in thyroid tumorigenesis 
are still unclear.
Some of the genetic mutations have been correlated with an increased 
likelihood of de-differentiation to an anaplastic phenotype, as seen in the 
subset of papillary and follicular thyroid tumours with a BRAF mutation. 
Additional genetic changes are required for a tumour to transform into this
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aggressive phenotype, and both p53 and p-catenin mutations are potential 
triggers of this process.
1.13 Thyrocyte tumour model
Human thyroid follicular epithelial cells give rise to a range of well-defined 
stages, from benign adenomas to aggressive, undifferentiated carcinomas. 
There are also two distinct pathways of tumorigenesis which can arise from the 
same follicular cell, which differ in their clinical and pathological behaviour. 
This is therefore an excellent model to use for studying the molecular changes 
involved in multi-step human tumorigenesis. The early development of a 
thyroid tumour is closely correlated with mutations of RAS and RET genes, 
and these are each associated with a different tumour phenotype. There is 
therefore a strong phenotype -  genotype association.
The thyroid has a distinct advantage over other tissues for developing a tissue 
culture tumour model. Firstly, thyroid cells can be easily obtained from surgical 
pathological material, and they remain viable in a simple monolayer culture 
with the same cell kinetics as those seen in the intact thyroid gland 
(Poghosyan and Wynford-Thomas, 2005). Secondly, thyroid tumorigenesis 
results in a dramatic increase in cellular proliferation in comparison to the 
normally quiescent thyroid gland, and is therefore simpler to model in tissue 
culture when compared to other human tissues which are continually renewing 
or differentiating.
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The major principle of our ‘in-house’ tissue culture research is that RAS 
mutation occurs at an early stage (follicular adenoma) in thyroid tumorigenesis, 
that this is a common event and that the introduction of RAS mutations into 
thyrocytes can stimulate cellular proliferation in vitro, mimicking the 
development of an in vivo adenoma. By introducing mutant RAS and RET into 
thyrocytes, our laboratory has developed an in vitro model of human thyroid 
tumorigenesis. This model has demonstrated the influence of the initiating 
oncogene on the evolving phenotype of the resulting thyrocyte colonies.
Thyrocytes in tissue culture normally undergo two or three p.d. before entering 
a state of irreversible quiescence. The expression of mutant RAS V12 induces 
an increase in proliferation and the generation of thyrocyte colonies, which 
show a normal thyroid epithelium phenotype and grow in continuous cell 
sheets (Bond et al., 1994). This proliferative response ceases after 20-25 pd, 
mimicking an in vivo ‘burnt out’ follicular adenoma. The introduction of mutant 
RAS does not induce a de-differentiation of the thyrocytes, and they continue 
to express thyroid-specific proteins such as thyroglobulin, TTF-1 and PAX8 
(Gire and Wynford-Thomas, 2000). Therefore the high frequency of RAS 
mutations seen in both benign and malignant follicular thyroid tumours 
(Lemoine et al., 1989; Suarez et al., 1990) is matched by the increase in 
thyrocyte proliferation seen in the RAS thyrocyte colonies. To summarise, the 
expression of mutant RAS in human thyrocytes generates a clonal expansion 
of cells which retain thyroid-specific gene expression and the resulting colonies 
demonstrate a phenotype that is consistent with a follicular adenoma, the first 
stage of follicular thyroid tumorigenesis.
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Papillary thyroid cancers develop de novo from normal thyroid follicular cells, 
unlike their follicular counterparts. As previously described, the RET/PTC 
rearrangement is a frequent finding in papillary tumours (Santoro et al., 1992). 
Research performed in our laboratory has shown that the introduction of 
rearranged RET into human thyrocytes also leads to an increase proliferation, 
similar to that seen with RAS (Wynford-Thomas, 1993b; Bond et al., 1994).
The resulting colonies had a different phenotypical appearance to the RAS 
colonies, with a fenestrated appearance, cell-free zones and infoldings that 
resembled papillae (Bond et al., 1994). The colonies grew more slowly, and 
the demarcation from surrounding thyrocytes was less clear. This data 
demonstrates that the expression of a RET rearrangement in human 
thyrocytes induces proliferation, and the colonies have a different phenotype 
compared to RAS colonies, which resembles the in vivo papillary phenotype, 
and is consistent with the RET/PTC rearrangement being an initiating event for 
papillary thyroid tumorigenesis.
The introduction of mutant p53 into thyrocytes in vitro (Bond et al., 1994) failed 
to elucidate an increase in proliferation, contrasting the effects of mutant RAS 
and RET expression. Our in vitro data is therefore in accordance with in vivo 
data (Ito et al., 1992), where p53 mutation only confers a growth advantage to 
poorly- and undifferentiated, late-stage thyroid tumours. The findings of the 
experiments with mutant RAS, RET and p53 indicate that our ‘in-house’ 
thyrocyte tumour model is a good representation of the in vivo thyroid tumour 
model.
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The majority of follicular adenomas eventually reach a quiescent end-point, 
and this has often been attributed to the inability to invade or promote new 
blood vessel formation. However, we have demonstrated that RAS-induced 
thyrocyte colonies, which resemble follicular adenomas, also reach a quiescent 
end-point in tissue culture. This data suggests that the mechanism 
responsible for the proliferation-barrier is cell-intrinsic, and independent of 
tissue architecture, since it occurs both in vivo and in vitro. The cyclin- 
dependent kinase inhibitor p16 has been postulated to have a role in mediating 
growth arrest, and mutations and deletions of this gene have been observed in 
many human cancers (Bos, 1989).
Jones et al., (2000) studied the expression of p16 in normal thyrocytes and in 
early and late-stage RAS-induced thyrocyte colonies by immunocytochemistry 
and Western blotting. They demonstrated that p16 is not expressed in normal 
thyrocytes, and that there is a 20-fold increase in p16 expression between 
early and late-stage RAS colonies, corresponding with the growth arrest of the 
late-stage thyrocytes colonies. This strongly suggests that p16 is a candidate 
gene for the proliferative lifespan barrier that limits tumour progression in 
epithelial cells.
To provide evidence to support this theory, Bond et al., (2004) designed a 
small interfering RNA (siRNA) that ‘knocks down’ p16 expression, and 
transfected this into RAS-induced thyrocytes colonies. This resulted in the 
outgrowth of proliferating clusters of cells, and the escape from the proliferation 
barrier normally seen in the RAS thyrocytes colonies. Therefore the 
abrogation of p16 expression is correlated with continued thyrocyte
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proliferation. This data supports the theory that p16 has a role in limiting 
oncogene-driven clonal expansion in thyroid cancer, and therefore there is a 
valid selection pressure to account for the genetic and epigenetic loss of p16 
seen in many human cancers.
1.14 Aims and hypothesis
Our thyrocyte cell culture studies suggest that at least one requirement for the 
progression from a benign adenoma to a clinically significant malignancy is the 
loss of p16 expression, and the resulting abrogation of an intrinsic ‘fail-safe” 
mechanism which normally limits the proliferative lifespan of the RAS-induced 
clones.
There is great clinical interest in the molecular mechanisms involved in the 
transition from a follicular adenoma to a follicular carcinoma. Follicular 
adenomas and carcinomas often have a remarkably similar phenotype with 
respect to cytology, architecture, and cell kinetics and differentiation markers. 
Currently, it is only by pain-staking histological examination of multiple tissue 
blocks for capsular or vascular invasion that malignancy can be diagnosed or 
excluded, and therefore patients with follicular adenomas undergo an un­
necessary operation which is not without risk. Frustrating as this may be for 
the clinician, these tumours make an ideal pair for comparison of gene 
expression profiles since it maximises the chances that any observed 
differences will be linked directly to the malignant phenotype rather than to 
spurious changes secondary to altered differentiation states. Research in this 
area could potentially lead to the identification of a definitive marker for
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distinguishing these two tumours in fine needle aspirates of thyroid nodules. 
This is a long-standing problem in the diagnosis and management of thyroid 
disease.
The overall strategy underlying my research is to analyse the expression of 
potential candidate genes involved in early thyroid tumorigenesis which are 
induced in the RAS thyrocytes colonies in our thyrocytes tumour model, and to 
compare this with the expression of these genes in human thyroid tumour 
samples. The human tissue samples will be drawn from existing archived 
tumour samples, from patients having surgery for thyroid cancer during the 
period of my research, and from colleagues’ tissue archives in France. I will 
analyse differences in gene expression in every stage of human thyroid 
tumorigenesis, using normal thyroid tissue, atypical adenomas, follicular 
adenomas and carcinomas, micro-papillary and papillary carcinomas, insular 
and anaplastic carcinomas.
The initial candidate gene that I will be investigating is p16, on the basis of the 
results obtained in our laboratory on mutant RAS thyrocytes colonies. I will 
also investigate the expression of two other cell cycle genes, the oncogene 
cyclin D1, and the tumour suppressor gene p21. I will investigate the 
expression of p16, cyclin D1 and p21 proteins using immunohistochemistry on 
formalin-fixed, paraffin embedded tissue samples. Further candidate genes 
will be identified following the analysis of Affymetrix microarrays performed on 
the RAS thyrocytes colonies.
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I hypothesise that p16 protein will not be expressed in normal thyroid tissue, 
and will be expressed in thyroid follicular adenomas. I expect this to be 
matched with a small increase in expression of the proliferation markers MCM2 
and cyclin A. In the follicular and papillary carcinomas, I hypothesise that p16 
expression will be down-regulated, in keeping with the progression to a 
malignant tumour, and that this will be matched by a further increase in 
expression of MCM2 and cyclin A, correlating with the increase in proliferation 
seen in these cancers. I expect there to be further loss of p16 expression in 
the poorly-differentiated and un-differentiated aggressive thyroid carcinomas, 
correlated with a greater increase in expression of MCM2 and cyclin A.
I also hypothesise that p21 expression will be correlated with p16 expression in 
the follicular adenomas, follicular and papillary carcinomas, with both proteins 
acting as tumour suppressors in the early stages of thyroid tumorigenesis. I 
expect the expression of cyclin D1 to be greater in the carcinomas than the 
adenomas, and that this will be correlated with the predicted loss of expression 
of both p16 and p21.
My research has the potential to provide novel information regarding the 
expression of cell cycle markers in thyroid tumorigenesis, and may also identify 
novel or unsuspected pathways, that are involved in malignant progression. 
Furthermore, these genes may be indicative of malignant follicular thyroid 
transformation and could potentially differentiate follicular adenomas from 
follicular carcinomas, thus solving one of the major problems in the treatment 
of thyroid cancer.
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CHAPTER 2 
METHODS 
2.1 Tissue samples
2.1.1 Archived thyroid tissue from Cardiff
Archived thyroid tissue was available as formalin-fixed, paraffin-embedded 
specimen blocks that had previously been collected for research purposes, after 
obtaining appropriate consent, by the University Hospital of Wales Pathology 
department. The samples comprised a selection of normal thyroid tissue, 
thyroid follicular adenomas, follicular carcinomas and papillary carcinomas, a 
normal tonsil, and a cervical carcinoma.
2.1.2 Acquisition of new Cardiff thyroid tissue
I developed a consent form after collaborating with the Pathology Department, 
University Hospital of Wales, Cardiff, UK and with Mr D Scott-Coombes, 
Consultant Endocrine Surgeon, University Hospital of Wales, Cardiff, UK. The 
local Research Ethics Committee approved the consent form. I collected 
thyroid samples from patients who had surgery for a suspected or proven 
thyroid carcinoma in 2003 - 2005, after the patient and the consultant surgeon 
had signed the consent form. Specimens from the tumour and / or the 
background normal thyroid tissue were fixed in formalin and embedded in 
paraffin following a standard protocol in the University Hospital of Wales 
Histopathology department.
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2.1.3 Acquisition of French thyroid tissue 
We had access to tissue sections from a variety of normal thyroids and thyroid 
tumours, which were donated to us by two French colleagues (addresses in 
Appendix I). Catherine de Micco sent us tissue sections of follicular, papillary, 
insular and anaplastic carcinomas. Brigitte Franc sent us tissue sections of four 
micropapillary carcinomas and five sections from six Tissue Micro-Arrays 
(TMAs) comprising normal thyroid, follicular and atypical adenoma, and 
follicular, papillary and insular carcinoma samples. All tissue was obtained after 
appropriate local consent was sought for the use of tissue for research 
purposes.
The concept of TMAs was first described by Kononen et al., (1998). A TMA is a 
slide containing multiple cores of several tissues on a single slide, allowing 
many tumours to be analysed in a short space of time. The TMAs that we used 
consisted of 1mm cores of tissue in triplicate of either thyroid tumours, or thyroid 
tumours with matched normal thyroid tissue. In total, we were able to analyse 
68 normal thyroid specimens, 16 follicular adenomas, 10 atypical adenomas, 8 
follicular carcinomas, 26 papillary carcinomas and 17 insular carcinomas. The 
TMA slides were stained and then scored by two people who were blinded to 
the pathology of each core (Elizabeth Ball and Professor Wynford-Thomas). 
The results of the immunostaining were sent to Brigitte Franc, who then sent us 
the key to identify the pathology of each core. Finally, the tissue cores were 
reviewed by both Brigitte Franc and Professor Wynford-Thomas, together with 
our immunohistochemistry results and the final pathology reports, and a couple 
of tissue cores that had been incorrectly diagnosed were identified and their 
histology re-confirmed.
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2.2 Preparation of tissue sections
I cut tissue sections from the formalin-fixed, paraffin-embedded tissue blocks 
using a microtome, after placing the blocks on ice for thirty minutes to aid 
cutting. After trimming the specimen block, I cut four micrometer-thick sections 
and floated them on a water-bath at 45°C using a paintbrush. Each section was 
lifted from the water-bath using a Surgipath Snowcoat X-tra™ pre-cleaned 
microslide (Surgipath Europe Limited), and incubated in an oven at 60°C 
overnight. I cut preliminary tissue sections from cervical carcinoma and thyroid 
follicular adenoma sample blocks that I used to validate the p16 antibody. Ruth 
Pitman (Electron Microscopy Laboratory, Histopathology department, University 
Hospital of Wales, Cardiff) cut all the remaining tissue sections.
In order to ensure accurate analysis of the antibodies used to immunostain a 
given tumour, only the minimum number of tissue sections was cut from a 
tissue block at a given time. This ensured that serial sections were stained, 
there was no wastage of tissue, and that the next time the tumour was studied 
with a different antibody group, the results could be accurately compared with 
those from the previous study. There would however be some loss of tumour 
and difference in microscopic appearance between research projects because 
the tumour blocks need to be trimmed prior to sectioning.
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2.3 Preparation of cultured cells for p16 immunohistochemistry
I used cultured Ori 3 cells (human thyroid follicular epithelial cells transfected 
with SV40) as a "biological" positive control for p16 immunostaining. These 
cells express SV40 large T, and therefore as expected express large quantities 
of p16, confirmed with Western blotting by Jones et al., 1996 and Lemoine et 
al., 1989. Cultured K1 cells (human papillary thyroid carcinoma cells 
expressing wild-type p53) were used as a “biological” negative control for p16 
immunostaining. They have a p16 gene deletion, demonstrated by Wyllie et al., 
1995 and Jones et al., 1996. The Ori 3 and K1 cells were grown in our 
laboratory under standard tissue culture conditions by Jane Bond (Henry 
Wellcome Building, University Hospital of Wales, Cardiff).
I fixed and embedded the Ori 3 and K1 cells in paraffin blocks according to the 
following established protocol described by Morgan (2001).
• Centrifuge 10 x 106 cells, wash and re-suspend in 10ml 10% 
formalin in isotonic phosphate buffered saline (PBS, pH 7) and 
allow to sediment for 2 hours.
• Discard the excess formalin, place the cell volume (1-1.5ml) to a 
1.5ml microcentrifuge tube, and allow to sediment for 20-30 
minutes.
• Remove the formalin supernatant, leaving the cells in a 10-50pl 
volume.
• Remove the part of the barrel of a 1ml syringe to which a needle 
would be attached. The piston assembly of the syringe forms the 
base of the mould and will be used to extrude the set mould.
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• Melt 4% agar (made in deionised water) in a water bath at 95°C 
and then transfer to a second water bath set at 60°C. Heat the 
microcentrifuge tube containing the cells in the same 60°C water 
bath using a foam float for 2-3 minutes.
• Transfer 20pl of agar to the tube using a plastic disposable pipette 
(diameter 3-4mm) that has been pre-warmed on a hot plate set at 
45°C. Mix the suspension carefully with the same pipette by 
taking it up and extruding it twice into the same tube, whilst 
holding the tube in the water bath.
• Quickly transfer the quantity of agar-cell mix, without air bubbles, 
to the mould. Allow the agar to set at room temperature for five 
minutes and then place in a refrigerator (4°C) for a further 2-3 
minutes.
• Extrude the agar from the mould using the syringe piston, and 
leave the plug in formalin-PBS for two hours at room temperature 
before placing in a standard paraffin-processing cassette.
• Dehydrate the plug in a step-wise fashion by transferring it to a 
10% ethanol solution for two 30-minute washes, repeated with 20- 
100% ethanol solutions in steps of 10%. From 100% ethanol, 
process the plug through several changes of xylene over two 
hours and then process in paraffin, again with several changes.
The reason for processing the cells into paraffin blocks is that there is some 
controversy in the literature regarding the scoring of p16 immunohistochemistry 
(see Chapter 2.5.1). Some authors believe that only nuclear staining is a true 
indicator of p16 expression, whereas others believe that both nuclear and
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cytoplasmic staining should be considered. Our Ori 3 cells in tissue culture 
show strong nuclear expression of p16, whilst a tissue block of cervical 
carcinoma (known p16-positive tissue, see Chapter 3.3.1) showed strong 
nuclear and cytoplasmic expression. I wanted to know whether the cytoplasmic 
expression of p16 was the result of tissue fixation and processing.
2.4 Immunohistochemistry Protocol
2.4.1 Antibody selection 
I performed a literature search to find studies using immunohistochemistry to 
detect each of the proteins that I was interested in (p16, cyclin A, MCM2, p21, 
cyclin D1, HLA-DR, PKR, MxA). After critically reviewing the literature, I chose 
two or three antibodies specific for each protein and trialled them at varying 
concentrations, incubation temperatures and incubation times, with both 
positive and negative controls (where available), using the protocols most 
commonly used in the selected papers. Where external positive and negative 
control tissues were not available, I used antibodies that had been thoroughly 
trialled in the literature with Western blotting and immunohistochemistry (p21, 
cyclin D1). A summary of the anti-p16 antibody literature search is given in 
Table 2.1. Table 2.2 provides information regarding the suppliers of my 
selected antibodies, and Table 2.3 describes the immunohistochemistry 
protocols that I used.
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Table 2.1 A table showing the results of the literature search for p16 
immunohistochemistry protocols
Author Ig Source Ig Clone Dilution HMAR Incubation
Geisler, 2002 Neomarkers ZJ11 1:60 yes 46C, O/N
Leversha, 2003 Neomarkers 16P04 1:100 yes RT, 60 mins
Geradts, 1995 Pharmingen rabbit 1:400 no 46C, O/N
Sakaguchi, 1996 Pharmingen rabbit 1:800 no 46C, O/N
Talve, 1997 Pharmingen G175-405 1:100 yes 46C, O/N
Hu, 1997 Pharmingen G175-405 5pg/ml yes 46C, O/N
Takeuchi, 1997 Pharmingen G175-405 5pg/ml yes RT, 60 mins
Emig, 1998 Pharmingen G175-405 1:200 yes RT, 30 mins
Matsuda, 1999 Pharmingen rabbit 1:400 no 46C, O/N
Niehans, 1999 Pharmingen G175-405 2pg/ml yes RT, O/N
Geradts 2000 Pharmingen G175-405 2pg/ml yes RT, O/N
Huang, 2000 Pharmingen G175-405 1:100 yes 46C, O/N
Hodges, 2002 Pharmingen G175-405 1:25 yes RT, 60 mins
Hilton, 2002 Pharmingen rabbit 1:1000 yes RT, O/N
Gerdes, 2002 Pharmingen G175-405 1:50 yes 46C, O/N
Murphy, 2003 Pharmingen G175-405 1:75 yes RT, 60 mins
Svensson, 2003 Pharmingen G175-405 1:200 yes RT, 60 mins
Lee, 1999 Oncogene Ab-1 2pg/ml yes 46C, O/N
Mariatos, 2000 Santa Cruz F-12 1:100 yes 4°C, O/N
Straume, 2000 Santa Cruz SC-467 1:200 no no
Cheng, 2003 Santa Cruz F-12 1:50 yes yes
Abbreviations used in table:
Ig -  Antibody
HMAR -  Heat-mediated antigen retrieval
RT -  room temperature 
O/N - overnight
54
Table 2.2 Manufacturer’s details for the antibodies that I used
Protein Antibody Clone Antibody Type Manufacturer
p16 G175-405 Mouse monoclonal Pharmingen
MCM2 Anti-MCM2 Mouse monoclonal GH Williams, UCL, London
cyclin A NCL - cyclin A Mouse monoclonal Novocastra
p21 SX118 Mouse monoclonal DAKO
cyclin D1 DCS-6 Mouse monoclonal DAKO
HLA-DR TAL.1B5 Mouse monoclonal DAKO
PKR sc-6282 Mouse monoclonal Santa Cruz
MXA n/a Mouse monoclonal G Kochs, Universitat Freiburg, Germany
Table 2.3 The immunohistochemistry protocols for each antibody that I used
Antibody Antibody
dilution
Peroxidase
block
HMAR EDTA pH Incubation details
p16 1:50 yes yes 7.0 60 minutes at RT
MCM2 1:1000 yes yes 7.0 60 minutes at RT
cyclin A 1:50 yes yes 7.0 60 minutes at RT
p21 1:50 yes yes 9.0 60 minutes at RT
cyclin D1 1:50 yes yes 9.0 60 minutes at RT
HLA-DR 1:200 yes yes 7.0 60 minutes at RT
MXA 1:1000 yes no n/a 60 minutes at RT
PKR 1:50 yes yes 7.0 60 minutes at RT
Abbreviations used in table:
RT - room temperature
HMAR -  Heat-mediated antigen retrieval
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2.4.2 Rehydration of slides
2.4.2.1 Manual technique
During 2002 -  2005, I rehydrated the slides manually. Slides were 
immersed in three changes of xylene and a series of ethanol solutions (100%, 
90%, 70%, 50% and 30%) for five minutes per solution, followed by immersion 
in a slow-running cold water bath for ten minutes. The alcohol and xylene 
solutions used for rehydration and dehydration of slides were freshly prepared 
on a weekly basis.
2.4.2 2 Automatic technique
During 2005 -  2006, I rehydrated the slides using the Shandon Varistain 
Gemini machine (Thermo Electron Corporation). In order to ensure that the 
machine produced identical results to the manual technique, I processed four 
separate sets of slides using both techniques. I used the cervical carcinoma 
(positive control for p16) and each technique produced identical results. I 
programmed the machine as follows: - 3 x 2  minutes xylene, 3 x 1  minute 100% 
ethanol, 3 x 1  minute running water bath, followed by distilled water for five 
minutes.
2.4.3 Heat-Mediated Antigen Retrieval (HMAR)
After rehydration of the slides, and prior to incubation with the primary antibody,
I used heat-mediated antigen retrieval when staining for the following 
antibodies: p16, cyclin A, p21, cyclin D1, HLA-DR and PKR. For p16, cyclin A, 
HLA-DR and PKR staining, the slides were inserted into a plastic slide rack, 
placed in a plastic jug containing one litre of 10mM EDTA at pH 7.0 and 
covered with cling-film wrap. The jug was micro-waved in a microwave oven for
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20 minutes at 800W. For p21 and cyclin D1, the EDTA solution used had a pH 
of 9.0 instead of 7.0. HMAR, initially described by Shi, S.R. et al., (1991) is a 
technique used to improve the reactivity of antigen epitopes that are masked 
during the process of formalin fixation, and most antibody-antigen reactions can 
be enhanced by this method (McQuaid et al., 1995).
2.4.4 Pre-treatment with a peroxidase-blocking solution
I pre-treated all slides with a peroxidase-blocking solution (DakoCytomation) 
prior to primary antibody incubation to minimise background staining. Each 
tissue section was outlined using a water-limiting pen (DAKO) to obtain more 
uniform immunohistochemical staining. Each slide was incubated with 200pl of 
the solution, and then rinsed with a buffer solution (DakoCytomation). 
Horseradish peroxidase is the most commonly used enzyme label, and is 
visualised using diaminobenzidine, which precipitates in a brown reaction end 
product, and it is this brown reaction that is scored. A peroxidase-blocking 
solution ensures that the brown reaction is not a product of endogenous 
peroxidase in the tissue.
2.4.5 Immunohistochemistry protocols
2.4.5.1 Manual technique
The initial p16, cyclin A, MCM2, p21 and cyclin D1 work during 2002 -  
2005 was done by hand. After HMAR and incubation with the peroxidase- 
blocking solution, the primary antibody was diluted to the desired concentration 
using DAKO antibody diluent (DakoCytomation). I then incubated the slides 
with 200pl of the diluted antibody for 60 minutes at room temperature in a 
humidified slide chamber. Separate slides containing tissue from each tumour
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studied were also incubated with mouse prolactin antibody and antibody diluent 
as negative controls, and a section of a known positive control tissue was tested 
in each batch of slides (apart from p21 and cyclin D1 staining). Finally, the 
slides were rinsed in three coplin jars containing a buffer solution 
(DakoCytomation), for five minutes per rinse.
The secondary antibody used was the Envision+ ™ solution (DakoCytomation). 
The Envision + system is based on a horseradish peroxidase-labelled polymer 
which is conjugated with secondary antibodies. The labelled polymer does not 
contain biotin or avidin, and therefore non-specific staining resulting from 
endogenous biotin is eliminated or significantly reduced (Sabattini et al., 1998). 
Thyroid tissue has a considerable amount of endogenous biotin, and therefore 
this system greatly reduces background staining of biotin. I incubated the slides 
with 200pl of the Envision+ ™ solution for 30 minutes at room temperature in a 
humidified slide chamber prior to rinsing in buffer solution (DakoCytomation) as 
before. The slides were then incubated with 200 pi of diaminobenzidine (DAB) 
solution (DakoCytomation) for five minutes, and rinsed with distilled water for 
five minutes.
2.4.5 2 Automatic technique
The interferon-based work (HLA-DR, PKR, MxA) and all follow-up p16, 
cyclin A, MCM2, p21 and cyclin D1 work in 2005-2006 was stained using the 
Dako Autostainer Plus machine (DakoCytomation). This technique was trialled 
several times against the manual technique using p16 on the positive cervical 
control tissue, and both techniques gave identical staining patterns. Details of 
the programming are listed in Appendix III.
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2.4.6 Dehydration of slides and haematoxylin counter-staining
2.4.6.1. Manual technique
For the initial p16, MCM2, cyclin A, p21 and cyclin D work, I dehydrated 
the slides manually. After exposure to filtered Mayer's haematoxylin for ten 
seconds the slides were placed in a slow running water bath for ten minutes, 
and then taken through a series of five graduated ethanol solutions of 
increasing strength (from 30% to 100%) and three changes of xylene, for five 
minutes per solution. The slides were then mounted with coverslips using a 
mounting solution (DakoCytomation).
2.4.6 2 Automatic technique
For the interferon-based work (HLA-DR, PKR, and MxA) and all sections 
stained during 2005 - 2006, I dehydrated the slides using the Shandon Varistain 
Gemini machine (Thermo Electron Corporation). I validated this technique by 
performing several runs using p16 staining with the positive cervical control 
against the manual technique, and each protocol gave comparable results. The 
machine was programmed as follows: - 1 minute slow running water, 10 
seconds in filtered Haematoxylin solution, 10 minutes slow running water, 2 x 2  
minutes 100% ethanol, 3 x 2  minutes xylene. The slides were mounted with 
coverslips using DAKO mounting solution (DakoCytomation).
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2.5 Scoring of antibody expression
2.5.1 p16
There are three different ways to interpret the results of immunohistochemical 
staining. The first method is to record the percentage area of tissue stained, as 
used by Taga et al,.(1997), Emig et al., (1998), Huang et al., (2000), Hilton et 
al., (2002), and Murphy et al., (2003). This simplistic method makes no 
allowances for differences in p16 staining intensity or heterogeneity within a 
sample, and could lead to false conclusions when interpreting results. For 
antibodies such as cyclin A where most tissues have an ‘all-or-nothing’ staining 
intensity, this scoring method is appropriate.
A second scoring system used records the intensity of staining, as used by 
Sakaguchi et al., (1996), Matsuda et al., (1999), and Geradts et al., (2000). 
This is another simple method that attributes a score for weak/absent, moderate 
and strong staining intensity, but again could lead to false conclusions. It gives 
no information regarding the percentage of tumour that has positive staining, 
and makes it difficult to compare a tumour with 5% cells with a high score, and 
a tumour with 100% cells with a low score.
The third method of immunohistochemical scoring records the staining index, as 
used by Straume et al., (2000), and Pizzi et al., (2003). The staining index is 
calculated by multiplying a score given for the intensity of staining with a score 
for the percentage of cells stained. It is a more accurate representation of the 
true staining picture, and does make some allowance for heterogeneity of both 
the area of staining and the intensity of staining within a sample, although it too 
has some limitations. A tumour with a mosaic distribution of staining will still be
60
represented by a single score, although this is a more accurate representation 
when compared with the previous two scoring systems. Therefore, care has to 
be taken when depicting results.
Finally, many papers quote the mean score for a given tumour group. This will 
give a reasonable representation of the scores for the tumours in that group, if 
the scores are normally distributed. However, I noted that this was often not the 
case, and therefore analysed the mean and median scores, as well as the 
range of scores, to get the most accurate interpretation of my results.
There is some discrepancy with regards to what is a positive result for p16 
expression. In the studies that scored a variety of human tumours on the basis 
of area, some papers accredited tumours with a positive result if more than 10% 
of the cells showed staining (Taga et al., 1997; Lee et al., 1999; Huang et al., 
2000; Cheng et al., 2003), whilst others used different cut-off points, ranging 
from 1% (Shi et al., 2000), to 5% (Hu et al., 1997; Gerdes et al., 2002) and 80% 
(Takeuchi et al., 1997). The various cut-offs also depended on whether the 
normal tissue studied was positive or negative for p16. With any scoring 
system, the difficulty lies in deciding when you accept a “weakly positive” or a 
“weakly negative” result as a valid finding, and what score constitutes a positive 
result.
We noted that normal thyroid tissue is negative for p16, and having observed 
heterogeneous staining in the majority of tumour sections, decided that scoring 
both the area and the intensity of staining would give the most accurate
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representation of the immunohistological picture, rather than an arbitrary cut-off 
value for negative and positive p16 expression.
Secondly, there is not a consensus in the literature concerning whether 
cytoplasmic staining is a true positive result for p16 expression. The majority of 
papers discounted cytoplasmic staining as non-specific staining (Niehans et al., 
1999; Shi et al., 2000; Straume et al., 2000; Pizzi et al., 2003), and only 
considered nuclear staining above background cytoplasmic staining as a 
positive result. However, there were a group of papers that did count 
cytoplasmic staining as a true positive result (Papdimitrakopoulou et al., 1997; 
Murphy et al., 2003; Svensson et al., 2003). Svensson reasoned that because 
the majority of cells with cytoplasmic staining of p16 also had nuclear p16 
staining, than the cytoplasmic staining indicated true p16 reactivity.
I mm u nocytochemistry performed in our laboratory on Ori 3 cells demonstrated 
strong positive nuclear staining. However, when the Ori 3 cells were processed 
into paraffin blocks to resemble tissue, both the nucleus and cytoplasm were 
stained (Chapter 3, Figure 3.1 A). I therefore attributed both cytoplasmic and 
nuclear staining as a positive result.
Two independent observers (blinded to the histological diagnosis) scored all 
slides, as previously described. For the TMA sections, five hundred cells per 
tissue core were counted. All three cores were scored for every tumour 
represented on the TMA slides, and an average I.D. score was calculated for 
each tumour. For the remaining tissue sections, five hundred cells 
representative of the tumour were counted. The cells were assigned to an
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intensity category of 0 (absent), 1 (weak), 2 (moderate), or 3 (strong). The 
percentage of cells in each intensity category was determined as N0, Ni, N2, 
and N3 respectively.
A weighted average intensity distribution (I.D.) score was calculated - 
I D. = [(N0x 0) + (Ni x 1) + (N2 x 2) + (N3 x 3)] /100
The I.D. score therefore ranged from 0 (absent staining in all cells) to a 
maximum of 3 (100% cells having a staining intensity of 3).
2.5.2 MCM2, cyclin A, p21
Since no background cytoplasmic staining was seen, only nuclear staining was 
taken as a positive result. There was no obvious gradation of nuclear intensity, 
with the vast majority of positive nuclei having the same intensity of staining. 
For the TMAs, five hundred cells per tissue core were counted. For the 
remaining tissue sections, five hundred cells representative of the tumour were 
counted, and the percentage of positive-staining nuclei (labelling index, L.l.) 
calculated.
2.5.3 cyclin D1
I observed both cytoplasmic and nuclear staining of cyclin D1 in the thyroid 
tumours studied. Each tissue section was scored using the Intensity 
Distribution score, by calculating the percentage of cells with positive staining,
and the intensity of the staining, using the calculation given in 2.5.1. Five
hundred cells representative of each tumour were counted.
63
2.5.4 HLA-DR, PKR, MxA 
We observed primarily cytoplasmic staining in this group of antibodies, which 
was generally of a uniform intensity. I counted five hundred cells representative 
of the tumour. However, the percentage of positively scoring cells for HLA-DR 
was generally in single figures, therefore I recorded the percentage of positive 
cells, and the intensity of staining in those cells (weak, moderate, strong) where 
appropriate.
2.6 Statistical analysis
All statistical analyses were performed using SPSS version 11.0 software 
(SPSS Inc., Chicago, IL). A p-value of <0.05 was taken to indicate a statistically 
significant relationship.
2.7 Photography
All slides were photographed using an Olympus BX51 microscope (Olympus 
UK Ltd., London) and a Leica DFC 320 camera, using Leica IM50 Image 
Manager Software (Leica Microsystems UK Ltd., Milton Keynes).
2.8 Scale bars
Photographs were taken of a graticule graduated in pms using the 4x,10x and 
20x optics -  the same magnifications at which my photographs were taken, 
using the same pixel density as the actual slide photographs. I made an Adobe 
Photoshop file with a black bar to correlate with 200 pms in length, and this was 
copied and pasted directly onto the Adobe photoshop pictures of the slides, 
correlating the 4x bar / 4x photograph, 10x bar / 10x photograph, 20x bar / 20x 
photograph.
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CHAPTER 3 
AN IMMUNOHISTOCHEMICAL STUDY OF p16INK4a EXPRESSION IN 
MULTISTEP THYROID TUMORIGENESIS
3.1 Introduction
The first aim of this chapter is to establish a protocol for p16 
immunohistochemistry and validate an anti-p16 antibody, using “biological” 
positive and negative controls. The second major aim is to analyse the 
immunohistochemical expression of p16 in normal thyroid tissue and at every 
stage in thyroid tumorigenesis, including follicular and atypical adenomas, well- 
differentiated (micro-papillary, papillary and follicular) carcinomas, and poorly- 
differentiated (insular and anaplastic) carcinomas. This will enable me to 
correlate the in vivo thyroid staining with the in vitro results produced in our 
laboratory using an established thyrocyte tumour model. This research will 
provide new information regarding p16 expression in thyroid tumorigenesis, 
and also help to confirm whether our thyrocyte culture model is indeed a valid 
representation of early thyroid tumorigenesis. The third aim of this chapter is 
to assess the proliferation of the benign and malignant thyroid tumours using 
anti-MCM2 and anti-cyclin A antibodies, and compare this with the p16 status 
of each tumour.
A key requirement for a cell to become neoplastic is to escape from the normal 
controls of cell proliferation (Hanahan and Weinberg, 2000). One such control 
that appears to be critical in limiting tumour development in many cell types 
operates through the tumour suppressor gene p16INK4A. p16 is a tumour
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suppressor gene and was first identified by Serrano et al., (1993). This protein 
is a cyclin-dependent kinase inhibitor, which acts as a negative regulator of cell 
cycle progression (Koh et al., 1995; Lukas et al., 1995). The p16 protein binds 
and inactivates cyclin-dependent kinases (cdks) 4 and 6, which are the 
catalytic partners for cyclins D1, D2 and D3.
When p16 binds to cdk4 and 6, it blocks the cyclin-dependent phosphorylation 
of the Retinoblastoma gene product, Rb (Sherr, 1996) and thus blocks the exit 
from the G1 phase of the cell cycle by preventing the initiation of DNA 
replication (Ohtani et al., 2004). Consistent with this, loss of p16 activity by 
gene deletion, mutation or transcriptional inactivation has now been found in a 
wide range of human cancers of both epithelial and mesenchymal origin 
(Nobori et al., 1994; Okamoto et al., 1994; Hirama and Koeffler, 1995; Sherr, 
1996; Talve et al., 1997, Ruas and Peters, 1998), at a frequency rivalling that 
of p53 mutation (Baylin et al., 1998).
The RAS family of GTPase proteins are involved in the regulation of cell 
growth and differentiation by signal transduction (Crespo and Leon, 2000). 
Mutations of the RAS oncogene family occur at a high frequency in several 
human epithelial tumour types, notably those of the pancreas, colon and 
thyroid (Bos, 1989; Jones et al., 2000; Skinner et al., 2004). RAS oncogene 
mutations were first reported in thyroid tumours in 1988 (Lemoine et al., 1988) 
and a meta-analysis by Vasko et al., (2003) showed that RAS mutations are 
more frequent in follicular compared with papillary thyroid tumours. The 
mutations may also be a marker for aggressive tumour behaviour, as 
suggested by Garcia-Rostan et al., (2003).
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RAS oncogene activation has been shown to be an early event in thyroid 
tumorigenesis (Lemoine et al., 1989; Namba et al., 1990b). Our laboratory has 
obtained strong experimental support for this using retroviral gene transfer 
studies in vitro. Whereas normal thyrocytes exhibit a very low proliferative 
rate, RAS oncogene activation drives proliferation (Bond et al., 2004), in sharp 
contrast to its growth-inhibitory effect on mesenchymal cells. The resulting 
epithelial clones retain thyroid-specific gene expression and display a 
phenotype consistent with that of a follicular adenoma.
Thyrocyte proliferation does not continue indefinitely however, terminating in a 
state resembling replicative senescence. Immunocytochemical and Western 
blot analyses showed that expression of the cyclin-dependent kinase inhibitor 
p1giNK4a jncreases jn 'late-stage' thyrocyte colonies, and this is closely 
correlated with a decrease in proliferative rate, therefore suggesting that p16 
expression has a role in limiting oncogene-driven clonal expansion in this 
human epithelial tumour model.
In vivo, the vast majority of thyroid adenomas also appear to reach a self- 
limiting quiescent end-point, which is often ascribed to insufficient ability to 
promote new blood vessel formation and/or mechanical restriction by the 
tumour capsule. The similarity between this self-limiting growth in vivo and our 
observations in tissue culture however raises the alternative possibility that a 
cell-intrinsic mechanism independent of tissue architecture is responsible, and 
that this may be mediated at least partly by up-regulation of p16 expression.
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I hypothesized from our thyrocyte results that p16 immunohistochemical 
expression would increase in vivo at the follicular adenoma stage, and further, 
that the escape from self-limiting growth that occurs in follicular and papillary 
cancers would be accompanied by a loss of p16 expression. I tested this 
hypothesis by performing immunohistochemical analysis on multiple samples 
of thyroid tissue, at multiple stages of thyroid tumorigenesis.
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3.2 Method
3.2.1 Immunohistochemistry
I performed immunohistochemistry on formalin-fixed, paraffin-embedded tissue 
sections and tissue microarrays (TMAs) following heat-mediated antigen 
retrieval in 10mM EDTA pH 7.0, using a microwave (20 minutes at 800W). I 
pre-treated the slides with a DAKO peroxidase "blocking" solution 
(DakoCytomation) prior to incubation (one hour at room temperature) with one 
of the following antibodies: -
(i) mouse monoclonal anti-p16 antibody clone G175-405, (BD Biosciences 
Pharmingen, San Diego, CA, USA) at a dilution of 1:50 (10pg/ml)
(ii) mouse monoclonal anti-MCM2 antibody (kindly donated by Prof. GH 
Williams, Dept of Pathology, University College London, London), at a 
dilution of 1:1000
(iii) mouse monoclonal anti-cyclin A antibody (clone NCL-Cyclin A, 
Novacastra Labs Ltd, Newcastle-upon-Tyne, UK) at a dilution of 1:50
Secondary amplification was accomplished using the DAKO Envision+ ™ kit 
(DakoCytomation), and I visualised antibody binding using DAB chromogen 
(DakoCytomation), followed by counterstaining with haematoxylin.
3.2.2 Scoring of slides
Two independent observers (blinded to the histological diagnosis) scored all 
the slides (EB and DWT). We scored the three TMA cores representing each 
tumour, and calculated the average score for each tumour. This average 
score was used for statistical analysis.
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3.2.2.1 p16 analysis
The observers assigned five hundred cells per sample to an intensity 
category of 0 (absent), 1 (weak), 2 (moderate), or 3 (strong) and the 
percentage of cells in each intensity category was determined as N0, Ni, N2, 
and N3 respectively. A weighted average score was then calculated (Intensity 
Distribution, I.D. score, range 0 - 3) as follows:-
I.D. = [(N0x 0) + (Ni x 1) + (N2 x 2 ) + (N3 x  3)] /100
3.2.2 2 Cyclin A and MCM2 analysis
The observers counted five hundred cells per sample, and calculated 
the percentage of positive-staining nuclei (labelling index, L.I.).
3.2.3 Statistical analysis
I performed all statistical analyses using SPSS version 11.0 software (SPSS 
Inc., Chicago, IL). I used the Mann-Whitney U test to calculate p-values for 
differences between thyroid tumours, and the Spearman rank correlation co­
efficient to correlate cyclin A and p16 values in a given thyroid tumour set.
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3.3 Results
3.3.1 anti-p16 antibody validation 
I performed a literature search to identify anti-p16 antibodies that had been 
previously used for immunohistochemical analysis of formalin-fixed, paraffin- 
embedded tissues (Table 2.1). After trialling both the Pharmingen rabbit 
polyclonal and Pharmingen mouse monoclonal antibodies, I selected the 
mouse monoclonal anti-p16 antibody clone G175-405 (Pharmingen) at a 
dilution of 1:50 (10mcg/ml). At this dilution, the monoclonal anti-p16 antibody 
produced the most consistent, reproducible results, with negligible background 
staining.
I fixed and embedded Ori 3 cells in paraffin blocks to mimic tissue (Morgan, 
2001) and used them as a "biological" positive control. These cells express 
SV40 large T, and therefore as expected express large quantities of p16, 
confirmed by Western blotting (Jones et al., 1996; Lemoine et al., 1989). I also 
similarly fixed and embedded K1 cells, which have been shown to have a p16 
gene deletion (Wyllie et al., 1995; Jones et al., 1996) to use as a “biological” 
negative control. A cervical carcinoma-in-situ was used as an additional 
positive control tissue (Murphy et al., 2003). For additional negative controls, I 
also stained slides with isotype-matched mouse monoclonal anti-prolactin 
antibody (Pharmingen), at a concentration of 1:50, and antibody diluent 
solution (DAKO).
The Ori 3 cells showed a strong cytoplasmic and nuclear reaction at an anti­
p ie  antibody dilution of 1:50 (Figure 3.1 A). The K1 cells did not demonstrate a 
positive reaction (Figure 3.2A). The cervical carcinoma showed strong positive
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staining in the neoplastic area only, with absent staining in the surrounding 
normal cervical tissue (Figure 3.3). Neither the Ori 3 or K1 cell pellets (Figure 
3.1B, 3.2B), nor the cervical carcinoma demonstrate a positive reaction when 
stained with the anti-prolactin antibody or the antibody diluent.
I did however observe a reduction in the intensity of staining of the cervical 
tissue. This was proportional to the time delay between preparing and staining 
each slide. I noticed that the longer the interval, the greater the reduction in 
staining intensity (Figure 3.4), and subsequently all slides were stained with 
anti-p16 antibody within one week from the date that the slide was prepared.
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Figure 3.1 A Immunohistochemical staining with anti-p16 antibody of an Ori 3 cell pellet 
showing a strong positive cytoplasmic and nuclear reaction.
Figure 3.1 B Immunohistochemical staining with antibody diluent of an Ori 3 cell pellet showing 
the absence of a positive reaction.1 i
Figure 3.2 A Immunohistochemical staining with anti-p16 antibody of a K1 cell pellet showing 
the absence of a positive reaction.
Figure 3.2 B Immunohistochemical staining with antibody diluent of a K1 cell pellet showing 
the absence of a positive reaction.
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Figure 3.3 Immunohistochemical staining with anti-p16 antibody of an HPV-positive cervical 
carcinoma showing a strong positive reaction in the carcinoma, and a negative 
reaction in the surrounding normal cervical tissue.
Figure 3.4 Immunohistochemical staining 
with anti-p16 antibody of an HPV-positive 
cervical carcinoma demonstrating the reduction 
in staining intensity proportional to the time 
interval between slide preparation and slide 
staining.
A = 1 day, B = 2 weeks, C = 2 months.
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3.3.2 p16 expression
3.3.2.1 Normal thyroid
All four normal thyroid tissue sections were negative for p16 expression 
(Fig 3.5 A, B). There were 68 normal thyroid tissue TMA cores, and the vast 
majority also showed no immunostaining for p16 (median I.D. score 0.05, 
range 0 - 1 .7 )  (Fig 3.5 C, D). There were four cases with p16 I.D. scores 
greater than 1.5 times the inter-quartile range in this group, and the pathology 
report for these cases described the thyroid sections as 'not cancer', 
compared to the remainder of cases which were described as normal thyroid 
tissue.
3.3.2 2 Follicular adenoma
All ten follicular adenoma tissue samples showed an up-regulation of 
p16 staining when compared to normal thyroid tissue (median I.D. score 0.55, 
range 0.2 -  1.4). The adenomas could be divided into two groups. Five (50%) 
cases had weak p16 staining, and five (50%) cases had a moderate intensity 
of staining (Figure 3.6 A, B). There were sixteen follicular adenoma TMA 
cores, and as predicted by our hypothesis, there was an increase in p16 
staining in this group when compared to normal thyroid tissue, with 
approximately 50% of cases showing weak to moderate staining in the majority 
of cells (Figure 3.7 A, B), (median I.D. score 0.45, range 0 - 1.9). This is a 
statistically significant increase compared to the normal group (p = 0.017).
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Figure 3.5 Immunohistochemical staining with anti-p16 antibody of two normal thyroid tissue 
sections (A,B) and two TMA cores (C,D) demonstrating the absence of a positive 
reaction. Scale bar represents 200pm.
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Figure 3.6 Immunohistochemical staining with anti-p16 antibody of two follicular adenoma tissue 
sections demonstrating a moderate (A) and strong (B) positive reaction. Scale bar 
represents 200pm.
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Figure 3.7 Immunohistochemical staining with anti-p16 antibody of two follicular adenoma tissue 
TMA cores demonstrating a positive reaction. Scale bar represents 200pm.
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3.3.2.3 Atypical adenoma
A total of ten atypical adenoma TMA cores were stained and these 
tumours also showed an increase in p16 expression when compared to normal 
thyroid tissue (Figure 3.8), (median I.D. score 1.6, range 0.25 - 2.95). Despite 
the wide spread of values, this increase was statistically significant (p<0.001) 
when compared to normal thyroid tissue.
3.3.2.4 Follicular carcinoma
Eight follicular carcinoma tissue sections were stained, and all of these 
cancers showed a further up-regulation in p16 expression when compared to 
the follicular adenoma tissue sections (median I.D. score 1.5, range 1.0 -  2.4) 
(Figure 3.9 A, B). All eight follicular carcinoma TMA cores showed an increase 
in p16 expression, and this was also greater than the up-regulation of p16 
seen in the follicular adenomas (Figure 3.9 C, D) (median I.D. score 1.00, 
range 0.1 - 1.95). This up-regulation was also a statistically significant 
increase (p<0.001) compared to the normal group.
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Figure 3.8 Immunohistochemical staining with anti-p16 antibody of an atypical adenoma TMA 
core demonstrating a moderate staining reaction. Scale bar represents 200pm.
Figure 3.9 Immunohistochemical staining with anti-p16 antibody of two follicular carcinoma tissue 
sections (A,B) and two TMA cores (C,D) demonstrating a moderate / strong positive 
reaction. Scale bar represents 200pm.
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3.3.2.5 Papillary carcinoma
Two micro-papillary carcinomas showed an up-regulation of p16 
expression (Figure 3.10 A, B). Eight papillary carcinoma tissue sections were 
stained, and these also demonstrated an up-regulation of p16 expression 
when compared to normal thyroid (median I.D. score 1.7, range 1.1 -  2.7). Six 
cancers showed intense p16 staining in 60-80% cells (Figure 3.12 A), and two 
showed weak / moderate staining in 50-70% cells. I stained 26 papillary 
carcinomas TMA cores, and this tumour group also showed a considerable up- 
regulation of p16 expression when compared to normal thyroid (median I.D. 
score 0.4, range 0-2.4), (Fig 3.12B), and this was statistically significant 
(p=0.001). A metastatic deposit from a papillary cancer also showed an up- 
regulation of p16 over-expression (Figure 3.13 A).
3.3.2 6 Insular carcinoma
Six insular carcinoma tissue sections were stained, and these could be 
divided into two groups; three tumours showed intense p16 staining, (Fig 3.14 
A1) and three tumours did not have p16 expression (Figure 3.14 B1, C1). I 
stained 17 insular carcinoma TMA cores, and as a whole, this tumour group 
showed an up-regulation of p16 staining when compared to normal thyroid 
tissue (median I.D. score 1.00, range 0 - 2.7, p<0.001). Although the median 
p16 I.D. score was similar to that of the follicular cancer group, there was a 
much wider range of values. Approximately one quarter of the insular 
carcinomas had intensely positive p16 staining (Figure 3.17 E1), half had weak 
to moderate p16 staining and the final quarter did not show any p16 
expression (Figure 3.17 F1).
Figure 3.10 Immunohistochemical staining with anti-p16 antibody of two micro-papillary thyroid 
carcinomas, demonstrating a strong positive reaction. Scale bar represents 200pm.
Figure 3.11 Immunohistochemical staining with anti-cyclin A antibody of two micro-papillary thyroid 
carcinomas. Case A shows two positive nuclei, and case B does not show a positive 
reaction. Scale bar represents 200pm.
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Figure 3.12
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V ,
Immunohistochemical staining with anti-p16 antibody of a papillary carcinoma tissue 
section (A) and a papillary carcinoma TMA core (B) demonstrating a strong positive 
reaction. Scale bar represents 200pm.
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Figure 3.13 Immunohistochemical staining with anti-p16 antibody (A) and anti-cyclin A antibody 
(B) of a metastatic deposit from a papillary carcinoma, showing up-regulation of both 
p16 and cyclin A expression. Scale bar represents 200pm.
• V.V.f
82
• . , =X
. i ♦ ' * . " ■ • ■ '  '*
.  - .  . '  !_
: ■ * • .*L »-*.»&• *+H . v. ■» .* '«
v -A * . .
B2
fFvS '
•  r*
i + t
k
< y  \  ‘ !
,  r *  -
•' • *3
?  t2 »
f X3f-------— '  • ■ -
1
Figure 3.14 Immunohistochemical staining with anti-p16 antibody (A1t B1, C1) and anti-cyclin A
antibody (A2, B2, C2) of three insular carcinoma tissue sections. Case A demonstrates 
a strong positive p16 and cyclin A reaction. Case B demonstrates a loss of p16 and 
an up-regulation of cyclin A expression. Case C demonstrates a positive p16 reaction 
in the background follicular carcinoma, and a loss of p16 expression and up-regulation 
of cyclin A expression in the insular carcinoma. Scale bar represents 200pm.
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Figure 3.15 Immunohistochemical staining with anti-p16 antibody (series 1), anti-MCM2 antibody 
(series 2) and anti-cyclin A antibody (series 3) of TMA cores representing the following 
tumour groups: A - follicular adenoma, B - atypical adenoma, C - follicular carcinoma, 
D - papillary carcinoma, E -p16-positive insular carcinoma, F - p16-negative insular
carcinoma. Scale bar represents 200pm.
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3 3.2.7 Anaplastic carcinoma
Two anaplastic carcinoma tissue sections arising from a papillary 
carcinoma were analysed. These cancers demonstrated a dramatic down- 
regulation in p16 expression in the anaplastic carcinoma section in contast to 
the strong p16 staining seen in the papillary carcinoma section (Figure 3.16). 
Both tumours showed only a very weak cytoplasmic staining in a minority of 
the tumour cells (Figure 3.17).
Chart 3.1 graphically represents the range of p16 I.D. values of the TMA cores 
for each tumour group studied. Clearly, the adenomas and carcinomas 
demonstrated an up-regulation of p16 expression when compared to the 
normal thyroid tissue. The atypical adenomas and insular carcinomas had the 
highest p16 I.D. scores. Whilst 75% of the follicular carcinomas had a p16 I.D. 
score between 0.9-1.2, there was a greater range of values in the papillary and 
insular carcinoma groups, with a greater percentage of tumours showing 
weaker or stronger staining than that seen in the follicular cancers. The p16 
TMA results are also depicted as a box plot in Chart 3.2, showing the median 
p16 I.D. score and the inter-quartile range for the normal thyroid, follicular and 
atypical adenomas, and the follicular, papillary and insular carcinomas. The 
TMA data is summarised in Table 3.1, and the tissue section data is 
summarised in Table 3.4.
Fig 3.16 Immunohistochemical staining with anti-p16 antibody showing an anaplastic carcinoma 
derived from a papillary carcinoma demonstrating strong p16 expression in the papillary 
region and a down-regulation of p16 expression in the anaplastic section. Scale bar 
represents 200pm.
;/'VP
Fig 3.17 Immunohistochemical staining with anti-p16 antibody showing two cases of an 
anaplastic carcinoma demonstrating the absence of p16 expression. Scale bar 
represents 200pm.
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Chart 3.1 Bar chart demonstrating the range of p16 I.D. scores in the normal thyroid, 
follicular and atypical adenoma, and follicular, papillary and insular carcinoma 
TMA cores. The stacked bars represent the percentage of cases per thyroid 
pathology group with a p16 I.D. score in a given range (0-0.49. 0.5-0.99, 1.0- 
1.49, 1.5-1.99, 2.0-2.49, 2.5-2.99).
100% n
90%
80%
70%
% of cases 
per tumour 
pathology 
witha p16 
I.D. score in 
a given range
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NT = normal thyroid FA = follicular adenoma AA = atypical adenoma
FC = follicular carcinoma PC = papillary carcinoma IC = insular carcinoma
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Chart 3.2 Box plot chart showing the range of p16 I.D. scores for cases within the first 
and third quartiles, and median values for the p16 I.D. score for normal 
thyroid, follicular and atypical adenoma, and follicular, papillary and insular 
TMA cores. The ‘whiskers’ represent the range of I.D. values of cases that fall 
within 1.5 times the inter-quartile range (IQR), 'O’ represent the I.D score of 
‘outlier’ cases whose I.D score is 1.5 — 3 times the IQR and ★’ represent the 
I.D. scores of ‘extreme’ cases whose I.D. value is >3 times the IQR.
3.00-
2.50-
2 .00 -
co
Q.
1.00 -
0.50-
0.00-
Atypical Follicular Papillary InsularNormal Follicular
Thyroid Adenoma Adenoma Carcinoma Carcinoma Carcinoma
Thyroid pathology
A = statistically significant result compared to normal thyroid (p < 0.05)
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3.3.3 MCM2 expression
3.3.3.1 Normal thyroid
A total of 68 normal thyroid TMA cores were stained with anti-MCM2 
antibody, and MCM2 expression was very low in this group (median L.l. = 0, 
range 0 -14.3). Four normal thyroid tissue sections were also immunostained, 
and showed negligible MCM2 expression (median L.l. = 0, range = 0 -  0.8), 
Fig 3.18A.
3.3.3 2 Follicular adenoma
Sixteen follicular adenoma TMA cores were stained, and there was a 7- 
8-fold increase in MCM2 expression (median L.l. =4.15, range 0 - 41.2), when 
compared to normal thyroid tissue, and this was statistically significant (p < 
0.001) (Fig 3.15 A2). Ten tissue sections were stained, and these also 
showed an increase in MCM2 expression (median L.l. = 5.0, range = 1 - 25), 
Figure 3.18 B.
3.3.3 3 Atypical adenoma
Ten atypical adenoma TMA cores were stained, and there was a 7-8- 
fold increase in MCM2 expression (median L.l. = 4.65, range 0.7 - 32.3), when 
compared to normal thyroid tissue, and this was statistically significant (p < 
0.001) (Fig 3.15 B2).
3.3.3 4 Follicular carcinoma
A total of eight follicular carcinoma TMA cores were stained, and this 
group showed a smaller (5-fold) though still significant increase in MCM2 
expression when compared to normal thyroid tissue (median L.l. = 1.35, range
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0 - 29.7, p=0.002) (Fig 3.15 C2). A further eight tissue sections were stained, 
and similarly these tumours showed an increase in MCM2 expression which 
was smaller than that seen in the follicular adenomas (median L.l. = 1.75, 
range = 0 -14), Figure 3.18C.
3.3.3 5 Papillary carcinoma
A total of 26 papillary carcinoma TMA cores were stained, and these 
cancers showed the greatest increase in MCM2 staining when compared to 
normal tissue (median L.l. = 7.35, range 0 - 63, p < 0.001), as shown in (Fig 
3.15 D2). Seven papillary carcinoma tissue sections were also stained, and 
this group also showed a greater increase in MCM2 expression when 
compared to normal thyroid tissue and the follicular tumours (median L.l. = 
12.0, range = 2 -  53), Figure 3.18D.
3.3.3 6 Insular carcinoma
A total of 17 insular carcinoma TMA cores were stained. These 
tumours showed a 5-fold increase in MCM2 expression when compared to 
normal thyroid tissue, and this was also statistically significant (median L.l. = 5, 
range 0 - 20, p < 0.001) (Fig 3.15 E2, F2).
Chart 3.3 graphically represents as a box plot the range of MCM2 L.l. scores in 
the TMA cores for the follicular and atypical adenomas, and follicular, papillary 
and insular carcinomas. The vast majority of both benign and malignant 
tumours had a low MCM2 score (<10). However, the papillary carcinoma 
group had the highest MCM2 L.l. scores (>40). The TMA data is summarised 
in Table 3.2 and the tissue section data in Table 3.5.
Figure 3.18
H ▼ *> :»0 1f
Immunohistochemical staining with anti-MCM2 antibody of normal thyroid tissue (A), 
follicular adenoma (B), follicular carcinoma (C) and papillary carcinoma (D) tissue 
sections. Scale bar represents 200pm.
Chart 3.3 Box plot chart showing the range of MCM2 L.l. scores for cases within the first 
and third quartiles, and median values for the MCM2 L.l. score for normal 
thyroid, follicular and atypical adenoma, and follicular, papillary and insular 
TMA cores. The ‘whiskers’ represent the range of L.l. values of cases that fall 
within 1.5 times the inter-quartile range (IQR), ‘O’ represent the L.l. score of 
‘outlier’ cases whose L.l. score is 1.5 -  3 times the IQR and * ’ represent the 
L.l. scores of ‘extreme’ cases whose L.l. value is >3 times the IQR.
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Thyroid pathology
A = statistically significant result compared to normal thyroid (p < 0.05)
92
3.3.4 Cyclin A expression
3.3.4.1 Normal thyroid
A total of 68 normal thyroid TMA cores were stained with anti-cyclin A 
antibody, and cyclin A expression was very low in normal thyroid tissue 
(median L.l. = 0, range 0 -  0.7). Four normal thyroid tissue sections were also 
stained, and these were negative for cyclin A expression, Figure 3.19A.
3.3.4 2 Follicular adenoma
A total of 16 follicular adenoma TMA cores were stained. Although the 
cyclin A expression in these benign tumours was still low in absolute terms, 
there was an 8-fold increase when compared with normal thyroid tissue 
(median L.l. = 0.5, range 0 - 3.7) (Fig 3.15 A3). Ten tissue sections were 
stained, and these also showed a small increase in cyclin A expression 
(median L.l. = 0.20, range = 0 -  1.1), Fig 3.19B.
3.3.4 3 Atypical adenoma
A total of ten atypical adenoma TMA cores were stained and a smaller 
(5-6-fold) increase in cyclin A expression was seen when compared with 
normal thyroid tissue (median L.l. = 0, range 0 - 3.3) (Fig 3.15 B3).
3.3.4 4 Follicular carcinoma
A total of eight follicular carcinoma TMA cores were stained and a 5-6 - 
fold increase in cyclin A expression was seen when compared to normal 
thyroid tissue (median L.l. = 0.15, range 0 - 2 )  (Fig 3.15 C3). A further eight 
follicular carcinoma tissue sections were stained, and these showed a
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comparable increase in cyclin A expression when compared to normal thyroid 
tissue (median L.l. = 0.10, range = 0 -  1.8), Figure 3.19C.
3.3.4.5 Papillary carcinoma
I stained two micro-papillary carcinoma tissue sections with anti-cyclin A 
antibody, and observed a small up-regulation in cyclin A expression when 
compared to the surrounding normal tissue (Figure 3.11 A, B). I also stained a 
metastatic deposit from a papillary carcinoma, and this showed a considerable 
up-regulation of cyclin A in the tumour when compared to the surrounding 
normal tissue (Figure 3.13 B). A total of 26 papillary carcinoma TMA cores 
were stained and these tumours showed a greater up-regulation of cyclin A 
expression when compared to the follicular carcinomas (median L.l. = 0.5, 
range 0 - 6.7) (Fig 3.15 D3). Seven papillary carcinoma tissue sections were 
also stained, and these similarly showed a greater increase in cyclin A 
expression when compared to both normal thyroid tissue and the follicular 
tumours (median L.l. = 1.20, range = 0 -  5), Figure 3.19D.
3.3.4 6 Insular carcinoma
I stained six insular carcinoma tissue sections, and all tumours showed 
an up-regulation of cyclin A expression when compared to normal thyroid 
tissue (Figure 3.14 A2, B2, and C2). A total of 17 insular carcinoma TMA 
cores were stained. These carcinomas showed a much greater increase in 
cyclin A expression than the other thyroid tumour groups studied, with a 20- 
fold increase in cyclin A expression when compared to normal thyroid tissue 
(median 1.00, range 0 - 21.7, p<0.001) (Figure 3.15 E3, F3). This did not
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correlate with the low in comparison up-regulation of MCM2 expression seen in 
the insular carcinomas.
Chart 3.4 graphically represents as a box plot the range of cyclin A L.l. scores 
in the TMA cores for the follicular and atypical adenomas, and follicular, 
papillary and insular carcinomas. The vast majority of both benign and 
malignant tumours had a low cyclin A L.l. score (<5). However, the insular 
cancer group had tumours with much higher cyclin A L.l. scores when 
compared to the well-differentiated carcinomas. The TMA data is summarised 
in Table 3.3 and the tissue section data is summarised in Table 3.6.
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Figure 3.19 Immunohistochemical staining with anti-cyclin A antibody of normal thyroid tissue (A), 
follicular adenoma (B), follicular carcinoma (C) and papillary carcinoma (D) tissue 
sections. Scale bar represents 200pm.
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Chart 3.4 Box plot chart showing the range of Cyclin A L.l. scores for cases within the 
first and third quartiles, and median values for the Cyclin A L.l. score for 
normal thyroid, follicular and atypical adenoma, and follicular, papillary and 
insular TMA cores. The ‘whiskers’ represent the range of L.l. values of cases 
that fall within 1.5 times the inter-quartile range (IQR), ‘O’ represent the L.l. 
score of ‘outlier’ cases whose L.l. score is 1.5 -  3 times the IQR and ‘★’ 
represent the L.l. scores of ‘extreme’ cases whose L.l. value is >3 times the 
IQR.
25.00-
20 .00 -
15.00-
10.00 -
5.00-
0.00-
Normal Follicular Atypical Follicular Papillary Insular
Thyroid Adenoma Adenoma Carcinoma Carcinoma Carcinoma
Thyroid pathology
A = statistically significant result compared to normal thyroid (p < 0.05)
97
Table 3.1 p16 Intensity Distribution (I.D.) mean score, range and standard error (S.E.) of
mean I.D. values for the TMA cores and tissue sections
Thyroid pathology No. cases Median I.D. Mean I.D. I.D. range S.E. mean
Normal Thyroid 68 0.05 0.17 0-1 .70 0.04
Follicular Adenoma 16 0.50 0.70 0-1.90 0.12
Atypical Adenoma 10 1.60 1.52 0.25-0.95 0.31
Follicular Carcinoma 16 1.15 1.26 0.10-2.40 0.13
Papillary Carcinoma 33 0.75 0.93 0-2.70 0.16
Insular Carcinoma 17 1.00 1.06 0-2.70 0.20
Table 3.2 MCM2 Labelling Index (L.l.) mean score, range and standard error (S.E.) of 
mean L.l. values for the TMA cores and tissue sections
Thyroid pathology No. cases Median L.l. Mean L.l. L.l. range S.E. mean
Normal Thyroid 68 0 0.63 0-14.30 0.23
Follicular Adenoma 26 4.15 8.00 0-41.20 1.93
Atypical Adenoma 10 4.65 7.15 0.7-32.30 2.87
Follicular Carcinoma 16 1.45 4.13 0-29.70 1.90
Papillary Carcinoma 33 9.00 17.85 0-63.00 3.31
Insular Carcinoma 17 5.00 5.92 0-20.00 1.32
Table 3.3 Cyclin A Labelling Index (L.l.) mean score, range and standard error (S.E.) of 
mean L.l. values for the TMA cores
Thyroid pathology No. cases Median L.l. Mean L.l. L.l. range S.E. mean
Normal Thyroid 68 0 0.04 0-1.40 0.02
Follicular Adenoma 26 0.3 0.65 0-3.70 0.18
Atypical Adenoma 10 0 0.50 0-3.30 0.35
Follicular Carcinoma 16 0.10 0.54 0-2.00 0.18
Papillary Carcinoma 33 0.7 1.28 0-6.70 1.29
Insular Carcinoma 17 1.00 3.34 0-21.70 1.40
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3.3.5 Co-expression of MCM2 and cyclin A 
The majority of normal thyroid tissue sections and TMA cores did not express 
either MCM2 or cyclin A protein. There was no significant correlation between 
these two proliferative markers (Spearman rank -0.108, p = 0.384), Chart 3.5.
Whilst MCM2 was slightly up-regulated in the atypical adenomas, cyclin A 
expression was negligible in eight out of 10 adenomas (Spearman rank 0.196, 
p = 0.588), Chart 3.6.
The follicular adenoma tissue sections and TMA cores showed a much larger 
increase in MCM2 expression compared to normal thyroid tissue. Cyclin A 
was also up-regulated in this tumour group in comparison to normal thyroid 
tissue, although the increase was low in comparison to that of MCM2. There 
was a statistically significant correlation between the expression of these 
proteins in the follicular adenomas (Spearman rank 0.627, p = 0.001), Chart 
3.7.
The follicular carcinoma group also expressed MCM2 at a higher level that 
normal thyroid tissue, but the increase was smaller than that seen in the 
follicular adenomas. Cyclin A was also up-regulated, at a similar level to the 
follicular adenomas. There was so significant correlation between the 
expression of these proteins (Spearman rank 0.208, p = 0.446), Chart 3.8.
The papillary carcinomas had the greatest up-regulation of MCM2 expression 
out of all the tumour groups analysed, and this was seen in both the tissue 
sections and the TMA cores. There was also an increase in cyclin A
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expression when compared to the follicular tumours, but this was not 
correlated with MCM2 expression (Spearman rank -0.179, p = 0.361), Chart 
3.9.
In contrast, the insular carcinomas had a lower level of MCM2 expression 
when compared to the other tumour groups, but had the highest level of cyclin 
A expression (Spearman rank -0.078, p = 0.086), Chart 3.10. However the two 
tumours with the highest cyclin A scores had the highest and the lowest MCM2 
scores.
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Chart 3.5 Scatter chart showing MCM2 and cyclin A expression in the normal thyroid
TMA cores
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Chart 3.6 Scatter chart showing MCM2 and cyclin A expression in the atypical adenoma 
TMA cores
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Chart 3.7 Scatter chart showing MCM2 and cyclin A expression in the follicular adenoma
tissue sections (o) and TMA cores ( ± )
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Chart 3.8 Scatter chart showing MCM2 and cyclin A expression in the follicular 
carcinoma tissue sections (o) and TMA cores (* )
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Chart 3.9 Scatter chart showing MCM2 and cyclin A expression in the papillary
carcinoma tissue sections (o) and TMA cores ( * )
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Chart 3.10 Scatter chart showing MCM2 and cyclin A expression in the insular carcinoma 
TMA cores
60.00
5 0 .0 0 -
£  4 0 .0 0 -
-J
CM 3 0 .0 0 -
20 00
10.00
0.00
25.0020.0015.0010.005.000.00
cyclin A L.l. score
103
3.3.6 Co-expression of p16 and MCM2
The vast majority of normal thyroid tissue sections and TMA cores did 
not express either MCM2 or p16 protein. There were a couple of cases which 
expressed p16, and this was not correlated with an increase in MCM2 
expression, Chart 3.11.
p16 was up-regulated in the atypical adenoma TMA cores compared to normal 
thyroid tissue, there was only a small increase in MCM2 expression, and this 
was not a significant correlation (Spearman rank -0.018, p = 0.96) Chart 3.12.
There was a similar increase of both p16 and MCM2 expression in the follicular 
adenoma tissue sections and TMA cores, Chart 3.13. This was a negative (but 
not statistically significant) correlation (Spearman rank -0.054, p = 0.793).
The follicular carcinomas, in contrast to the follicular adenomas, had a smaller 
up-regulation of MCM2 when compared to the adenomas, and this was 
observed in both the tissue sections and the TMA cores. The increase in 
MCM2 expression was not correlated with the observed increase in p16 
expression (Spearman rank 0.084, p = 0.757), Chart 3.14.
The papillary carcinoma tissue sections and TMA cores had the highest 
increase in MCM2 expression when compared to normal thyroid tissue, and 
this could not be correlated with the increase in p16 expression in these 
tumours, since the cases with the highest MCM2 L.l. scores either very high or 
very low p16 I.D. scores (Spearman rank 0.116, p = 0.548), Chart 3.15.
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The insular carcinomas showed a small increase in MCM2 expression when 
compared to the papillary carcinomas, and this group had the widest range of 
p16 I.D. scores, and there was no significant correlation between expression of 
these proteins in this tumour group (Spearman rank 0.422, p = 0.92), Chart 
3.16.
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Chart 3.11 Scatter chart showing p16 and MCM2 expression in the normal thyroid TMA
cores
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Chart 3.12 Scatter chart showing p16 and MCM2 expression in the atypical adenoma 
TMA cores
6 0 .0 0 -
5 0 .0 0 -
£  4 0 .0 0 -
- J
CM 3 0 .0 0 -
20 .00 -
10 .00 -
0.00-
2.50 3.001.50 2.000.50 1.000.00
p16 I.D. score
106
Chart 3.13 Scatter chart showing p16 and MCM2 expression in the follicular adenoma
tissue sections (o) and TMA cores (± )
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Chart 3.14 Scatter chart showing p16 and MCM2 expression in the follicular carcinoma 
tissue sections (o) and TMA cores (* )
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Chart 3.15 Scatter chart showing p16 and MCM2 expression in the papillary carcinoma
tissue sections (o) and TMA cores ( * )
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Chart 3.16 Scatter chart showing p16 and MCM2 expression in the insular carcinoma 
TMA cores
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3.3.7 Co-expression of p16 and cyclin A 
The vast majority of normal thyroid TMA cores and all four tissue sections did 
not express cyclin A expression, and most of these cases were also negative 
for p16 expression. There were a couple of TMA cores that did express p16, 
and the pathological report for these specimens simply labelled them as ‘not 
cancer’ (Chart 3.17).
p16 was up-regulated in the atypical adenomas whilst cyclin A expression 
remained low, with eight out of 10 adenomas not expressing cyclin A 
(Spearman rank -0.035, p = 0.924) (Chart 3.18).
There was a small increase in cyclin A expression in the follicular adenoma 
tissue sections and TMA cores when compared to normal thyroid tissue, and 
this was not significantly correlated with the observed up-regulation of p16 
seen in these tumours (Spearman rank 0.062, p = 0.763) (Chart 3.19).
The follicular carcinoma group also showed a small increase in cyclin A 
expression, at a similar level to that seen in the follicular adenomas. Similarly, 
this was not correlated with the significant increase in p16 expression seen in 
these cancers (Spearman rank 0.099, p = 0.715) (Chart 3.20).
There was also an up-regulation of both p16 and cyclin A expression in the 
papillary carcinoma tissue sections and TMA cores. However, unlike the 
follicular adenomas and carcinomas, this was a statistically significant positive 
correlation (Spearman rank 0.47, p = 0.012), (Chart 3.21).
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The insular carcinoma group also expressed p16 and cyclin A at a higher level 
than that seen in normal thyroid tissue, although there was not a significant 
correlation between the two proteins (Spearman rank -0.078, p = 0.767) (Chart 
3.22). One case had a much higher level of cyclin A expression, and this was 
in an insular carcinoma that did not express p16, as shown on the scatter 
chart. This tumour was identified as being a particularly aggressive tumour 
with a p53 mutation (cyclin A L.l. = 21.7, p16 I.D. = 0).
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Chart 3.17 Scatter chart showing p16 and cyclin A expression in the normal thyroid TMA
cores
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Chart 3.18 Scatter chart showing p16 and cyclin A expression in the atypical adenoma 
TMA cores
25.00
20.00
O  15.00
O  10.00 
>» o
o.oo- a
0.00 1.50
p16 I.D. score
111
Chart 3.19 Scatter chart showing p16 and cyclin A expression in the follicular adenoma
tissue sections (o) and TMA cores ( * )
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Chart 3.20 Scatter chart showing p16 and cyclin A expression in the follicular carcinoma 
tissue sections (o) and TMA cores ( * )
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Chart 3.21 Scatter chart showing p16 and cyclin A expression in the papillary carcinoma
tissue sections (o) and TMA cores ( * )
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Chart 3.22 Scatter chart showing p16 and cyclin A expression in the insular carcinoma 
TMA cores. The highlighted point (<^ ) represents a particularly aggressive 
tumour with a p53 mutation
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3.4 Discussion
Our study is the first to define p16 protein expression patterns in vivo 
throughout the neoplastic progression of thyroid tumours, and to correlate this 
with p16 expression in an in vitro thyrocyte tumour model. This study is also 
the first to demonstrate the down-regulation of p16 expression in insular and 
anaplastic carcinomas. The panel of thyroid tumours that I studied represents 
the largest tumour group to date that has been investigated for p16 protein 
expression.
I investigated the complete thyroid tumorigenesis pathway, starting with a 
thyrocyte culture model, progressing from normal thyroid tissue through to un­
differentiated anaplastic thyroid carcinoma. I also correlated p16 expression 
with the proliferation status of the thyroid tumour groups by analysing the 
expression of the proliferation markers MCM2 and cyclin A, to confirm whether 
loss of p16 expression is related to an increase in tumour proliferation.
I initially hypothesised that p16 expression would be induced in vivo in follicular 
adenomas, and that this expression would be down-regulated in follicular and 
papillary carcinomas, in keeping with tumour progression to a malignant 
phenotype. Consistent with this hypothesis generated by our in vitro studies, 
the data presented here show that p16 protein expression is indeed switched 
on in early stage thyroid tumorigenesis.
I had access to a large number of normal thyroid tissue specimens, and the 
vast majority of these did not show p16 expression, with a median p16 I.D. 
score of 0.05. The TMA cores and the full tissue sections had equivalent
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results. There were four cases of normal thyroid tissue in the TMA group that 
did show an up-regulation of p16 protein expression. The pathology report for 
these cases simply listed them as ‘not cancer’ instead of normal thyroid tissue; 
therefore it is difficult to draw conclusions regarding the mechanism for the up- 
regulation in these cases.
In agreement with my hypothesis, the follicular adenomas demonstrated an up- 
regulation in p16 protein expression, to correspond with the increase in p16 
expression seen in RAS-induced thyrocyte colonies which genotypically and 
phenotypically resemble follicular adenomas. This was weak or moderate 
expression in both the TMA cores and the full tissue sections, with a mean 
TMA I.D. score of 0.50.
The atypical adenomas as a group also demonstrated a statistically significant 
up-regulation in p16 expression, with a mean p16 I.D. score of 1.6 (p<0.001), 
although there was a wide variety in the I.D. scores for these tumours. Some 
cases only had very weak staining in a small proportion of cells, whereas 
others had very intense staining, and some of the highest p16 I.D. scores out 
of all the tumour groups studied. The exact biological nature of atypical 
adenomas is unclear, as phenotypically they resemble thyroid carcinomas but 
do not have the invasive features of either follicular or papillary cancers. Tzen 
et al., (2003) suggested that they may represent a direct precursor of 
anaplastic carcinoma. This pre-malignant behaviour might explain the wide 
range of values for this tumour group.
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Following on from our in vitro work, I hypothesised that p16 expression would 
be down-regulated in thyroid carcinomas, and that this would be correlated 
with an increase in tumour proliferation, as has been reported in many 
epithelial tumours. Contrary to the hypothesis, however, there was no 
evidence of any fall-off in p16 expression between the follicular adenomas and 
the well-differentiated follicular carcinomas.
p16 staining was still present in the follicular cancer group, and this expression 
was seen in the majority of the TMA cores and tissue sections, with almost 
90% cases showing moderate p16 staining (median p16 I.D. score 1.15). 
There was a statistically significant increase in p16 expression when compared 
with normal thyroid tissue (p<0.001). Surprisingly, the follicular carcinomas 
also showed an increase in p16 expression when compared to the follicular 
adenomas, and this was unexpected.
The two micro-papillary carcinomas showed an up-regulation of p16 
expression. These tumours are occult, indolent carcinomas, and therefore 
behave similarly to the follicular adenomas, although they do have the potential 
to invade and metastasise. The up-regulation in p16 expression in these 
carcinomas is consistent with the hypothesis that p16 is induced in pre- 
malignant or early stages of tumorigenesis, and therefore I initially predicted 
that p16 would be down-regulated in the papillary carcinomas.
However, like the follicular carcinomas, both the papillary carcinoma TMA 
cores and tissue sections showed an up-regulation in p16 expression 
compared to normal thyroid, with a median I.D. score of 0.75, (p=0.001). This
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tumour group had a wider range of p16 I.D. scores than the follicular 
carcinomas, and also had higher p16 I.D. scores than those seen in the 
follicular cancer group. There was a group of papillary TMA cores that 
demonstrated a down-regulation or loss of p16 expression.
Papillary carcinomas develop from a different set of genetic mutations than the 
follicular tumours. Together with RAS mutations, they also arise from BRAF 
mutations and RET/PTC rearrangements. This may be one of the reasons for 
the greater variation in p16 I.D. scores in the papillary carcinomas, and the 
level of up- or down-regulation of p16 expression may depend on whether the 
tumour has a RAS, BRAF or RET mutation.
One reason for the down-regulation or loss of p16 expression seen in a 
subgroup of the papillary carcinomas could be the difference in differentiation 
between this group and the remainder of the cancers. Papillary carcinomas 
can be either well- or poorly-differentiated, with the poorly-differentiated 
cancers having a worse clinical prognosis. If p16 is lost at a later stage in 
thyroid tumorigenesis, I would expect the poorly-differentiated tumours to lose 
p16 expression. I am not able to confirm whether this hypothesis is correct, 
because the pathology reports for the TMA cores do not mention whether each 
tumour is well-or poorly differentiated.
Insular carcinomas are poorly-differentiated tumours, and develop at a later 
stage in the thyroid tumorigenesis pathway. They are therefore a more 
aggressive tumour with a higher proliferation rate that the well-differentiated 
follicular and papillary tumours. This tumour group, like the atypical adenomas
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demonstrated a wide range of p16 I.D. values. As a group, there was a 
statistical increase in p16 expression in the insular carcinoma TMA cores when 
compared to normal thyroid tissue (median p16 I.D. score 1.00, p<0.001).
However, the insular cancers could be divided into three groups based on their 
p16 I.D. scores. Half the tumours showed weak or moderate staining similar to 
that seen in the follicular and papillary carcinomas. One quarter of the tumours 
demonstrated intense p16 staining, at a level comparable to that of the atypical 
adenomas, and these tumours had higher scores than either the follicular or 
papillary carcinomas. The final quarter of cases had either a down-regulation 
or loss of p16 expression, similar to that seen in the subgroup of papillary 
cases. The analysis of the insular carcinoma full tissue sections also 
demonstrated two sub-groups, one with an increase in p16 expression 
compared to the follicular and papillary carcinomas, and one with a complete 
loss of p16 expression.
Finally, I also performed p16 immunohistochemistry on two anaplastic 
carcinomas, both derived from a papillary carcinoma, with both anaplastic and 
papillary tumours represented on each slide. The papillary carcinoma sections 
showed an up-regulation in p16 expression, and the anaplastic carcinoma 
sections showed a down-regulation in p16 expression compared to the 
neighbouring papillary tumour. The data from the insular and anaplastic 
carcinomas suggests that a down-regulation or loss of p16 expression is only 
seen at a late stage in thyroid tumorigenesis, in the poorly- or undifferentiated 
carcinomas.
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I correlated the expression of p16 to the proliferation status of the thyroid 
tissue using two proliferation markers, MCM2 and cyclin A. MCM2 belongs to 
a family of six proteins (MCM 2 - 7 )  that are essential for the initiation and 
regulation of DNA replication (Mendez and Stillman, 2000; Labib et al., 2001). 
They were first discovered in yeast, and form part of the replicative complexes 
(Meng et al., 2001) ensuring that chromatin is competent for replication. After 
S phase, the MCM proteins irreversibly dissociate from chromatin, so that DNA 
replication only occurs once during each cell cycle.
The proteins are expressed in all phases of the cell cycle, and their expression 
depends on the proliferative state of the cell. They are not present in 
quiescent or terminally differentiated cells (Madine et al., 2000; Stoeber et al., 
2001). The presence of MCM2 protein expression implies that a cell is either 
replicating, or has the potential to replicate. Their expression level has been 
inversely correlated with the degree of tumour differentiation (Stoeber et al., 
2001).
MCM2 expression was negligible in normal thyroid specimens, and this was 
expected since the thyroid is a quiescent tissue. The follicular and atypical 
adenoma groups both showed a seven-to-eight fold increase in MCM2 
expression, and this was a significant increase when compared to normal 
thyroid tissue.
The follicular carcinoma group also demonstrated an up-regulation of MCM2 
expression. Although this was smaller than that seen in the adenoma groups, 
it was still significantly greater than normal thyroid tissue. The papillary
119
carcinoma group had the greatest up-regulation of MCM2 expression, with a 
20-fold increase compared to normal thyroid tissue, suggesting that papillary 
carcinomas have a greater potential to proliferate than follicular carcinomas. 
The insular carcinomas also had an up-regulation of MCM2 expression, but 
this was similar to that seen in the follicular adenomas and carcinomas.
The expression of MCM2 protein has been assessed in the literature as a 
potential marker to identify neoplasia. Freeman et al., (1999), analysed MCM2 
expression in a wide variety of normal and malignant tissues, and showed that 
in normal tissues, MCM2 protein expression was confined to proliferative 
compartments, whilst it was expressed in the majority of dysplastic and 
malignant tissues. MCM2 proteins may have an important role in tumour 
detection, with Williams et al., (1998), using positive MCM2 staining to identify 
both low-grade and high-grade pre-malignant cervical carcinomas from normal 
cervical tissue. MCM2 staining has also been used to detect bladder 
carcinoma cells in urine (Stoeber et al., 1999). It has been highlighted as a 
potential molecular marker of clinical outcome in prostate carcinoma (Meng et 
al., 2001) and breast carcinoma (Gonzalez et al., 2003), and as a tool for 
detection of colorectal carcinoma in stool (Davies, R.J. et al., 2002).
My data suggests that the observed up-regulation of MCM2 expression seen in 
the follicular adenomas and follicular and papillary carcinomas could potentially 
be used as a molecular marker to identify thyroid neoplasms from normal 
thyroid tissue. However it is unlikely that MCM2 could be used to accurately 
identify follicular carcinomas from follicular adenomas, since both tumour 
groups had similar levels of MCM2 expression.
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The second proliferation marker that I used was cyclin A. This protein is 
maximally expressed during the S-phase of the cell cycle (Pines and Hunter, 
1989, Yam et al., 2002). Cyclin A is synthesized during DNA replication and at 
the G2/M transition point of the cell cycle (Bukholm et al., 2003). It is involved 
in both transcription and replication, and is a marker for cells that are in the S- 
phase of the cell cycle (Pagano et al., 1992; Zindy et al., 1992), and therefore 
is expressed in cells that are actively proliferating.
Cyclin A expression, like MCM2 expression, was negligible in normal thyroid 
specimens, and this was expected because the thyroid is a quiescent tissue. 
The follicular adenoma group showed an eight fold increase in cyclin A 
expression. This was also expected because follicular adenomas are slow- 
growing, indolent tumours. Surprisingly, eight out often atypical adenomas did 
not express cyclin A protein. These tumours are thought to be an intermediate 
phase between normal thyroid tissue and anaplastic tissue, and I therefore 
expected them to have a higher proliferation rate than the benign adenomas. 
One explanation for the low proliferation rate is that the atypical adenomas are 
being kept ‘in check’ until further genetic mutations are acquired before de­
differentiation and a subsequent increase in proliferation rate.
The follicular cancers, like the follicular adenomas, showed a small increase in 
cyclin A expression when compared to normal thyroid tissue (median L.l. = 
0.10). The two micro-papillary carcinomas that were analysed over-expressed 
cyclin A when compared to the adjacent normal thyroid tissue, and the TMA 
papillary carcinomas also over-expressed cyclin A, although this was also at a 
low level, similar to that seen in the follicular adenomas and carcinomas. This
121
data is in keeping with the indolent nature of both of these thyroid cancer 
types.
In the insular carcinoma group however there was a much larger, 20-fold 
increase in cyclin A expression when compared to normal thyroid tissue, in 
contrast to the relatively low levels of MCM2 protein expression seen in this 
tumour group. The insular carcinoma full issue sections also demonstrated a 
considerable up-regulation of cyclin A expression when compared to the 
adjacent normal thyroid tissue. This data is in keeping with the more 
aggressive nature of these tumours, and their higher proliferative rate.
Cyclin A expression has been studied in the literature as an alternative 
molecular marker of neoplasia or clinical prognosis. Scott et al., (2003), 
analysed cyclin A expression in colorectal carcinomas, and observed an 
increase in the expression of cyclin A in colonic adenomas and carcinomas 
when compared to normal colonic tissue, which suggests an increased entry 
into S-phase for malignant colonic cells. Scott’s study compared cyclin A 
expression with MCM2 expression in colorectal tumours, and observed an 
increase in MCM2 expression from 54.9% to 66.8% when comparing normal 
colon with adenocarcinoma, and an increase in cyclin A expression from 
19.7% to 37.4%, with a significant positive correlation between the two 
proliferative markers. Furihata et al., (1997) showed an increase in cyclin A 
expression in transitional cell carcinoma (TCC) of the renal pelvis, and over­
expression was related to a poorer prognosis. Cyclin A over-expression was 
also noted in dysplastic lesions, indicating that this may be an early event in 
TCC carcinogenesis.
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My analysis of these two proliferation markers in thyroid adenomas and 
carcinomas has added to the few studies in the literature using MCM2 and 
cyclin A expression to assess thyroid cancer proliferation. Mehrota et al., 
(2006), observed an up-regulation of MCM2 expression in papillary and 
follicular carcinomas when compared to follicular adenomas, and Guida et al., 
(2005) showed an up-regulation of MCM5 and MCM7 in anaplastic thyroid 
carcinoma, with negligible staining in normal thyroid tissue and papillary 
carcinomas. Ito et al., (2002), observed that cyclin A over-expression was 
significantly linked to carcinoma differentiation, with anaplastic carcinomas 
having a greater expression than follicular and papillary carcinomas, 
suggesting that this protein is involved in the rapid progression of poorly- 
differentiated and un-differentiated thyroid tumours.
My data suggests that the observed up-regulation of cyclin A expression could 
not be reliably used as a molecular marker of neoplasia, because of the 
negligible expression of cyclin A protein in the follicular adenomas. It also 
appears that cyclin A expression would not be a useful indicator of clinical 
prognosis, because the expression levels were generally similar in the well- 
differentiated and the poorly-differentiated tumours, although several of the 
insular carcinomas did have far greater levels of cyclin A expression than the 
follicular and papillary carcinomas.
There was not a significant correlation between the expression of p16 and both 
MCM2 and cyclin A in the follicular adenomas and follicular carcinomas. This 
was expected because both of these tumours are slow-growing with a low
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proliferative rate. I demonstrated a significant positive correlation between p16 
expression and cyclin A expression in the papillary carcinomas, although the 
level of cyclin A expression remained at a low level when compared to the 
insular carcinomas.
It is only at the more aggressive stages of poorly-differentiated (insular) or 
undifferentiated (anaplastic) carcinoma that our data suggests the presence of 
abnormalities of the p16 pathway, as evidenced by loss of expression in some 
tumours or, paradoxically by very high-level expression in others, the latter 
being a well-recognised secondary response to downstream defects such as 
loss of pRb function. Unfortunately, these relatively rare tumours have not 
been sufficiently investigated at the genetic level to provide corroborating 
evidence.
The suggestion that the inhibitory effect of p16 is lost in these cancers is highly 
consistent with their dramatically increased proliferative rate. The analysis of 
the insular carcinoma group lends some evidence towards this. Those insular 
tumours with a high p16 I.D. score had a low cyclin A L.l. value, and vice 
versa, suggesting that loss of p16 expression correlates with an increase in 
proliferation. Interestingly, this increase in cyclin A expression in the poorly- 
differentiated carcinomas was not matched by the expression of MCM2, which 
was elevated in all stages of thyroid tumorigenesis. One explanation for this 
may be that MCM2 expression, unlike cyclin A, can be elevated in cells which 
although exited from GO are arrested in G1 and are not actively cycling 
(Stoeber et al., 2001).
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There are potential problems that can arise when analysing TMA cores, 
because only a tiny portion of the tumour is represented with each core. To 
improve the accuracy of immunohistochemical results, three cores were taken 
from each tumour and an average p16 I.D. or MCM2 / cyclin A L.l. score was 
calculated for each tumour. I assumed that the cores are an accurate 
representation of the original tissue. However, if a tumour only has a small 
area of focal staining, which is not included in a core, that core will not provide 
a true depiction of p16 protein expression in that tumour. Conversely, if a core 
is taken from such a focus of staining in an otherwise negatively-staining 
tumour, that core will also falsely represent the staining pattern in that tumour. 
By performing immunohistochemistry on full tissue sections I was able to 
corroborate my results with those of the TMA cores, and both sets of slides 
produced similar patterns of p16 expression in follicular adenomas, follicular 
and papillary carcinomas.
I only had access to a limited number of TMA slides, and was therefore unable 
to repeat the staining to confirm results that were either a lot higher or lower 
than those obtained for the rest of the cores within a tumour group. I was 
blinded to the pathological diagnoses of each TMA core to reduce bias when 
scoring each core for p16, MCM2 and cyclin A expression. However I was not 
blinded to the pathology of the full tissue sections, and this is a potential 
source of bias when interpreting the immunostaining for these slides.
Care must also be taken when comparing my data with that of other published 
studies. The presence of conflicting results in the literature can be attributed to 
different immunohistochemistry protocols and the use of different antibodies.
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Another factor that can produce discrepant results between studies is the use 
of different scoring systems to interpret the staining pattern. Therefore 
conclusions can only accurately be drawn when comparing studies that used 
the same methodology and scoring systems, and this can be hindered if these 
are not accurately described.
Several genetic analyses of p16 in thyroid tumour cell lines and primary thyroid 
tumours have been published. The majority of these studies reported that a 
structural alteration of the p16 gene was common in thyroid tumour cell lines. 
Calabro et al., (1996), reported deletions, point mutations and structural gene 
alterations in four thyroid cancer cell lines, and Jones et al., (1996), observed 
homozygous deletion of the entire p16 coding sequence in both follicular and 
papillary cancer cell lines. Elisei et al., (1998), reported point mutations, 
deletions and loss of heterozygosity in cell lines from poorly and 
undifferentiated thyroid carcinoma cell lines. This suggests that p16 may be a 
key tumour suppressor gene in early thyroid tumorigenesis, although Yane et 
al., (1996), found no evidence of gene deletion or mutation in thyroid cancer 
cell lines.
In contrast, alteration of the p16 gene appears to be a rare event in primary 
well-differentiated thyroid tumours. Elisei et al., (1998), observed a point 
mutation in one of 12 papillary carcinomas and no mutations in follicular 
adenomas. Neither Yane et al., (1996), nor Calabro et al., (1996), found 
evidence of p16 genetic abnormalities in primary follicular, papillary and 
anaplastic thyroid carcinomas. Similarly, Tung et al., (1996), only found p16
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mutation (loss of heterozygosity) in the minority of follicular and papillary 
thyroid tumours; however this study reported p16 mutations in two out of four 
anaplastic tumours.
Hypermethylation is an alternative mechanism for gene inactivation. Boltze et 
al., (2003), used a methylation-specific polymerase chain reaction to analyse 
p16 methylation in thyroid tumorigenesis. They detected this in 13% normal 
thyroid tissue, 33% follicular adenomas, 44% papillary and 50% follicular 
carcinomas, and in 85% undifferentiated carcinomas and this correlated with 
the loss of p16 protein expression. Their data suggests that p16 methylation is 
a common early event in thyroid tumorigenesis, and is associated with 
dedifferentiation of thyroid cancers. They also demonstrated p16 
immunohistochemical expression in 87% normal tissue, in contrast to my own 
results. Hoque et al., (2005) also studied p16 promoter hypermethylation in 
follicular adenomas and follicular and papillary carcinomas. This group failed 
to detect p16 hypermethylation in either the adenomas or the carcinomas, in 
contrast to the results obtained by Boltze’s group.
Although hypermethylation of the p16 gene has been detected by Boltze et al., 
(2003), in both well-differentiated and undifferentiated thyroid carcinomas, 
Hoque et al., (2005) were unable to detect hypermethylation well-differentiated 
carcinomas, and it is therefore difficult to ascertain the true prevalence of p16 
promoter hypermethylation in thyroid tumorigenesis in light of such conflicting 
results.
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Our published observations with regard to p16 expression in thyroid tumours 
(Ball et al., 2007) are consistent with several published studies at the DNA and 
RNA level, which indicate that genetic abnormalities of p16 such as point 
mutations and loss of heterozygosity in benign tumours and well-differentiated 
cancers are rare (Calabro et al.,1996; Tung et al.,1996; Yane et al.,1996; 
Elisei et al.,1998), in contrast to the frequent inactivation of p16 by gene 
deletion, mutation or methylation in thyroid cancer cell lines in vitro (Wyllie et 
al., 1995; Calabro et al.,1996; Elisei et al.,1998). Although hypermethylation of 
the p16 gene in vivo has been detected by Boltze et al., (2003), in both well- 
differentiated and undifferentiated thyroid carcinomas, Hoque et al., (2005) 
were unable to detect hypermethylation in well-differentiated carcinomas, and 
it is therefore difficult to ascertain the true prevalence of p16 promoter 
hypermethylation in thyroid tumorigenesis in light of such conflicting results.
Our results are also in agreement with a more limited, immunohistochemical 
study of p16 in thyroid tumours (Ferenc et al., 2004a). This group detected 
p16 protein over-expression in 19.3% follicular adenomas and 66.7% follicular 
carcinomas. Several studies have been published that have analysed p16 
expression using immunohistochemistry in thyroid tumours following the 
submission of my own work for publication. Barroeta et al., (2006), analysed 
53 benign and 37 malignant follicular-derived thyroid tumours, and reported 
p16 expression in 2% adenomas and 46% carcinomas. One reason for the 
low rate of expression in the benign tumour group is their high cut-off point for 
a positive result of 25% cells showing positive staining. Ferru et al., (2006), 
reported similar results to my own findings, with over-expression of p16 in 
follicular adenomas, and follicular and papillary carcinomas. Lam et al.,
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(2007), analysed 44 cases of papillary thyroid carcinoma and observed p16 
over-expression in 89% cases. This data gives support to my own data which 
shows that p16 is genuinely up-regulated in early thyroid tumorigenesis, and 
that this expression of the protein increases in well-differentiated thyroid 
tumours.
Although it was initially speculated that these alterations of the p16 gene may 
be due to a cell culture artefact, loss of p16 function and/or expression has 
been clearly demonstrated in many primary carcinomas. In non-small cell lung 
carcinomas, loss of p16 expression is demonstrated in 36.3 -  43% of tumours, 
and is associated with a worse clinical prognosis (Kashiwabara et al., 1998; 
Huang et al., 2000; Cheng et al., 2003; Geradts, 2003). Hu et al., (1997), 
Schutte et al., (1997), Kawesha et al., (2000) and Gerdes et al., (2002) showed 
loss of p16 expression in 41.9 - 87% pancreatic carcinomas, and an 
association with worse histological grade, shorter survival times and 
metastasis in those cases with loss of p16 expression.
Our finding that the loss of p16 expression / function is correlated with 
relatively “late” stages of tumorigenesis is also consistent with data from other 
tumour types, notably colorectal cancer and malignant melanoma. Palmqvist 
et al., (2000), and Zhao et al., (2003) demonstrated low p16 expression in 
normal colonic mucosa, an up-regulation of p16 expression in colorectal 
adenomas, and a further increase in p16 staining intensity in the majority of 
colorectal carcinomas although a select sub-group of colorectal cancers did 
show loss of p16 expression, and Palmqvist questioned whether this loss of
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p16 expression was a lack of initial up-regulation rather than a genuine down- 
regulation of expression.
This finding was also demonstrated by Dai et al., (2000), who analysed cyclin 
A and p16 expression in colonic neoplasms, and reported that colorectal 
cancers demonstrated an up-regulation in p16 expression which correlated 
inversely with cyclin A expression and therefore proliferation. The increase in 
cyclin A expression was also correlated with a worse prognosis, and p16 and 
cyclin A staining were mutually exclusive, suggesting that p16 is functional in 
inhibiting the G1/S phase checkpoint of the cell cycle and thereby preventing 
proliferation of a tumour.
Likewise, in malignant melanomas both Reed et al., (1995), and Polsky et al., 
(2001), observed that loss of p16 expression was not essential for tumour 
progression, with the majority of melanomas-in-situ and primary invasive 
tumours retaining p16 protein expression. Reed showed that loss of p16 
expression was related to the ability for a melanoma to metastasise, with 52% 
primary invasive tumours and 72% metastatic tumours showing a partial or 
complete loss of p16 expression.
There are several potential explanations for the variations seen in p16 
expression over the spectrum of thyroid tumorigenesis. Because p16 is not 
normally expressed in human tissues, the up-regulation seen in adenomas and 
carcinomas in a wide range of human malignancies must at least partly be in 
response to the oncogenic events involved in tumour initiation. Expression of
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the p16 protein appears to be driven by features of the neoplastic state. This 
may simply be in response to an increase in proliferation of the tumour cells, 
and therefore p16 stalls the cells at the G1/S phase checkpoint, allowing the 
cell the chance to repair initiating neoplastic genetic alterations, or p16 may act 
through other pathways, as it has been linked to angiogenesis and anoikis 
(loss of epithelial cell anchorage) from in vitro studies, as reviewed by Rocco 
and Sidransky (2001).
Another suggestion is that the cells lose the expression of a downstream 
protein in the Rb pathway, such as Rb protein itself. Cells without a p16 
mutation would continue to over-express p16, but this would be ineffectual in 
the presence of abnormal Rb protein. However those cells that had acquired a 
p16 mutation would not have a selective advantage because of the 
downstream mutation in the Rb pathway. Alternatively, there may be an 
alternative pathway implicated in tumorigenesis that functions independently of 
the Rb pathway, and therefore a p16 gene mutation would also give the clone 
of cells a selective advantage.
It is of course possible that the changes in p16 observed here do not reflect 
any causal role in tumour progression. However, this seems extremely 
unlikely, given the wealth of experimental evidence both from in vitro and 
experimental animal studies supporting the importance of p16 as a tumour 
suppressor gene and indeed the albeit-indirect evidence here for abnormality 
of the pathway in late stage thyroid tumours. We propose therefore the 
following model.
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We suggest that p16 expression is induced in early stage tumours as a 
response to oncogene activation (e.g. RAS or RET) and / or an inappropriately 
extended proliferative lifespan (Jones et al., 2000; Skinner et al., 2004). The 
expression of this cell cycle inhibitor reaches a level sufficient to severely limit, 
but not to totally block oncogene-induced proliferation. This restraint is 
maintained even if and when further oncogenic events result in malignant 
transformation (conferring the ability to invade and metastasise) hence 
explaining the characteristically slow growth of well-differentiated thyroid 
cancers. In rare cases however, loss of the p16 pathway subsequently occurs, 
either through loss of p16 expression itself, or through downstream lesions 
(resulting in paradoxical increase in expression) which allows a much more 
rapid and aggressive pattern of tumour growth as seen in insular and 
anaplastic cancers.
One striking feature of thyroid tumorigenesis that this simple model does not 
adequately explain, however, is the rarity with which progression from the 
slowly-proliferating well-differentiated to the rapidly growing insular or 
undifferentiated cancers occur in practice. This would not be expected if p16 
were the only rate limiting step in this process since firstly there would clearly 
be an extremely strong selection pressure for loss of p16, and secondly, loss 
of p16 expression (notably through promoter methylation) appears to be a 
particularly high-frequency genetic event in human cancers in general.
To complete the model, we speculate therefore that in thyroid tumorigenesis, 
as opposed to many tumour types, either there is an unusually low 
spontaneous frequency of p16 inactivation, or more likely, that there is
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redundancy in growth control, such that p16 is just one of two (or more) growth 
inhibitory pathways, all of which must be inactivated within the same cell in 
order for progression to the aggressive phenotype to occur. Such a “belt and 
braces” regulatory system would neatly explain why most thyroid cancers carry 
such a favourable prognosis.
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3.5 Conclusions
• p16 is not normally expressed in normal thyroid tissue
• Consistent with our in vitro data, p16 expressed in follicular adenomas 
and micro-papillary carcinomas
• P16 continues to be over-expressed in follicular and papillary 
carcinomas, and the increase in expression in comparison with the 
follicular adenomas is statistically significant
• Loss of p16 expression was only seen at a late stage of tumorigenesis, 
in a sub-group of insular carcinomas, and in anaplastic carcinomas
• A dramatic increase in cyclin A expression, and therefore tumour 
proliferation, was only seen in the insular carcinomas, and correlated 
with loss of p16 expression.
• This work represents the most comprehensive study to date regarding 
p16 expression and proliferation in multi-step thyroid tumorigenesis
• We speculate that another pathway must also be involved in the 
progression from well- to poorly- and un-differentiated thyroid 
carcinomas, which may be p16-dependent or ip16-independent
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3.6 Further work
In order to investigate whether the immunohistochemical expression of p16, 
MCM2 or cyclin A is associated with a worse clinical prognosis or the presence 
of metastatic disease, long-term clinical follow-up is needed of the patients 
who donated thyroid tissue for research purposes. In order to fully assess 
whether p16 is truly down-regulated in anaplastic carcinomas, the study should 
ideally be repeated with larger numbers of anaplastic carcinomas, and 
equivalent numbers of cases for all the thyroid tumour groups studied. 
However, this may be difficult to achieve because of the low incidence of 
thyroid cancer, as stated in chapter 1, and because of the rarity of 
transformation of thyroid cancers to the undifferentiated phenotype.
Since the role of the Rb pathway in early thyroid tumorigenesis is still unclear, 
the immunohistochemical analysis of the expression of other proteins in this 
pathway, such as p21 and cyclin D1, will further elucidate the function of this 
pathway in thyroid tumorigenesis, and this will form the basis of chapter 4. In 
order to investigate potential candidates for the second, as yet undiscovered 
pathway involved in early thyroid tumour progression, our laboratory is 
analysing gene expression in thyrocyte end-stage RAS colonies. This has the 
potential to highlight unexpected genes that may be involved in this pathway, 
and chapter 5 concerns the protein expression of some of these genes in 
benign and malignant thyroid tumours.
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CHAPTER 4 
AN IMMUNOHISTOCHEMICAL STUDY OF p21WAF1/C1?1 AND CYCLIN D1 
EXPRESSION IN MULTISTEP THYROID TUMORIGENESIS
4.1 Introduction
Having previously investigated p16 expression in thyroid cancers and identified 
that loss of p16 expression was not a key event in early thyroid tumorigenesis, 
I looked at the protein expression of the following two potential candidates, 
cyclin D1 and p 2 iWAF1/c,p1, in follicular adenomas, and follicular and papillary 
carcinomas, which had previously analysed for p16 expression. This novel 
research will contribute to the existing knowledge regarding the function of 
these proteins in thyroid tumorigenesis, and explore the potential relationships 
between p16 and cyclin D1 / p21 expression in the progression from benign to 
malignant thyroid cancers.
The loss of regulation and control of the cell cycle, leading to uncontrolled cell 
proliferation, is a hallmark of cancer (Hanahan and Weinberg, 2000). 
Progression through the cell cycle is driven by the sequential activation and 
inactivation of cyclin-dependent kinases (CDK). These enzymes are activated 
when they bind to cyclins, their regulatory subunits (Hartwell and Kastan, 
1994). The cyclin D -  cdk4/6 complexes phosphorylate pRB protein, releasing 
E2F transcription factors and allowing the cell to progress from G1 to S phase 
(Nevins, 2001). These events also enable the activation of cyclin E-cdk2 and 
cyclin A - cdk2, which are essential for S phase. There are several key 
checkpoints which control the cell cycle, with one of the most important
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checkpoints at the G1/S phase stage of the cell cycle (Murray, 1994). The p53 
protein is one of the most important proteins controlled by the G1/S phase 
checkpoint. If a cell has genomic abnormalities or DNA damage, the p53 
pathway is activated to arrest the cell in G1 until the DNA is repaired or the cell 
undergoes apoptosis (Vogelstein and Kinzler, 1992). Inactivation of both the 
Rb and the p53 pathways is a key requirement for tumorigenesis in most 
human malignancies.
The cyclin proteins therefore control the passage of the cell through the G1/S 
phase checkpoint (Sherr, 1995; Hall and Peters, 1996; Pestell et al., 1999). 
The connection between cyclin D and tumorigenesis was made with the 
discovery of over-expression of the PRAD1 (cyclin D1) gene, located at 11q13, 
in parathyroid adenomas (Motokura et al., 1991). Over-expression of cyclin 
D1, by either translocation or amplification of the gene, has been implicated in 
the development of several human malignancies (Ewen and Lamb, 2004), 
such as breast (Buckley et al., 1993; Zhu et al., 1998), bladder (Takagi et al., 
2000), oesophageal (Jiang et al., 1992) and head and neck carcinomas (Smith 
et al., 2001). This up-regulation is thought to overwhelm the checkpoints of the 
normal cell cycle, and lead to uncontrolled cell proliferation (Dirks and Rutka, 
1997). Cyclin D1 over-expression has been associated with a higher incidence 
of lymph node metastases, a poor clinical prognosis and more aggressive 
tumour behaviour (Khoo et al., 2002a).
Alternatively, instead of over-expression of positive growth regulators such as 
the cyclins, under-expression of cyclin-dependent kinase inhibitors (cki) such 
as p16 and p21 leads to uncontrolled cell proliferation. Our tissue culture work
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on p16 expression in thyrocytes led us to believe that p16 was a key tumour 
suppressor gene in early thyroid tumorigenesis; however my work in chapter 3 
did not confirm this. Another candidate tumour suppressor gene for is p21.
The p 2 iWAF1/c,p1 gene was the first cki to be identified (el-Deiry et al., 1993; 
Harper et al., 1993), and is a direct regulator of cdk activity and a mediator of 
p53-induced growth arrest. The actions of p21 have been thoroughly reviewed 
by Sherr and Roberts (1999), and Dotto, (2000). p21 is a direct transcriptional 
target of p53, and it mediates the growth-inhibitory effects of p53 by arresting 
the cell cycle in G1 phase (el-Deiry et al., 1994). At low cellular 
concentrations, it facilitates the formation of cyclin D1 -  cdk4/6 complexes, 
whilst at higher concentrations it inhibits cyclin D1 - cdk4/6 and cyclin E - cdk2 
complexes (Harper et al., 1995) and prevents the cell entering S phase. P21 is 
also activated by p53-independent mechanisms and is involved in terminal 
differentiation, cellular senescence and apoptosis (Zeng and el-Deiry, 1996; 
Lundberg and Weinberg, 1999). Therefore a decreased expression of p21 
would be expected in human tumours, with a resulting increase in cell 
proliferation.
Having previously established that p16 is up-regulated during the transition 
from normal thyroid tissue to a follicular adenoma, I hypothesised that p21 
would also be up-regulated in follicular adenomas, acting as a tumour 
suppressor gene to prevent uncontrolled cellular proliferation. However, 
because of the unexpected continued up-regulation of p16 in both follicular 
and papillary carcinomas, I was uncertain whether p21 would also be 
expressed in these tumours, and what the relationship between these two
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tumour suppressor genes would be at this stage of thyroid tumorigenesis. I 
also hypothesised that cyclin D1 expression would be induced in the follicular 
adenomas, in response to the increase in cell proliferation, and that cyclin D1 
would be further up-regulated in both the follicular and papillary carcinomas. 
Additionally, this suggested increase in cyclin D1 expression in the carcinomas 
could be correlated with a reciprocal down-regulation in p21 expression. By 
correlating both cyclin D1 and p21 expression with p16 expression in benign 
and malignant thyroid tumours, I will be able to provide new information 
regarding the function of this molecular pathway in thyroid tumorigenesis.
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4.2 Method
4.2.1 Immunohistochemistry
I performed immunohistochemistry on formalin-fixed, paraffin-embedded tissue 
sections and tissue microarrays (TMAs) following heat-mediated antigen 
retrieval in 10mM EDTA pH 9.0, using a microwave oven (20 minutes at 
800W). I pre-treated the slides with a DAKO peroxidase-blocking solution 
(DakoCytomation) prior to incubation for one hour at room temperature with 
one of the following antibodies: -
(i) mouse monoclonal anti-cyclin D1 antibody clone DCS-6 
(DakoCytomation) at a dilution of 1:50
(ii) mouse monoclonal anti-p21 antibody clone SX118 (DakoCytomation) at 
a dilution of 1:50
Secondary amplification was accomplished using the DAKO Envision+ ™ kit, 
and I visualised antibody binding using DAB chromogen (DakoCytomation), 
followed by counterstaining with haematoxylin.
4.2.2 Scoring of slides
4.2.2.1 cyclin D1
I assigned five hundred cells per sample to an intensity category of 0 
(absent), 1 (weak), 2 (moderate), or 3 (strong) and the percentage of cells in 
each intensity category was determined as No, Ni, N2, and N3 respectively. I 
then calculated a weighted average (Intensity Distribution, I.D. score, range 0 - 
3) as follows:-
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I.D. = [(N0x 0 ) + (Ni x 1) + (N2 x 2 ) + (N3 x  3)] / 1 0 0
4.2.2.2 p21
I counted five hundred cells per sample, and calculated the percentage 
of positive-staining nuclei (labelling index, L.I.). All cells showed the same 
degree of staining intensity therefore this was not factored into the scoring 
system.
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4.3 Results
I performed a literature search to identify anti-cyclin D1 and anti-p21 antibodies 
that had been used for immunohistochemistry of formalin-fixed, paraffin- 
embedded tissues. I selected an anti-cyclin D1 and an anti-p21 antibody that 
had both been thoroughly validated in the literature.
Bartkova et al., (1994), developed the mouse monoclonal antibody DCS-6 
against cyclin D1 and validated it by immunoblotting. This antibody showed 
strong reactivity with recombinant cyclin D1, and a lack of cross- reaction both 
with cyclins D2 and D3, and in human cell lines not expressing cyclin D1 
mRNA. The antibody has since been widely used in the literature for 
immunohistochemistry on formalin-fixed, paraffin-embedded tissues.
The p21 antibody, clone SX118, was generated by Fredersdorf et al., (1996), 
and validated against cell lines known to be positive and negative for p21 
using an enzyme-linked immunosorbent assay (ELISA), which provided a 
molecular basis for the SX118 antibody to immunoblot and immunoprecipitate 
human p21. They then used this antibody to analyse p21 expression in human 
tissues, including normal thyroid tissue, using immunohistochemistry, and only 
observed a positive reaction in occasional thyroid epithelial cells.
For both cyclin D1 and p21 immunohistochemistry I used isotype-matched 
mouse monoclonal anti-prolactin antibody at an equivalent dilution (1:50), and 
antibody diluent solution (DakoCytomation) as negative controls.
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4.3.1 Expression of cyclin D1 
Four normal thyroid tissue sections did not show cyclin D1 staining (Figure 
4.1). I analysed ten follicular adenomas, and the majority (80%) showed an 
up-regulation in cyclin D1 expression when compared to normal thyroid tissue 
(median cyclin D1 I.D. score = 0.43). Two out of the ten cases did not show 
cyclin D1 expression, four cases showed weak cyclin D1 expression (I.D. 
range 0.2 - 0.45), and four cases had moderate cyclin D1 expression (I.D. 
range 1.1-1.7). Examples of two follicular adenomas with moderate cyclin D1 
staining are shown in Figure 4.2.
Eight follicular carcinomas all showed an up-regulation of cyclin D1 expression 
compared to normal thyroid tissue and the follicular adenomas (median cyclin 
D1 I.D. score = 1.35). Three of the eight cases had weak cyclin D1 expression 
(I.D. range 0.4 - 0.8), four of the eight cases had moderate cyclin D1 
expression (I.D. range 1.3 -1.5), and the remaining case showed strong cyclin 
D1 expression (I.D. 2.3). Examples of two follicular carcinomas with moderate 
and strong cyclin D1 staining are shown in Figure 4.3.
The seven papillary carcinomas, like the follicular carcinomas, also showed an 
up-regulation of cyclin D1 expression when compared with normal thyroid 
tissue and the adenomas (median cyclin D1 I.D. score = 1.2). One tumour 
was negative, two of the seven cases had weak cyclin D1 expression (I.D. 
range 0.5-0.6), and four tumours had moderate cyclin D1 expression (I.D. 
range 1.2-1.7). Examples of two papillary carcinomas with moderate cyclin D1 
staining are shown in Figure 4.4.
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Chart 4.1 graphically represents the range of cyclin D1 I.D. values of the 
follicular adenomas, and the follicular and papillary carcinomas. All three 
tumour groups over-expressed cyclin D1 when compared to normal thyroid 
tissue, which did not show cyclin D1 expression. However, the follicular and 
papillary carcinomas had a higher median cyclin D1 I.D. score than the 
follicular adenomas.
The median cyclin D1 values for the follicular adenomas, follicular and papillary 
carcinomas, together with the first and third quartiles are represented as a box 
plot in Chart 4.2. This graph clearly demonstrates the increase in cyclin D1 
expression observed in the transition from adenoma to carcinoma. The cyclin 
D1 results for every tumour analysed in this study are summarised in Tables 
4.1, 4.2 and 4.3.
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Figure 4.1 Immunohistochemical staining with anti-cyclin D1 antibody of two samples of 
normal thyroid tissue, showing the absence of cyclin D1 expression. Scale bar 
represents 200 pm.
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Figure 4.2 Immunohistochemical staining with anti-cyclin D1 antibody of two cases of a
follicular adenoma, showing one adenoma with moderate staining (A), and one with 
both weak and moderate staining (B). Scale bar represents 200 pm.
145
f  t  r,
Figure 4.3 Immunohistochemical staining with anti-cyclin D1 antibody of two cases of a
follicular carcinoma. Case A shows moderate cyclin D1 expression, and case B 
shows strong cyclin D1 expression. Scale bar represents 200 pm.
Figure 4.4 Immunohistochemical staining with anti-cyclin D1 antibody of two cases of a
papillary carcinoma. Cases A and B show moderate cyclin D1 expression. Scale 
bar represents 200 pm.
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Chart 4.1 Bar chart demonstrating the heterogeneity of cyclin D1 staining of thyroid 
follicular adenomas, follicular and papillary carcinomas. The stacked bars 
represent the percentage of cases with a cyclin D1 I.D. score in a given range 
(0, 0.1-0.5, 0.6-1.0, 1.1-1.5, 1.6-2.0, 2.1-2.5)
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Chart 4.2 Box plot chart showing the first and third quartiles and median values for the 
cyclin D1 I.D. score for the follicular adenomas, follicular and papillary 
carcinomas. The ‘whiskers’ represent the range of I.D. values of cases that 
fall within 1.5 times the inter-quartile range (IQR).
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4.3.2 Expression of p21 
The four normal thyroid tissue sections that were stained did not show p21 
expression (Figure 4.5). I performed immunohistochemistry on ten follicular 
adenomas, and these tumours showed a small up-regulation in p21 expression 
when compared to normal tissue (median p21 L.l. score = 0.5). Four out of the 
ten cases did not show p21 expression, five cases had p21 expression in 1-3% 
of cells, and one case had p21 expression in 15% cells. Examples of two 
follicular adenomas, one with no p21 expression and one with weak p21 
expression are shown in Figure 4.6.
I stained eight follicular carcinomas, and these tumours could be divided into 
two groups. Five of the eight cases (62.5%) did not show p21 expression. 
The remaining three cases (37.5%) had a considerable up-regulation of p21 
expression when compared to normal thyroid tissue and the follicular 
adenomas (L.l. range 10-20). The median p21 L.l. score for the follicular 
carcinomas was 0. Examples of two follicular carcinomas showing an up- 
regulation of p21 expression are shown in Figure 4.7.
I then performed immunohistochemistry on seven papillary carcinomas and 
like the follicular carcinomas, these also showed an up-regulation of p21 
expression when compared with the follicular adenomas (median p21 L.l. 
score = 10). Two tumours were negative, and the remaining five tumours had 
between 5-20% cells showing p21 immunopositivity. Examples of two papillary 
carcinomas showing an up-regulation of p21 expression are shown in Figure 
4.8.
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Chart 4.3 graphically represents the range of p21 I.D. values of the follicular 
adenomas, and the follicular and papillary carcinomas. All three tumour 
groups over-expressed p21 when compared to normal thyroid tissue, which did 
not show p21 expression. Although all three tumour groups had cases that did 
not show p21 expression, overall the follicular and papillary carcinoma cases 
that did show p21 expression had higher p21 I.D. values than the follicular 
adenomas.
The median p21 values for the follicular adenomas, follicular and papillary 
carcinomas, together with the first and third quartiles are represented as a box 
plot in Chart 4.4. This graph demonstrates the increase in p21 expression 
observed in the transition from adenoma to carcinoma. The p21 results for 
every tumour analysed in this study are summarised in Tables 4.1, 4.2 and 4.3.
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Figure 4.5 Immunohistochemical staining with anti-p21 antibody of two samples of normal
thyroid tissue, showing the absence of p21 expression. Scale bar represents 200pm.
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Figure 4.6 Immunohistochemical staining with anti-p21 antibody in two cases of a follicular 
adenoma. Case A does not show p21 expression, and case B has weak p21 
expression, with 3% cells demonstrating a positive nuclear reaction. Scale bar 
represents 200 pm.
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W **J .Figure 4.7 Immunohistochemical staining with anti-p21 antibody of two samples of a follicular 
carcinoma. Cases A and B show an up-regulation of p21 expression with 10-20% 
cells expressing p21. Scale bar represents 200pm.
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Figure 4.8 Immunohistochemical staining with anti-p21 antibody in two cases of a papillary
carcinoma. Cases A and B show an up-regulation of p21 expression, with 10-20% 
cells demonstrating a positive nuclear reaction. Scale bar represents 200 pm.
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Chart 4.3 Bar chart demonstrating the heterogeneity of p21 staining in thyroid follicular 
adenomas, follicular and papillary carcinomas. The stacked bars represent 
the percentage of cases with a p21 L.l. score in a given range (0, 1-5, 6-10, 
11-15, and 16-20)
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Chart 4.4
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Box plot chart showing the first and third quartiles, and median values for the 
p21 L.l. score for follicular adenomas, follicular and papillary carcinomas. The 
‘whiskers’ represent the range of I.D. values of cases that fall within 1.5 times 
the inter-quartile range (IQR), and the * ’ represents the I.D. score of an 
‘extreme’ case whose I.D. value is >3 times the IQR.
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4.3.3 Co-expression of cyclin D1 and p21 
Cyclin D1 expression was up-regulated in the follicular adenomas, with a 
median I.D. score of 0.45. p21 expression remained low in the adenomas, 
with 0-3% cells per tumour showing p16 expression, and a median L.l. score of 
0.5. There was one outlier, with a p21 L.l. score of 15, and this tumour had 
one of the lowest cyclin D1 I.D. scores of 0.4. There was no significant 
correlation between these two proteins in this tumour groups (Spearman rank 
0.428, p = 0.218), Chart 4.5.
In the follicular carcinoma group, cyclin D1 expression was considerably up- 
regulated when compared to the follicular adenomas (median I.D. score 1.35). 
Meanwhile, 67.5% of the cancers did not show p21 expression, and 37.5% of 
the cancers had a greater up-regulation of p21 expression than that seen in 
the majority of the follicular adenomas (L.l. range 10-20). There was no 
significant correlation between these two proteins in this tumour groups 
(Spearman rank 0.178, p = 0.673), Chart 4.6.
Both cyclin D1 and p21 expression were up-regulated in the papillary 
carcinoma group. The median cyclin D1 I.D. score was 1.2 and the median 
p21 L.l. score was 10. There was no significant correlation between these two 
proteins in this tumour groups (Spearman rank 0.436, p = 0.328), Chart 4.7, as 
tumours with a high cyclin D1 score had either a high or a low p21 L.l. score.
Figure 4.9 shows cyclin D1, p21 and p16 staining in a representative follicular 
adenoma, follicular carcinoma and papillary carcinoma.
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Figure 4.9 Immunohistochemistry showing p16 (A1.B1.C1), cyclin D1 (A2.B2 C2) and p21 (A3.B3.C3) expression in a thyroid follicular adenoma (A), 
follicular carcinoma (B) and papillary carcinoma (C). Brown staining represents a positive reaction. Scale bar represents 200pm.
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Chart 4.5 Scatter chart showing cyclin D1 and p21 expression in the follicular adenomas
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Chart 4.6 Scatter chart showing cyclin D1 and p21 expression in the follicular 
carcinomas
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Chart 4.7 Scatter chart showing cyclin D1 and p21 expression in the papillary 
carcinomas
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4.3.4 Co-expression of cyclin D1 and p16 
In the follicular adenoma tumour group, the cyclin D1 I.D. score ranged from 
0-1.7, and the p16 I.D. score ranged from 0.2-1.4. Generally, the adenomas 
with the higher p16 I.D. scores also had a higher level of cyclin D1 expression, 
although there was one case that had a high p16 I.D. score (1) and a low 
cyclin D1 I.D. score (0.2) (Chart 4.8). There was a positive correlation 
between p16 and cyclin D1 expression (Spearman rank 0.721, p = 0.19) which 
neared statistical significance.
The follicular carcinomas (Chart 4.9) also showed an up-regulation of both 
cyclin D1 and p16 expression, and this correlation was statistically significant 
(Spearman rank = 0.789, p = 0.02). Similarly the papillary carcinomas (Chart
4.10) demonstrated an up-regulation of cyclin D1 and p16 expression, and this 
was also a statistically significant correlation (Spearman rank = 0.793, p = 
0.033).
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Chart 4.8 Scatter chart showing cyclin D1 and p16 expression in the follicular adenomas
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Chart 4.10 Scatter chart showing cyclin D1 and p16 expression in the papillary 
carcinomas
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4.3.5 Co-expression of p21 and p16 
In the follicular adenoma tumour group, p21 expression was negligible, with 
90% tumours having 0-3% cells showing p21 expression. In contrast, p16 
protein was over-expressed when compared to normal thyroid tissue (Chart
4.11). One adenoma had a higher p21 L.l. score (15), and this case had one 
of the lowest p16 I.D. scores (0.3). There was a negative correlation between 
these two proteins in the follicular adenomas, although this was not significant 
(Spearman rank -0.261, p = 0.466).
The follicular carcinomas all showed an up-regulation of p16 expression when 
compared to normal thyroid tissue. However, just over half of the tumours did 
not express p21, whilst the remaining cases had a considerable up-regulation 
of p21 expression when compared to normal thyroid tissue (Chart 4.12). There 
was not a significant correlation between p16 and p21 in the follicular cancer 
tumour group (Spearman rank 0.412, p = 0.311).
The papillary carcinomas also showed an up-regulation of p16 expression 
when compared to normal thyroid tissue. There was also an up-regulation of 
p21 expression when compared to the follicular adenomas, as 75% tumours 
had an L.l. score ranging from 5-20. However, two of the cancers with the 
highest p16 I.D. scores did not show p21 expression (Chart 4.13). There was 
not a significant correlation between p16 and p21 in the papillary cancer 
tumour group (Spearman rank 0.257, p = 0.578).
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Chart 4.11 Scatter chart showing p21 and p16 expression in the follicular adenomas
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Chart 4.12 Scatter chart showing p21 and p16 expression in the follicular carcinomas
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Chart 4.13 Scatter chart showing p21 and p16 expression in the papillary adenomas
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Table 4.1 Immunohistochemistry results for cyclin D1, p21 and p16 expression in thyroid
follicular adenomas (FA)
Pathology cyclin D1 
I.D. score
p21
L.l. score
p16
I.D. score
MCM2 
L.l. score
cyclin A 
L.l. score
FA 0 0 0.2 3 0
FA 0.4 15 0.3 1 0.4
FA 0.35 2 0.5 25 0.3
FA 0.45 2 0.5 1 0
FA 0 3 0.6 15 1.1
FA 1.2 0 0.8 4 0
FA 0.2 1 1 2 0.7
FA 1.1 2 1 8 0.5
FA 1.7 0 1 12 0
FA 1.1 0 1.4 6 0.1
Table 4.2 Immunohistochemistry results for cyclin D1, p21 and p16 expression in thyroid
follicular carcinomas (FC)
Pathology cyclin D1 
I.D. score
p21
L.l. score
p16
I.D. score
MCM2 
L.l. score
cyclin A 
L.l. score
FC 0.8 0 1 1.2 0
FC 0.4 15 1.1 5 1.8
FC 0.5 0 1.2 1 0
FC 1.4 0 1.5 2.3 0
FC 1.5 0 1.5 0 0.6
FC 1.3 0 1.6 0.6 0
FC 2.3 10 1.8 14 0.2
FC 1.5 20 2.4 3 1.1
Table 4.3 Immunohistochemistry results for cyclin D1, p21 and p16 expression in thyroid
papillary carcinomas (PC)
Pathology cyclin D1 I.D. 
score
p21
L.l. score
p16
I.D. score
MCM2 
L.l. score
cyclin A 
L.l. score
PC 0 5 1.1 38 0
PC 0.6 10 1.3 12 0.5
PC 0.5 0 1.7 7 1.2
PC 1.6 10 1.7 11 3
PC 1.2 20 1.8 2 0.7
PC 1.5 0 2 53 1.2
PC 1.7 15 2.7 18 5
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4.3.6 Co-expression of cyclin D1 and MCM2 
In the follicular adenoma tumour group, cyclin D1 expression was up-regulated 
compared to normal thyroid tissue, with a median I.D. score of 0.45. MCM2 
expression was also higher in this group when compared to normal thyroid 
tissue, with a median L.l. score of 5 (range 1-25). There was no statistically 
significant correlation between the expression of these proteins in the follicular 
adenomas studied (Spearman rank 0.055, p = 0.880) (Chart 4.14).
The follicular carcinomas expressed cyclin D1 at a greater level than that seen 
in the follicular adenomas, with a median I.D. score of 1.35. However, MCM2 
protein was expressed at a similar level to the follicular adenomas, with a 
median L.l. score of 1.75 (range 0 -  14). There was no statistically significant 
correlation between the expression of these proteins in the follicular 
carcinomas studied (Spearman rank 0.419, p = 0.301) (Chart 4.15).
The papillary carcinomas expressed cyclin D1 at a level similar to that seen in 
the follicular carcinoma group, with a median I.D. score of 1.2. Interestingly, 
MCM2 expression was much higher in the papillary carcinomas when 
compared to both benign and malignant follicular tumours, with a median L.l. 
score of 12.0 (range 2 -  53), although there was not a significant correlation 
between the expression of these proteins in the papillary carcinomas studied 
(Spearman rank -0.500, p = 0.253) (Chart 4.16).
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Chart 4.14 Scatter chart showing cyclin D1 and MCM2 expression in the follicular
adenomas
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Chart 4.16 Scatter chart showing cyclin D1 and MCM2 expression in the papillary 
carcinomas
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4.3.7 Co-expression of cyclin D1 and cyclin A 
As stated previously, in the follicular adenoma tumour group, cyclin D1 
expression was up-regulated compared to normal thyroid tissue. The 
expression of cyclin A was induced in the follicular adenomas when compared 
to normal thyroid tissue, but this was at a low level (median L.l. score 0.2, 
range 0 -  1.1). There was no statistically significant correlation between the 
expression of these proteins in the follicular adenomas studied (Spearman 
rank 0.044, p = 0.904) (Chart 4.17).
Cyclin D1 was expressed at a higher level in the follicular carcinomas when 
compared to the adenomas, as previously described. Cyclin A was also 
expressed in this group of tumours, but this was at a low level similar to that 
shown in the follicular adenomas (median L.l. score 0.10, range 0 -  1.8). There 
was no statistically significant correlation between the expression of these 
proteins in the follicular carcinomas studied (Spearman rank -0.268, p = 0.521) 
(Chart 4.18).
The papillary carcinomas also showed an up-regulation of cyclin D1 
expression when compared to normal tissue. Interestingly, cyclin A expression 
was slightly higher in the papillary carcinomas when compared to both benign 
and malignant follicular tumours, with a median L.l. score of 1.20 (range 0 -  5), 
although there was not a significant correlation between the expression of 
these proteins in the papillary carcinomas studied (Spearman rank 0.649, p = 
0.115) (Chart 4.19).
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Chart 4.17 Scatter chart showing cyclin D1 and cyclin A expression in the follicular
adenomas
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Chart 4.18 Scatter chart showing cyclin D1 and cyclin A expression in the follicular 
carcinomas
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Chart 4.19 Scatter chart showing cyclin D1 and cyclin A expression in the papillary 
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4.3.8 Co-expression of p21 and MCM2 
The expression of p21 was minimally induced in the follicular adenomas when 
compared to normal thyroid tissue, and only one tumour had an L.l. score >10. 
MCM2 expression was induced higher in these tumours when compared to 
normal thyroid tissue, but this was also at a low level, with a median L.l. score 
of 5 (range 1-25). There was no statistically significant correlation between the 
expression of these proteins in the follicular adenomas studied (Spearman 
rank 0.286, p = 0.423) (Chart 4.20).
Five out of the eight follicular carcinomas did not express p21, and the 
remaining three tumours expressed p21 with an L.l. score > 10. MCM2 protein 
was induced at a similar level to that seen in the follicular adenomas, with a 
median L.l. score of 1.75 (range 0-14). There was no statistically significant 
correlation between the expression of these proteins in the follicular 
carcinomas studied (Spearman rank -0.191, p = 0.651) (Chart 4.21).
The papillary carcinomas as a group had the greatest percentage of tumours 
expressing p21, although the level of expression was similar to that seen in the 
follicular carcinomas. However, MCM2 protein was expressed at a much 
higher level than that seen in the follicular tumours, and there was a negative 
correlation between the expression of these proteins in the papillary 
carcinomas studied (Spearman rank -0.273, p = 0.554) (Chart 4.22).
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Chart 4.20 Scatter chart showing p21 and MCM2 expression in the follicular adenomas
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Chart 4.22 Scatter chart showing p21 and MCM2 expression in the papillary carcinomas
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4.3.9 Co-expression of p21 and cyclin A 
As stated previously, the expression of p21 was minimally induced in the 
follicular adenomas when compared to normal thyroid tissue, and only one 
tumour had an L.l. score >10. Cyclin A was induced in the follicular adenomas 
when compared to normal thyroid tissue, but this was also at a low level 
(median L.l. score 0.2). There was a negative correlation between the 
expression of these proteins in the follicular adenomas studied (Spearman 
rank -0.030, p = 0.934) (Chart 4.23).
Only three out of the eight follicular carcinomas expressed p21, although these 
tumours had higher L.l. scores that the follicular adenomas. Cyclin A was also 
expressed in this group of tumours, but at a similarly low level to that shown in 
the follicular adenomas (median L.l. score 0.10). There was also a negative 
correlation between the expression of these proteins in the follicular 
carcinomas studied (Spearman rank -0.480, p = 0.229) (Chart 4.24).
Five out of the seven papillary carcinomas expressed p21, although the level 
of expression was similar to that seen in the follicular carcinomas. However, 
cyclin A expression was higher in the papillary carcinomas when compared to 
both benign and malignant follicular tumours, with a median L.l. score of 1.20. 
Interestingly, there was a positive correlation (instead of a negative correlation) 
between the expressions of these proteins in the papillary carcinomas studied 
(Spearman rank 0.156, p = 0.738) (Chart 4.25).
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Chart 4.23 Scatter chart showing p21 and cyclin A expression in the follicular adenomas
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Chart 4.24 Scatter chart showing p21 and cyclin A expression in the follicular carcinomas
2 0 0 0 - A
1 500- A.
3
— S 10.00-
2 00 3.00
c y c l i n  A  L . l .  s c o r e
Chart 4.25 Scatter chart showing p21 and cyclin A expression in the papillary carcinomas
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4.4 Discussion
The study of the molecular genetics of a tumour is important in developing 
treatment strategies for the disease. It helps us understand the natural 
progression of the disease, and potentially lead to a cure or a method to 
diagnose the tumour at an earlier stage. It can also allow us to determine the 
predicted behaviour of a tumour, for example the likelihood of metastases or a 
shortened survival time, and tailor treatment accordingly.
One of the major checkpoints that have to be overcome during neoplastic 
transformation is the G1-S phase cell cycle checkpoint. Three major genes 
that are involved in control of this checkpoint via the Rb pathway are p16, 
cyclin D1 and p21. Our study is the first to define cyclin D1 and p21 
expression in thyroid follicular adenomas, follicular and papillary carcinomas, 
and to correlate their expression with the expression of p16 in the same 
tumour groups.
I hypothesised that cyclin D1 would be up-regulated in the follicular adenomas, 
and my results support this hypothesis. Cyclin D1 was not expressed in 
normal thyroid tissue, and was up-regulated in the follicular adenomas with 
80% cases demonstrating weak or moderate cyclin D1 expression (median L.l. 
score 0.43). Furthermore, there was an up-regulation of cyclin D1 expression 
in both the follicular and papillary carcinomas when compared to the follicular 
adenomas. The follicular carcinomas had a median L.l. score of 1.35, and the 
papillary carcinomas had a median L.l. score of 1.2, and there was no obvious 
difference in cyclin D1 expression between the two tumour groups. The 
increase in cyclin D1 expression during transition from an adenoma to a
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carcinoma was expected, because of their malignant phenotype and the 
increase in proliferative rate seen in the carcinomas, as shown in chapter 3.
My immunohistochemical results are comparable with those previously 
published. Ferenc et al., (2005), reported an increase in cyclin D1 expression 
in 13 of 57 (23%) follicular adenomas and in 3 of 12 (25%) follicular 
carcinomas. Lazzereschi et al., (1998), observed cytoplasmic cyclin D1 
expression in 72% of the follicular adenomas and 63% of the papillary 
carcinomas studied. Both Wang et al., (2000), and Saiz et al., (2002), 
demonstrated cyclin D1 over-expression in thyroid tumours, with the 
carcinomas staining more strongly than the adenomas and Wang reported that 
cyclin D1 expression was greatest in the poorly- and undifferentiated cancers. 
However, Temmim et al., (2006), only observed small areas of focal staining 
with surrounding weak or negative tissue in 23 out of 50 follicular and papillary 
tumours, with the remaining tumours not showing cyclin D1 expression.
Lantsov et al., (2005), demonstrated cyclin D1 expression in micro-papillary 
carcinomas and a further increase in cyclin D1 expression in papillary 
carcinomas when compared to normal thyroid tissue. Khoo et al., (2002b), 
reported that 20 out of 22 micro-papillary carcinomas that had metastasised 
had widespread cyclin D1 expression, whilst only three out of 34 micro- 
papillary carcinomas without metastases showed cyclin D1 expression. All the 
authors reported that normal thyroid tissue did not express cyclin D1 protein.
In summary, the data in the literature suggests that cyclin D1 staining is 
negligible in normal thyroid tissue, and that follicular and papillary carcinomas
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demonstrate an up-regulation in cyclin D1 expression when compared with 
follicular adenomas, although Temmim et al., (2006), only demonstrated weak 
expression in these tumours. Finally, the more aggressive poorly or un­
differentiated tumours have the highest levels of cyclin D1 expression.
The differences in immunohistochemical expression of cyclin D1 seen in these 
studies can be partly attributed to the different cut-off points used to determine 
what counts as a positive result and what constitutes as over-expression of 
cyclin D1. Another reason for these differences is the use of different 
immunohistochemical protocols and antibodies in the quoted papers. It is only 
feasible to compare results and therefore draw accurate conclusions about 
cyclin D1 expression in thyroid tumorigenesis by analysing only those studies 
that used the same antibodies, immunohistochemical protocols and scoring 
systems.
I observed that p21 was not expressed in normal human thyroid tissue. There 
was a minimal up-regulation of p21 expression in follicular adenomas, with 
nine out of ten tumours only having 0-3% positive cells, and a median L.l. 
score of 0.5. This was surprising, and was not consistent with my hypothesis 
that the tumour suppressor gene p21, like p16, would be up-regulated in the 
follicular adenoma group.
However, p21 was up-regulated in a sub-group of both the follicular and 
papillary carcinomas. 37.5% of the follicular carcinomas expressed p16 (L.l. 
range 10-20), although the median L.l. score for this group was 0. However 
the tumours that did express p21 had a greater percentage of positively
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staining cells when compared to the follicular adenomas. Five out of the seven 
papillary carcinomas also showed an up-regulation in p21 expression, and the 
range of L.l. values was similar to that seen in the follicular carcinomas (L.l. 
range 5-20). There was no obvious difference in p21 expression between the 
follicular and the papillary cancers.
My results are similar to those previously published by Ito et al., (1996), 
Zedenius et al., (1996), Hermann et al., (2001), and Pickett et al., (2005). 
These authors demonstrated an up-regulation in p21 expression in both 
follicular and papillary carcinomas when compared to follicular adenomas, with 
an average of 12-53% cells per tumour showing p21 expression. In contrast, 
Ferenc et al., (2004b), observed similar levels of p21 expression in follicular 
adenomas and carcinomas, with approximately 14% cells in each tumour 
staining positively for p21.
Okayasu et al., (1998), showed a significant up-regulation of p21 expression in 
poorly-differentiated papillary and anaplastic thyroid cancers when compared 
to well-differentiated papillary cancers and follicular adenomas, with an 
average of 80% cells showing p21 immunopositivity in the more aggressive 
tumour group. In contrast, Brzezinski et al., (2005), reported a significant 
decrease in p21 expression in well- and poorly-differentiated papillary 
carcinomas when compared to indolent micro-papillary tumours, and only the 
micro-papillary tumour group showed over-expression of p21.
In summary, the data in the literature suggests that p21 is not expressed in 
normal thyroid tissue, and is expressed in follicular adenomas, and in both
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well- and poorly-differentiated carcinomas. There is some discrepancy 
regarding whether p21 is up-regulated or down-regulated during the transition 
from a well- to a poorly-differentiated tumour. The differences in p21 
expression in these studies can be also be partially attributed to the different 
scoring systems used. For example, Hermann et al., (2001), used >10% cells 
as a cut-off point for a positive result, Ferenc et al., (2004b), used >20% cells 
as a cut-off point, and Brzezinski et al., (2005), scored 11-50% cells as a 
positive result and >50% cells as over-expression of p21. Also, as before, a 
range of different antibodies and immunohistochemistry protocols were used, 
so it is therefore difficult to accurately compare results between papers. 
Finally, most studies, like my own, analysed only small numbers of cases for 
each tumour group, and therefore repeating these experiments with a much 
larger sample group, and with similar numbers of cases in each tumour group, 
would give a more accurate result.
One of the original findings in this study is the correlation of cyclin D1 and p16 
staining in the follicular adenomas, follicular and papillary carcinomas. I 
demonstrated a positive correlation between cyclin D1 and p16 expression in 
the follicular adenomas, and this finding was consistent with my hypotheses 
from chapters 3 and 4. I also demonstrated a statistically significant positive 
correlation between the expression of cyclin D1 and p16 in the follicular 
carcinomas (p = 0.02) and the papillary carcinomas (0.033). Although the 
increase in p16 expression in the carcinomas was unexpected, the increase in 
cyclin D1 expression was not. If the reason for cyclin D1 over-expression in 
these slow-growing indolent tumours is because of the neoplastic drive to 
proliferate, p16 could be over-expressed as a mechanism to keep these
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tumours ‘in-check’, and therefore prevent uncontrolled proliferation until other 
genetic mutations are acquired which result in a more poorly-differentiated 
tumour phenotype.
I have shown in chapter 3 that p16 is down-regulated in the poorly- and 
undifferentiated thyroid tumours, and suggested that this is related to the 
considerable increase in proliferation in these aggressive cancers, as well as 
their increasing potential to metastasise and invade, and their worse clinical 
prognosis. Therefore I would expect cyclin D1 to be expressed at an even 
higher level in these poorly-differentiated cancers, as shown by Wang et al., 
(2000).
The second original finding in this study is the correlation of p21 and p16 
staining in the follicular adenomas, follicular and papillary carcinomas. There 
was a very low level of p21 expression in the follicular adenomas with 90% of 
cases having 1-3% positively staining cells. In contrast, there was a much 
greater increase in p16 expression in the adenomas when compared to normal 
thyroid tissue, consistent with the hypothesis from chapter 3.
Whilst p16 continued to be over-expressed in both the follicular and papillary 
carcinomas, at a level higher than that seen in the follicular adenomas, a 
similar up-regulation of p21 expression was not seen in these cancers. Over 
half of the follicular carcinomas did not express p21. The follicular carcinomas 
that did express p21 had between 10-20% positively staining cells. However 
these three cases had the lowest and the highest p16 I.D. scores, and there
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was therefore not a statistically significant relationship between the expression 
of these two proteins in follicular carcinomas.
Similarly, in the papillary carcinoma group, there was an up-regulation of p21 
expression, at a similar level to that seen in the follicular carcinomas. However 
a significant relationship between p21 and p16 expression could also not be 
demonstrated for this tumour group. The tumours that did not express p21 had 
high p16 I.D. scores, and the tumours that did express p21 had both high and 
low p16 I.D. scores.
This data suggests that p21 does not have a major role to play in cell cycle 
control in the progression from a benign to a malignant well-differentiated 
thyroid tumour. This is because of the minimal up-regulation in p21 expression 
seen between the follicular adenomas and the follicular and papillary 
carcinomas, and the lack of correlation with p16 expression, suggesting that 
p16 is a more important tumour suppressor gene in thyroid tumorigenesis. 
These results may also help to explain why there is such a wide variation in 
immunohistochemical expression of p21 in thyroid tumours in the literature.
The immunohistochemical expression of both cyclin D1 and p21 has been 
widely studied in several human malignancies. In colorectal tumorigenesis, 
colorectal adenomas show an increase in p21 expression (Doglioni et al., 
1996), with a mean of 10.5% cells per adenoma showing p21 expression. 
They demonstrated a considerable increase in cyclin D1 expression in the 
colorectal carcinomas studied, with 50% cases showing p21 over-expression 
in heterogenous small clusters. In contrast, Sinicrope et al., (1998), and
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McKay et al., (2000), observed a down-regulation of p21 expression in colon 
carcinomas when compared to adenomas, and they suggested that this loss of 
p21 expression in colorectal tumours may be responsible for unrestrained 
proliferation. In correlation with the reduction in p21 expression seen in colon 
cancer, McKay et al., (2000), observed an increase in cyclin D1 expression in 
52.4% carcinomas, and an over-expression of cyclin D1 in 26% primary 
tumours and 38% metastatic deposits.
Jung et al., (2001), observed an up-regulation of cyclin D1 expression in 30% 
cells at the invasive front of colorectal carcinomas. The majority of these cells 
were not actively proliferating, and many were also positive for p16 expression. 
This was unexpected, since cyclin D1 promotes and p16 inhibits passage 
through the cell cycle. They hypothesised that the dual expression of p16 and 
cyclin D1 kept the cells in a state of quiescence, which may allow them to 
differentiate to a mesenchymal or more malignant phenotype, and that the 
future loss of p16 may lead to unrestrained cell proliferation. This is similar to 
my own results in well-differentiated, slow-growing thyroid tumours, in which 
both cyclin D1 and p16 were up-regulated.
Guner et al., (2003), studied p21, p16 and cyclin D1 expression in 
oesophageal carcinomas, and demonstrated a mean of 10% tumour cells 
staining positively for p21. In the same tumour group, a mean of 30% cells per 
tumour were positive for cyclin D1 expression. The tumours with a high p16 
and a low cyclin D1 expression (presumed to indicate an intact Rb pathway), 
had an excellent prognosis, whilst those tumours with over-expression of cyclin 
D1 and loss of either p16 or p21 had a shorter overall survival, implicating that
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the Rb pathway is crucial in the development of oesophageal carcinoma. 
Takeuchi et al., (1997), reported similar findings, with cyclin D1 over­
expression and p16 loss being correlated with metastatic spread and a shorter 
survival time.
Several authors have studied p21 expression in gastric carcinomas, and the 
majority report that loss of p21 expression is linked to a poor prognosis, shorter 
survival time and a more aggressive tumour phenotype (Liu et al., 2001; Noda 
et al., 2001; Noda et al., 2002), although some papers found no correlation 
between prognosis and p21 expression (Kaye et al., 2000). Noda’s group 
(2002) also noted that loss of p21 expression contributed to an increase in 
proliferation in patients with early stage gastric carcinoma, highlighting the 
tumour suppressor gene function of p21.
Normal prostatic tissue does not show p21 expression. Doganavsargil et al., 
(2006), found that p21 was over-expressed in both carcinoma-in-situ and 
prostate cancers, and that p21 expression was greatest in those tumours with 
extra-prostatic invasion which was contrary to expectations. Since p21 is a 
tumour suppressor, the loss of its activity is expected to correlate with 
increased tumour proliferation and therefore a worse prognosis. Drobnjak et 
al., (2000), studied cyclin D1 expression in prostate carcinomas, and found 
that it was over-expressed in 11% primary tumours and 68% bony metastases, 
with a significant correlation between cyclin D1 over-expression and an 
increase in tumour proliferation. These results suggest that cyclin D1 over­
expression is an indicator of a poor outcome.
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Li et al., (2006), reviewed p21 and cyclin D1 expression in malignant 
melanomas. They summarised that p21 expression is over-expressed in both 
primary malignant melanomas and in metastases, although there was a down- 
regulation in the metastases when compared with the primary tumours. Cyclin 
D1 is also up-regulated in melanocyte cell lines, malignant melanomas and in 
melanotic metastases at a frequency ranging from 35-61%, suggesting that up- 
regulation of cyclin D1 together with loss of p21 is associated with metastatic 
spread and a worse prognosis.
In summary, in oesophageal, gastric and some colorectal cancers, the loss of 
p21 expression and an increase in cyclin D1 expression is associated with a 
worse prognosis. In malignant melanoma and prostate carcinoma, an increase 
in both cyclin D1 and p21 expression is seen in primary cancers and their 
metastases, and is therefore associated with a worse prognosis. The increase 
in expression of both p21 and cyclin D1 seen in melanoma and prostate 
cancer is in keeping with the published findings in thyroid cancer.
Mitra et al., (1999), studied sarcoma cell lines and observed that expression of 
p16 and the corresponding inhibition of the cell cycle were associated with a 
post-transcriptional induction of p21. Therefore p16 inhibited cyclin D-cdk4/6 
complexes, and p21 inhibited cyclin E-cdk2 complexes, and this functional 
cooperation between these two tumour suppressor genes constitutes another 
level of regulation of cell growth via the cell cycle, and a common element in 
the Rb and p53 pathways. This induction of p21 in the cell lines could be a 
possible explanation for the limited up-regulation of p21 expression seen in 
thyroid tumours that I analysed. The continued expression of p16 in these
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well-differentiated tumours acts by keeping the tumours ‘in check’, and 
simultaneously induces p21 expression as another means of regulating the 
G1-S phase checkpoint. However, p21 mutations are only seen at low levels 
in human tumours in comparison to other tumour suppressor genes such as 
p16, which gives more support to p21 having a limited role to play in the 
regulation of the cell cycle in neoplasia.
I also correlated the expression of cyclin D1 and p21 with that of two markers 
of proliferation, namely MCM2 and cyclin A, described in Chapter 3. As stated 
previously, cyclin D1 is not expressed in normal thyroid tissue, is expressed in 
thyroid follicular adenomas, and at a higher level in both follicular and papillary 
carcinomas. In keeping with the oncogenic role of cyclin D1 expression, I 
hypothesized that MCM2, a marker of cells that are capable of proliferating, 
would be positively correlated with cyclin D1 expression. This was true for the 
follicular adenomas and carcinomas; however there was a negative correlation 
between cyclin D1 and MCM2 expression in the papillary carcinomas, although 
this was not statistically significant.
The analysis of p21 and MCM2 expression produced similar findings. The 
expression of p21 protein was up-regulated in the follicular adenomas, and 
further up-regulated in the follicular and papillary carcinomas. The expression 
of MCM2 was also induced in the adenomas and to a greater extent in the 
carcinomas, however there was a negative correlation between p21 and 
MCM2 expression in both the follicular and papillary carcinomas. This may be 
in keeping with the tumour suppressor action of p21, although I have 
suggested that p21 has a minimal role in early thyroid tumorigenesis.
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Cyclin D1 and cyclin A, a marker of the S-phase of the cell cycle, were 
expressed in the follicular adenomas at a higher level than that seen in normal 
thyroid tissue, and the expression of both proteins was higher still in the 
follicular and papillary carcinomas. There was no statistically significant 
correlation between these two proteins for either the benign or malignant 
tumours. I have already described that the expression of cyclin D1 and p16 
are significantly correlated, and suggested that both proteins are keeping the 
cell ‘in check’, until further mutations are acquired which eventually lead to 
uncontrolled proliferation, and therefore I did not expect to see a significant 
positive correlation between cyclin D1 and cyclin A in these tumour groups. I 
hypothesise that there should be a positive correlation between these two 
proteins in the poorly-differentiated and undifferentiated thyroid carcinomas, in 
keeping with the increase in proliferation seen in these tumours.
Both p21 and cyclin A were expressed at low levels in the follicular adenomas, 
and there was no significant correlation in this tumour group. However, there 
was a negative correlation between the two proteins in the follicular carcinoma 
group, with the three cases that expressed p21 having very low levels of cyclin 
A expression. This negative correlation may be in keeping with the role of p21 
as a tumour suppressor gene. This negative correlation was not observed in 
the papillary carcinoma group, and there was no significant correlation 
between cyclin A and p21 in these tumours.
While analysing my results, I had to take several factors into consideration. I 
was not blinded to the pathology of the tumour sections prior to staining with 
anti-cyclin D1 and anti-p21 antibodies, and this is a source of bias. I also only
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had access to small numbers of cases for each tumour group (follicular 
adenomas, follicular carcinomas and papillary carcinomas), which meant that 
my potential conclusions and statistical analyses might be different if a larger 
sample size was analysed. I assessed both the intensity and area of positive 
staining when scoring cyclin D1 expression to give a more accurate 
representation of the cyclin D1 status for each tumour, rather than using an 
arbitrary value to designate a ‘positive’ or ‘negative’ result, as has been used in 
previously published studies.
I have contributed to the existing knowledge regarding the Rb pathway and cell 
cycle control in early thyroid tumorigenesis by demonstrating a positive, 
statistically significant correlation between cyclin D1 and p16 expression in 
follicular carcinomas and papillary carcinomas. I was unable to demonstrate a 
significant correlation between either p21 and p16 expression or p21 and 
cyclin D1 expression in the progression from a benign to a malignant thyroid 
tumour. I was also unable to demonstrate a significant correlation between 
p21 / cyclin D1 expression and MCM2 / cyclin A expression.
I therefore conclude that p21 has a minimal role to play in the abrogation of cell 
cycle control, or that this gene is mutated at a very late stage in thyroid 
tumorigenesis. This is because, according to previously published results, p21 
continues to be expressed, although at low levels, in the undifferentiated 
aggressive anaplastic thyroid tumours, which are by definition undergoing 
uncontrolled proliferation. However the majority of cells in all thyroid cancers 
are negative for p21 expression. p21 may be acting as a tumour-suppressor 
gene to arrest proliferation only in the sub-population of cells in which it is
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expressed. Furthermore, p53 mutation only occurs in these aggressive 
tumours, and therefore p53-mediated control of the cell cycle must also be lost, 
so that in these cancers, p21 must be being induced by p53-independent 
pathways. These p53-independent pathways may however give the sub­
populations of p21-expressing tumour cells a different advantage in the 
malignant process, for example in de-differentiation or metastasis.
My results are in keeping with the known fact that well-differentiated thyroid 
cancers are indolent, slow-growing tumours, and this has been confirmed by 
the low levels of cyclin A expression seen in the well-differentiated thyroid 
tumours. The data indicates that the increase of both p16 and cyclin D1 
expression in these adenomas may keep the cells in a slowly cycling state until 
they attain some of the other features needed to become malignant, as 
described by Hanahan and Weinberg (2000), namely self-sufficiency in growth 
signals, evasion of apoptosis, sustained angiogenesis and the ability to invade 
tissues and metastasise.
The continued increase in cyclin D1 and p16 expression seen in the malignant 
follicular and papillary carcinomas was unexpected, as stated in chapter 3. 
This may be one of the mechanisms behind the continued low proliferative rate 
in these tumours. A thyroid cancer may only develop unlimited replicative 
potential once all of the neoplastic features are in place as a result of further 
genetic mutations and rearrangements, as seen in the undifferentiated 
anaplastic carcinomas which have continued over-expression of cyclin D1, and 
a down-regulation of p16 expression (Ball et al., 2007).
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It takes a finite amount of time for these genetic and epigenetic mutations to 
occur, and there needs to be a sustainable period of clonal expansion of the 
tumour cells for there to be a chance of another subsequent event, and for this 
event to co-operate with the previous one in the malignant transformation. 
Because thyroid cancers have such a slow turnover there is only a very small 
likelihood of all these genetic events occurring to produce an aggressive, 
rapidly proliferating tumour, in contrast to colorectal carcinomas and malignant 
melanomas, since their normal tissues have a much higher turnover. This 
would explain why there is such a low incidence and prevalence of anaplastic 
cancer when compared with follicular and papillary thyroid carcinoma.
Having ascertained that neither the loss of p16 or p21 is individually 
responsible for progression of early thyroid tumours to a malignant phenotype, 
there must either be another member of the Rb pathway that is mutated (for 
example cdk4), or another / several Rb-dependent or independent pathways 
involved in early thyroid tumorigenesis. This is because a follicular adenoma 
can develop into a follicular carcinoma without the loss of p16 or p21 
expression. The tumour cells must be able to keep dividing, albeit slowly, in 
the presence of these tumour suppressor genes and this may be due to one or 
several pathways that maintain control over cell replication and tumorigenesis 
that are hitherto undiscovered.
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4.5 Conclusions
• p21 expression is minimally expressed in thyroid follicular adenomas, 
and is up-regulated in some follicular and papillary carcinomas.
• cyclin D1 expression is up-regulated in follicular adenomas and is up- 
regulated in some follicular and papillary carcinomas.
• There is a statistically significant correlation between cyclin D1 and p16 
expression in the follicular and papillary carcinomas.
• There is no significant correlation between p21 and p16 expression in 
follicular and papillary carcinomas.
• Thyroid follicular cells are therefore able to transform into a malignant 
phenotype that has the ability to metastasise whilst still expressing the 
cell cycle inhibitors p16 and p21.
• Another hitherto undiscovered pathway may also be involved in the 
control of thyroid tumorigenesis, which prevents uncontrolled 
proliferation until the tumour develops a more aggressive phenotype, or 
other candidate genes in the Rb pathway may need to become mutated 
before cell cycle control is lost.
186
4.6 Further work
The repetition of this study with a much larger sample size, including poorly- 
differentiated papillary, insular and anaplastic carcinomas, would give a more 
accurate representation of the relationships between cyclin D1, p21 and p16 
expression in thyroid tumorigenesis. The observers should be blinded to the 
diagnosis of each tissue specimen.
Long-term clinical follow-up of the patients would allow for analysis of cyclin 
D1, p21 and p16 expression with regards to metastases, tumour recurrence 
and length of survival, and to assess whether these genes can be used to 
determine clinical prognostic outcomes.
Co-analysis of other members of the Rb pathway, such as cdk4, cdk6, cyclin E 
and pRb, together with p16, cyclin D1 and p21 would further elucidate the 
function and abrogation of the Rb pathway during thyroid tumorigenesis.
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CHAPTER 5 
AN IMMUNOHISTOCHEMICAL STUDY OF INTERFERON-STIMULATED 
GENE EXPRESSION IN MULTISTEP THYROID TUMORIGENESIS
5.1 Introduction
I have previously discussed the biological characteristics of thyroid tumours in 
Chapter 1, which range from benign, indolent follicular adenomas, to slow- 
growing yet potentially fatal follicular and papillary carcinomas, and rapidly 
proliferating, aggressive anaplastic carcinomas. A considerable amount of 
work has been published regarding the genetic changes involved in thyroid 
tumorigenesis, for example mutations in RAS, BRAF and RET/PTC. However, 
the early genetic mutations involved in the development of thyroid tumours 
either de novo from normal thyroid tissue or from follicular adenomas are not 
clear.
The forced expression of RAS in thyrocytes induces proliferation, and after 20- 
25 population doublings (p.d.) the clones stop dividing, and at this stage they 
are phenotypically similar to a follicular adenoma (Bond et al., 1994). The 
nature of the mechanism inhibiting this proliferation is uncertain. The number 
of p.d. that the thyrocytes undergo is too large to be explained by the 
“premature senescence” induced by RAS in fibroblasts (Serrano et al., 1997). 
Jones et al., (2000), demonstrated that this mechanism was telomere- 
independent, since the growth arrest was not prevented by the forced 
expression of sufficient telomerase to prevent telomere erosion. This growth 
arrest is tightly correlated with a progressive increase in p16 expression. My
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work on p16 expression in thyroid tumours in vivo in Chapter 3 indicates that 
this is not the only gene involved in early thyroid tumorigenesis, and that a 
second pathway appears to be in play. The analysis of p21 and cyclin D1 
expression in the same thyroid tumour groups also suggests the presence of 
another protein or pathway influencing thyroid tumorigenesis and cell 
proliferation.
One of the candidate mechanisms for this second pathway is the interferon 
pathway. There is long-standing evidence in the literature to suggest that the 
interferons and their downstream effectors have a role to play in tumour 
suppression. HLA-DR is one of the major interferon-stimulated genes that has 
been extensively studied in the literature, and de novo expression of HLA-DR 
has been observed in a wide range of human tumours, including melanoma 
(Brocker et al., 1984; Wilson et al., 1984; Natali et al., 1986), and breast 
(Feinmesser et al., 2000), lung (Wilson et al., 1984; Dammrich et al., 1990), 
and colon cancer (Daar et al., 1982; Norheim Andersen et al., 1996). In 
colorectal carcinoma, where the multiple stages of tumorigenesis can be easily 
defined (adenoma, well- and poorly-differentiated carcinoma), the data are 
consistent with ISG expression beginning in the late-stage adenomas. This 
data suggests that the up-regulation of interferon-stimulated genes such as 
HLA-DR may have some clinical relevance.
In order to evaluate whether the interferon pathway was a potential trigger for 
the in vitro growth arrest seen in RAS-induced thyrocytes colonies, our 
laboratory performed large scale expression profiling using high-density 
Affymetrix GeneChip oligonucleotide microarrays on untreated thyrocytes
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colonies, and early- and late-stage RAS- induced thyrocyte colonies. Our data 
revealed a striking and un-expected up-regulation of many interferon- 
stimulated genes (ISG) in the RAS-induced colonies, and included ISGs 
involved in interferon signalling, antigen processing, and antigen presentation 
and antiviral responses. This up-regulation correlated with the spontaneous 
arrest of clonal expansion in these colonies. Additionally, the microarrays 
identified that the p16 gene increased in expression in the senescent late- 
stage RAS-induced colonies, and this confirms the in vitro protein expression 
of p16 in these colonies, described in chapter 3.
The up-regulation of ISGs occurred in the absence of experimentally-provided 
interferon to the tissue culture medium. This led us to postulate that this 
induction of interferon signalling in these thyrocytes may be a novel innate 
tumour suppressor mechanism in human epithelial cells, acting either by 
affecting the immunogenicity of the cells, or by controlling cell proliferation. 
Furthermore, the potentially cell-autonomous expression of these interferon- 
stimulated genes may act in tandem with established cell cycle inhibitors such 
as p16 in the early stages of thyroid tumorigenesis to restrain tumour growth.
The up-regulation of ISGs seen in this early stage of thyroid tumorigenesis 
may have a role to play in tumour suppression and limiting oncogene-induced 
proliferation, potentially by the enhancement of the tumour’s immunogenicity 
(Kaplan et al., 1998). Alternatively, the activation of RAS and the tissue culture 
micro-environment could act as “stress signals” that are triggering the 
interferon pathway (Wright and Shay, 2001).
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My earlier work involving p16 expression in vivo suggests that our model of 
early-stage thyroid tumorigenesis is a good representation of the in vivo 
neoplastic transformation. I therefore hypothesised from the Affymetrix data 
that the up-regulation of ISGs seen in vitro would also occur at the follicular 
adenoma stage in vivo. In order to test this hypothesis, I selected three ISGs 
that were up-regulated in the RAS colonies (HLA-DR, PKR and MxA) to use for 
immunohistochemical analysis on follicular adenomas, follicular and papillary 
carcinomas. This is the first study to analyse the immunohistochemical 
expression of these ISGs in thyroid tumours, and correlate their expression 
with that of p16. My work will further enhance our understanding of the 
complex pathways involved in early thyroid tumorigenesis.
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5.2 Method
5.2.1 Immunohistochemistry 
I performed immunohistochemistry on formalin-fixed, paraffin-embedded tissue 
sections. I used heat-mediated antigen retrieval (HMAR) prior to incubation 
with anti-HLA-DR and anti-PKR antibodies, using one litre of 10mM EDTA (pH 
7.0) in a microwave oven (20 minutes at 800W). The sections being stained 
with anti-MxA antibody did not undergo HMAR. I then pre-treated the slides 
with a DAKO peroxidase-blocking solution (DakoCytomation) prior to
incubation for one hour at room temperature with one of the following
antibodies:-
(i) mouse monoclonal anti-HLA-DR antibody clone TAL.1B5
(DakoCytomation) at a dilution of 1:200
(ii) mouse monoclonal anti-PKR antibody sc-6282 (Santa-Cruz) at a
dilution of 1:50 (4pg/ml)
(iii) mouse monoclonal anti-MxA antibody (kindly supplied by G Kochs, 
Universitat Freiberg, Germany at a dilution of 1:1000)
Secondary amplification was accomplished using the DAKO Envision+ ™ kit, 
and I visualised antibody binding using DAB chromogen (DakoCytomation), 
followed by counterstaining with haematoxylin.
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5.2.2 Scoring of slides 
I counted five hundred cells per slide, and calculated the percentage of 
positive-staining cells (labelling index, L.I.). The majority of tumours analysed 
were negative for all three antibodies, therefore I simply described the area 
and intensity of staining seen in those tumours that did show positive 
immunoreactivity for the given antibody, rather than give each tumour an 
individual staining score.
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5.3 Results
5.3.1 anti-HLA-DR, PKR, MxA antibody validation
I performed a literature search to look for research using anti-HLA-DR, anti- 
PKR and anti-MxA antibodies for immunohistochemical analysis of formalin- 
fixed, paraffin-embedded tissues. The majority of papers used the monoclonal 
DAKO anti-HLA-DR antibody and the monoclonal Santa-Cruz anti-PKR 
antibody. I selected these antibodies and trialled them at a range of dilutions 
for different incubation times. The dilutions that I used (stated above) gave the 
most reproducible results with minimal background staining. I used a normal 
human tonsil as a positive control tissue, and for negative controls I used an 
isotype-matched mouse monoclonal anti-prolactin antibody (Pharmingen) at 
equivalent dilutions, and antibody diluent solution (DAKO). The tonsil showed 
a strong positive reaction with all three antibodies (Figure 5.1), and produced a 
negative reaction when immunostained with the anti-prolactin antibody and the 
antibody diluent (Figure 5.2).
5.3.2 Expression of HLA-DR
Four sections of normal thyroid tissue were stained, and all samples did not 
show HLA-DR protein expression (Figure 5.3). Ten follicular adenomas were 
analysed for HLA-DR expression, and all ten tumours did not show HLA-DR 
expression (Figure 5.4). I stained eight follicular carcinomas, and seven of the 
eight tumours did not show HLA-DR immunoreactivity (Figure 5.5A). However 
one of the carcinomas showed a small focus of intense HLA-DR staining, and 
this staining was reproduced on serial sections (Figure 5.5B).
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Seven papillary carcinomas were immunostained, and four of the seven were 
negative for HLA-DR expression. The remaining three tumours however 
demonstrated a moderate intensity of HLA-DR expression in 60-80% of the 
papillary tumour cells (Figure 5.6). Two of the three HLA-DR positive tumours 
had a strong lymphocytic infiltrate. The staining results are summarised in 
Tables 5.1, 5.2 and 5.3.
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Figure 5.1 Immunohistochemical staining with anti-HLA-DR antibody (A), anti-PKR antibody (B) 
and anti-MxA antibody (C) of human tonsil tissue, demonstrating a positive brown 
reaction.
Figure 5.2 Immunohistochemical staining with anti-prolactin antibody (A) and antibody diluent 
solution (B) of human tonsil tissue demonstrating the absence of a positive reaction.
196
f it *
& ■
?Tff!
*r-'.
y,{
A ..
%*x: t
* * » <  • m9* - Hri
* V *, .
.*"« *»tv.
£V .\
Figure 5.3 Immunohistochemical staining with anti-HLA-DR antibody of normal thyroid tissue 
showing the absence of a positive reaction. Scale bar represents 200pm.
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Immunohistochemical staining with anti-HLA-DR antibody of two follicular adenomas 
showing the absence of a positive reaction. Case A demonstrates the brown staining 
of associated dendtiric cells. Scale bar represents 200pm.
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Figure 5.5 Immunohistochemical staining with anti-HLA-DR antibody of two follicular carcinomas.
Case A represents a tumour that does not express HLA-DR. Case B represents the 
tumour with a cluster of positively staining cells. Both cases also demonstrate a 
positive reaction in associated dendritic cells. Scale bar represents 200pm.
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Figure 5.6 Immunohistochemical staining with anti-HLA-DR antibody of two papillary carcinomas, 
showing a positive brown cytoplasmic reaction, with associated positively staining 
dendritic cells. Scale bar represents 200pm.
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5.3.3 Expression of PKR
All four sections of normal thyroid that were immunostained did not show PKR 
expression (Figure 5.7). Out of the ten follicular adenomas, eight did not show 
PKR expression. The remaining two adenomas demonstrated a moderate 
intensity of cytoplasmic staining in 75-85% of the tumour cells (Figure 5.8). 
Five out of the eight follicular carcinomas were negative for PKR expression. 
Two out of the remaining three tumours had 2-3 positively-staining cells in the 
whole tumour, but overall these tumours were negative for PKR expression. 
One of these was the carcinoma previously described that had the intense 
focus of HLA-DR staining (Figure 5.9A). The remaining follicular carcinoma 
showed some PKR expression, with 25% cells demonstrating weak 
cytoplasmic staining, and 10% tumour cells demonstrating a moderate staining 
intensity (Figure 5.9B).
Three of the seven papillary carcinomas did not show express PKR (Figure 
5.10A). One cancer demonstrated weak expression in 15% cells. Two 
papillary cancers had weak expression in 50-70% cells with moderate 
expression in 10% cells, and the final tumour had weak staining in 10% cells 
and a moderate staining intensity in 60% cells. Two of the three papillary 
cancers with the higher PKR expression also had a lymphocytic infiltrate 
(Figure 5.10B). The staining results are summarised in Tables 5.1, 5.2 and 
5.3.
Figure 5.7 Immunohistochemical staining with anti-PKR antibody of normal thyroid tissue 
showing the absence of a positive reaction. Scale bar represents 200pm.
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Figure 5.8 Immunohistochemical staining with anti-PKR antibody of two follicular adenomas. 
Case A does not express PKR, and case B demonstrates a positive reaction. 
Scale bar represents 200pm.
Figure 5.9 Immunohistochemical staining with anti-PKR antibody of two follicular carcinomas.
Case A represents the area of the tumour that had the cluster of HLA-DR expressing 
cells, and this tumour does not show PKR expression. Case B is the follicular
cancer that had an up-regulation of PKR expression, as shown by the brown 
cytoplasmic reaction. Scale bar represents 200pm.
Figure 5.10 Immunohistochemical staining with anti-PKR antibody of two papillary carcinomas.
Case A is a cancer that did not express PKR protein, and case B is a papillary cancer 
with a lymphocytic infiltrate that showed an up-regulation of PKR expression. Scale 
bar represents 200pm.
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5.3.4 Expression of MxA
The four sections of normal thyroid were all negative for MxA expression 
(Figure 5.11). All ten follicular adenomas also did not show MxA 
immunoreactivity (Figure 5.12). Seven out of the eight follicular carcinomas 
did not demonstrate MxA expression (Figure 5.13A). The remaining cancer 
had a small cluster of cells that demonstrated a strong cytoplasmic reaction 
(Figure 5.13B). This was the same cancer that had an intense focus of HLA- 
DR staining, and the MxA staining focus was in the same position as the HLA- 
DR focus. The MxA focus was also reproduced in serial sections.
Five out of the seven papillary carcinomas did not demonstrate MxA 
expression (Figure 5.14A). The remaining two cancers showed weak 
cytoplasmic reactivity in 80% of the tumour cells (Figure 5.14B), and these two 
cases also showed an up-regulation of both HLA-DR and PKR expression. 
Only one of the MxA-positive tumours had a lymphocytic infiltrate. The 
staining results are summarised in Tables 5.1, 5.2 and 5.3.
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Figure 5.11 Immunohistochemical staining with anti-MxA antibody of normal thyroid tissue 
showing the absence of a positive reaction. Scale bar represents 200pm.
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Figure 5.12 Immunohistochemical staining with anti-MxA antibody of two follicular adenomas 
showing the absence of a positive reaction. Scale bar represents 200pm.
■ Kui •*" **
203
n r
. i 1
Figure 5.13
*s '■ \* ■ «
Immunohistochemical staining with anti-MxA antibody of two follicular carcinomas. 
Case A is a cancer that did not show MxA expression. Case B represents the area 
of the tumour that had the cluster of HLA-DR expressing cells, and this tumour also 
shows MxA expression in the same area of the cancer, as shown by a brown 
cytoplasmic reaction. Scale bar represents 200pm.
Figure 5.14 Immunohistochemical staining with anti-MxA antibody of two papillary carcinomas. 
Case A is a cancer that did not express MxA protein, and case B is a papillary cancer 
without a lymphocytic infiltrate that showed an up-regulation of MxA expression. Scale 
bar represents 200pm.
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5.3.5 Co-expression of p16 with HLA-DR, PKR and MxA 
HLA-DR and MxA were not expressed in the follicular adenomas. PKR was 
up-regulated with moderate expression in 75-80% tumour cells in 20% of the 
adenomas. As stated previously, p16 is up-regulated in the follicular 
adenomas, and the two tumours that expressed PKR had a p16 I.D. score of 
0.5 and 0.8 (range 0.2 -  1.4). There was no significant correlation between 
p16 and ISG expression in the thyroid follicular adenomas studied.
HLA-DR and MxA were only expressed in one follicular carcinoma in an 
identical cluster of cells. This cancer had a p16 I.D. score of 1.6 (range 1-2.4), 
Figure 5.15. There was not an obvious correlation between the expression of 
ISGs and p16 in the follicular carcinomas, since the majority of tumours did not 
express ISGs. PKR was only up-regulated in one cancer, with 30% cells 
showing weak or moderate PKR staining, and this case had the lowest p16 I.D. 
score of 1.
It was only in the papillary carcinoma group that a trend could be observed 
between p16 and ISG expression. Three of the cancers with the lower p16 I.D. 
scores (1.1, 1.7, 1.7) did not express HLA-DR, PKR or MxA. One of the 
cancers with a low p16 I.D. score (1.3) did demonstrate an up-regulation of 
both HLA-DR and MxA, whilst another case with a mid-range p16 I.D. score 
(1.8) demonstrated weak PKR expression. The remaining two cases showed 
a large (in comparison to the other tumours studied) increase in HLA-DR, PKR 
and MxA expression, and these cases also had the highest p16 I.D. scores (2, 
2.7), Figure 5.16.
Fig 5.15 Immunohistochemical staining showing p16 (A), HLA-DR (B), PKR (C) and MxA (D) 
expression in the follicular carcinoma that expressed HLA-DR and MxA in a small 
cluster of cells. This area is shown in all four photographs. Scale bar represents 200pm.
Fig 5.16 Immunohistochemical staining showing p16 (A), HLA-DR (B), PKR (C) and MxA (D) 
expression in a papillary carcinoma. The same area is shown in all four photographs. 
Scale bar represents 200pm.
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Table 5.1 Immunohistochemistry results for HLA-DR, PKR, MxA and p16 expression in
thyroid follicular adenomas (FA).
Pathology HLA-DR PKR MxA p16
FA 0 0 0 0.2
FA 0 0 0 0.3
FA 0 0 0 0.5
FA 0 75% mod. 0 0.5
FA 0 0 0 0.6
FA 0 85% mod. 0 0.8
FA 0 0 0 1
FA 0 0 0 1
FA 0 0 0 1
FA 0 0 0 1.4
Table 5.2 Immunohistochemistry results for HLA-DR, PKR, MxA and p16 expression in 
thyroid follicular carcinomas (FC).
Pathology HLA-DR PKR MxA p16
FC 0 25% weak, 10% mod. 0 1
FC 0 0 0 1.1
FC 0 0 0 1.2
FC 0 0 0 1.5
FC 0 2 cells only 0 1.5
FC Intense focus 2 cells only Intense focus 1.6
FC 0 0 0 1.8
FC 0 0 0 2.4
Table 5.3 Immunohistochemistry results for HLA-DR, PKR, MxA and p16 expression in 
thyroid papillary carcinomas (PC).
Pathology HLA-DR PKR MxA p16
PC 0 0 0 1.1
PC* 60% mod. 70% weak, 10% mod. 0 1.3
PC 0 0 0 1.7
PC 0 0 0 1.7
PC 0 15% weak 0 1.8
PC* 65% mod. 10% weak, 60% mod 80% weak 2
PC 80% mod. 50% weak, 10% mod. 80% weak 2.7
The two papillary carcinomas marked with had a lymphocytic infiltrate.
The staining intensity was categorised as weak, moderate (mod.) and intense.
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5.4 Discussion
The exact molecular mechanisms involved in thyroid tumorigenesis remain 
unclear. Much work has been published regarding the members of the 
RAS/RAF/MAPK pathway, and we know that these genes are involved in both 
follicular and papillary thyroid carcinogenesis. However the alterations in the 
pathways controlling cellular proliferation and differentiation are less clear. I 
have investigated the expression of members of the Rb pathway, namely p16, 
p21, and cyclin D1, in all stages of thyroid tumorigenesis, and have so far been 
unable to provide a clear picture with regards to the events leading to 
uncontrolled cell proliferation in thyroid cancer. There appears to be a further, 
as yet unknown, pathway involved in the progression from adenoma to 
carcinoma, and from well-differentiated to poorly- and undifferentiated thyroid 
cancer.
This led us to perform Affymetrix microarrays on normal thyrocytes, early- and 
late-stage RAS-induced thyrocyte colonies, with the latter phenotypically 
resembling burnt-out thyroid adenomas in vivo. The resulting data revealed an 
unexpected up-regulation of interferon-stimulated genes in the late-stage RAS 
colonies, including the genes HLA-DR, PKR and MxA, and this was in the 
absence of interferon in the culture medium. I hypothesised therefore that 
these ISGs were in some way acting as a tumour suppressor mechanism, 
potentially in tandem with p16, in early thyroid tumorigenesis. We could not be 
certain, however, whether these genes were acting individually, or in the same 
pathway, and how many of the up-regulated genes were actually functional in 
initiating tumour development, as opposed to being a result of malignant 
progression.
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My work is the first study to look collectively at the immunohistochemical 
expression of HLA-DR, PKR and MxA in thyroid tumours, specifically in 
follicular adenomas and follicular and papillary thyroid carcinomas. It is also 
the first body of work to compare the expression of these three ISGs with that 
of p16 in benign and well-differentiated thyroid tumours.
HLA-DR is a Molecular Histocompatibility Complex (MHC) antigen, and these 
are thought to regulate the immunologic interaction of immune cells and play a 
fundamental role in antigen recognition by helper T-lymphocytes. There are 
two classes of MHC antigens in humans, and HLA-DR belongs to class II. In 
humans, class II MHC genes are coded for by genes located in the HLA-D 
region on chromosome 6. This region can be further divided into three 
regions; HLADP, HLADQ, HLADR. Class II MHC antigens are commonly 
expressed on B-cells, T-cells, monocytes, macrophages, Langerhans cells of 
the skin, dendritic cells in lymph nodes and endothelial cells (Winchester and 
Kunkel, 1979; Kaufman et al., 1984). HLA-DR expression has been detected 
on epithelial cells in several benign and malignant tumours, although no clear 
prognostic significance has emerged.
HLA-DR was not expressed in the normal thyroid tissue that I studied. I also 
found that HLA-DR was generally not up-regulated in either the follicular 
adenomas or the follicular and papillary carcinomas. This was unexpected and 
the data is inconsistent with my original hypothesis, where HLA-DR was 
expressed in the late-stage RAS colonies which resemble follicular adenomas.
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Interestingly, one of the follicular carcinomas had an isolated focus of intense 
HLA-DR expression in a small cluster of cells, which was persistent in serial 
sections. There was also a dramatic up-regulation of HLA-DR expression in 
three out of the seven papillary carcinomas, with 60-80% cells demonstrating a 
strong positive reaction. Two of these three papillary tumours had a 
lymphocytic infiltrate, suggesting that the induction of HLA-DR expression may 
in part be due to infiltration of lymphocytes into the tumour, although this 
cannot be the only mechanism involved, since a follicular and a papillary 
carcinoma also showed HLA-DR expression without such an infiltrate.
The data from the literature indicates that, like my findings, thyroid cells do not 
normally exhibit HLA-DR; however this protein can be induced in vitro by IFN 
gamma (Weetman et al., 1985). Panza et al., (1982), were the first group to 
report a strong association between HLADR and thyroid cancer. Lindhorst et 
al., (2002), studied HLA-DR expression in the complete spectrum of thyroid 
tumorigenesis, and found HLA-DR to be expressed on the cell membrane of 
both follicular and papillary cancer cells; however some anaplastic cancer cells 
had diffuse cytoplasmic staining. Follicular cancers have the weakest level of 
staining, followed by papillary cancers, and the aggressive, anaplastic cancers 
had the strongest degree of staining. The increase in HLA-DR expression 
correlated with an increase in proliferation in the poorly-differentiated tumours.
This in contrast to previous studies by Lloyd et al., (1985), Lucas-Martin et al., 
(1988), and Betterle et al., (1991), where only a low level of HLA-DR 
expression was seen in anaplastic carcinoma tissue sections. Lloyd’s group 
also studied HLA-DR expression in follicular adenomas and follicular and
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papillary carcinomas, and observed negligible levels of staining in the follicular 
adenomas and carcinomas, with an up-regulation in expression in the majority 
of papillary cancers.
Since then there have been several studies published with varying results 
concerning the correlation between HLA-DR expression and lymphocytic 
tumour infiltration. Lloyd et al., (1985), Kamma et al., (1998), and Knoll et al., 
(1992), performed immunohistochemistry on thyroid papillary carcinomas, and 
observed an up-regulation in HLA-DR expression when compared with normal 
tissue. This expression ranged from widespread staining, to scattered cells 
and concentrated small and large foci of positivity. These authors noted a 
close correlation between HLA-DR expression and a lymphocytic infiltrate.
Feinmesser et al., (1996), concluded that HLA-DR expression in papillary 
carcinomas was generally correlated with lymphocytic infiltration of the tumour, 
and that the intensity of HLA-DR expression was stronger in the tumours with 
distant metastases, compared to tumours that had not metastasised. 
However, there were a small number of cases, including some cases with 
distant metastases, which had HLA-DR expression without this infiltration of 
immune cells. There are several other studies than have confirmed that HLA­
DR expression can occur in papillary carcinoma of the thyroid without the 
presence of a lymphocytic infiltrate (Goldsmith et al., 1988; Lucas-Martin et al., 
1988; Fisfalen et al., 1990).
To summarise, the vast majority of studies have shown an up-regulation of 
HLA-DR expression in papillary carcinomas, and that for follicular adenomas
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and carcinomas the expression of HLA-DR, when present, is weaker than that 
which is seen in papillary carcinomas. This corresponds with my own 
immunohistochemical data. There is some discordance regarding HLA-DR 
expression in anaplastic carcinomas, with some studies reporting an up- 
regulation and others reporting a loss of expression in these tumours. 
Secondly, the expression of HLA-DR in papillary thyroid carcinomas occurs 
both in the presence and absence of a lymphocytic infiltrate.
The expression of HLA-DR is often altered in human tumours when compared 
with the normal tissue from which the tumours originate. However the up- 
regulation of HLA-DR in tumours has been shown to have both a positive 
(Esteban et al., 1990) and a negative effect (Ruiter et al., 1986) effect with 
regard to prognosis. Rajendra et al., (2006), investigated HLA-DR expression 
in Barrett’s oesophagus (a pre-malignant precursor lesion of oesophageal 
cancer) and found an up-regulation of HLA-DR expression in 51.6% of lesions 
when compared to 11.7% of normal control tissue. It was previously reported 
that this HLA-DR expression is down-regulated in the transition from adenoma 
to carcinoma, with only 16% tumours expressing HLA-DR (Rockett et al., 
1995).
This down-regulation in tumours when compared with their corresponding pre- 
malignant lesions has also been noted in colon, cervical, laryngeal and breast 
carcinomas (Garrido et al., 1993). These results suggest that the induction of 
HLA-DR expression may confer an advantage to the host in terms of restricted 
tumour growth, and that HLA-DR is in part acting as a tumour suppressor. 
Normal colonic mucosa does not express HLA-DR; however de novo
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expression has been reported in both colorectal adenomas and carcinomas. 
HLA-DR is also up-regulated in 38% colorectal adenomas, and its expression 
was correlated with increasing tumour size and the grade of dysplasia 
(Norheim Andersen et al., 1996). Patients with HLA-DR positive tumours have 
been shown to have a better survival than those patients without HLA-DR 
expression (Andersen et al., 1993), although this relationship has not been 
demonstrated by other studies (Ghosh et al., 1986; Moller et al., 1991). It has 
been demonstrated that some colon cancers that express multiple genetic 
mutations owing to DNA mismatch correction defects are highly immunogenic, 
as shown by a dense lymphocytic infiltrate (Kim et al, 1994), which may 
explain the favourable prognosis in this group of patients.
This relationship between HLA-DR expression and an improved survival in 
colorectal carcinoma was also reported by Lovig et al., (2002). An up- 
regulation of HLA-DR expression has also been seen exclusively in primary 
cervical carcinomas, and is absent in their corresponding metastases 
(Cromme et al., 1994). Overall, HLA-DR is up-regulated in several human 
carcinomas; however its role in tumorigenesis is still unclear. The expression 
of HLA-DR can be linked to an improved prognosis in colorectal, laryngeal and 
breast carcinoma (Brunner et al., 1991; Concha et al., 1991), whilst loss of 
expression can be associated with a worse prognosis or the presence of 
metastases in colorectal and cervical carcinoma and malignant melanoma 
(Lopez-Nevot et al., 1988).
PKR is a double-stranded RNA-activated protein kinase that is induced by 
interferons (Lengyel, 1982; Hovanessian, 1989). PKR is activated by binding
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to double-stranded RNA (Galabru et al., 1989). Once activated, PKR 
phosphorylates eukaryotic initiation factor 2-alpha (elF2-a), a subunit of 
translation initiation factor 2. The elF2-a then down-regulates cellular or viral 
translations of proteins (Lengyel, 1982). Furthermore PKR also induces 
apoptosis and suppresses cellular growth, differentiation and proliferation 
(Meurs et al., 1993; Yeung et al., 1996; Williams, 1999), and has a role to play 
in controlling the activation of several transcription factors such as p53. PKR 
may therefore have a role as a tumour suppressor gene (Jagus et al., 1999).
PKR was not expressed in the normal thyroid tissue that I studied. I observed 
an up-regulation of PKR expression in two out of the ten follicular adenomas 
that were stained, with 75-80% cells showing a positive reaction. This is partly 
consistent with my hypothesis that ISGs are up-regulated in vivo in follicular 
adenomas. Only one out of seven follicular carcinomas showed an up- 
regulation of PKR expression with 35% cells showing a positive result, and this 
was a down-regulation when compared with the two follicular adenomas that 
expressed PKR. It is difficult to draw accurate conclusions regarding whether 
the reduced expression in the one positively staining follicular carcinoma is a 
true down-regulation in staining intensity compared to the two follicular 
adenomas, and a much larger series of thyroid tumours would have to be 
immunostained to investigate whether PKR has a potential role as a tumour 
suppressor gene in early thyroid tumorigenesis.
PKR was also expressed in four out of the seven papillary carcinomas, and 
there was a down-regulation in the intensity of staining when compared to the 
adenomas. Two of the cancers that expressed PKR had a lymphocytic
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infiltrate. Most of the positively staining papillary carcinoma cells had a weak 
intensity of staining, in comparison to the moderate intensity of staining seen in 
the follicular adenomas. This lends further evidence to the hypothesis that 
PKR may act as a tumour suppressor in thyroid tumorigenesis.
To date there has only been one published study researching the expression 
of PKR in thyroid cancer. Terada et al., (2000), analysed 80 papillary 
carcinomas and two follicular carcinomas. Like my own data, PKR was not 
expressed in normal thyroid tissue. However, 94% of the papillary carcinomas 
were positive for PKR expression, and this was predominantly localised in the 
cytoplasm of the tumour cells and at the peripheral invading front. Only one of 
the two follicular cancers showed PKR expression, and this was of a weaker 
intensity than that seen in the papillary tumours. The up-regulation in PKR 
expression was correlated with those tumours that had a greater degree of 
vascular invasion. Finally, the tumours with the highest PKR scores had the 
lowest proliferative rates, as judged by Ki-67 expression. This inverse 
correlation with proliferation has also been reported in head and neck 
carcinoma (Haines et al., 1996). The up-regulation of PKR expression seen in 
this series of papillary carcinomas, and the increase in staining intensity seen 
in the papillary carcinomas compared to the follicular carcinomas is consistent 
with my own data.
Elevated levels of PKR expression have been demonstrated in several human 
cancers, including breast (Haines et al., 1996), colon (Singh et al., 1995), lung 
(Haines et al., 1992), head and neck (Haines et al., 1993) and hepatocellular 
carcinomas (Shimada et al., 1998), as well as in the cell lines derived from
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these tumours (Haines et al., 1996; Kim et al., 2000; Kim et al., 2002). Kim’s 
group (2002) demonstrated that there is an increase in PKR expression which 
is consistent with the transition from a colorectal adenoma to a carcinoma, and 
this is similar to my own findings in thyroid tumorigenesis.
However the role of PKR in tumorigenesis varies according to the individual 
cancer. Increased expression of PKR has been correlated with a better 
prognosis in head and neck carcinoma and some studies analysing colorectal 
carcinomas (Haines et al., 1993; Singh et al., 1995). In contrast, Terada et al., 
(2000), as previously stated, reported that high PKR expression correlated with 
vascular invasion and satellite tumour nodules in thyroid cancer. Kim et al., 
(2002) also stated that the lymph node metastases from malignant melanomas 
had high levels of PKR expression.
These varying results are similar to the data regarding the significance of HLA­
DR expression in human malignancies. At present, it is still unclear whether 
PKR is acting as a tumour suppressor gene in some carcinomas, or as a 
cellular response to neoplasia or it may act via an as yet undisclosed pathway. 
The analysis of PKR expression in poorly-differentiated and anaplastic thyroid 
carcinomas will help elucidate the role of PKR expression in thyroid 
tumorigenesis.
MxA is a 78kDa protein that belongs to the super-family of dynamin-like 
GTPases (Flohr et al., 1999), and they are key components of the anti-viral 
state that is induced in many species such as rodents and humans by the 
expression of type I interferons (Haller and Kochs, 2002). The Mx proteins
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were first discovered over twenty years ago in an inbred mouse strain that 
showed a high degree of resistance towards a particular influenza virus 
(Horisberger et al., 1983). In humans, two distinct MxA GTPases, MxA and 
MxB are encoded on chromosome 21. Only MxA has anti-viral activity, and 
this is against a wide spectrum of viruses including bunyaviruses, 
orthomyxoviruses and hepatitis B virus. The MxA proteins can self-assemble 
into oligomeric complexes and they bind to viral nucleocapsids and block their 
intracellular transport (Haller and Kochs, 2002), and it has been suggested that 
these proteins function as an intra-cellular surveillance system to monitor the 
cell for viral infection. MxA is now widely accepted as a sensitive marker of 
interferon a / (3 activity (Roers et al., 1994).
The expression of MxA was negligible in the vast majority of all the thyroid 
tumours studied. There was no expression of MxA protein in either normal 
thyroid tissue or in the follicular adenomas. This was unexpected, and was not 
consistent with my earlier hypothesis. Seven out of the eight follicular 
carcinomas did not express MxA protein; however one case had a small 
cluster of cells with an intense focus of positive staining. This same case had 
an intense focus of HLA-DR expressing cells in the same location. Because 
both MxA and HLA-DR expression were induced in this cluster of cells, it is 
highly unlikely that this is an artefact of immunohistochemical processing, and 
represents a true induction of ISG expression.
Five out of the seven papillary cancers that were immunostained did not 
express MxA protein. However the remaining two cancers demonstrated weak 
staining in 80% cells and one of these tumours had a lymphocytic infiltrate.
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This data suggests that MxA has a minimal role to play in early thyroid 
tumorigenesis, since it is not expressed in the majority of thyroid adenomas 
and well-differentiated carcinomas.
There is very little published data regarding MxA immunohistochemistry, and 
the majority of papers concern its up-regulation in viral-induced diseases such 
as hepatitis (Leifeld et al., 2001). To date there are no published studies 
regarding MxA expression in human cancers. My study is therefore the first to 
investigate the immunohistochemical expression of MxA in thyroid 
tumorigenesis.
One potential source of bias in this study was the fact that I was not blinded to 
the pathological diagnosis of the tissue specimens prior to performing 
immunohistochemistry. Also, I only had access to a relatively small number of 
cases for each tumour group. Because the numbers of positively-staining 
cases were so low for each tumour group, a much larger number of samples 
need to be stained to be able to draw more accurate conclusions. There is 
very little information in the literature regarding the immunohistochemical 
expression of PKR and MxA in human cancers, and therefore there is little 
data regarding the ideal immunohistochemical protocols and scoring methods 
for these antibodies.
There was no obvious correlation between p16 expression and HLA-DR, PKR 
and MxA expression in the follicular adenomas and follicular carcinomas, since 
the ISGs were not expressed in the majority of these tumours. However, the 
increase in ISG expression observed in two of the three papillary carcinomas
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that expressed all three proteins did appear to be linked to an increase in p16 
expression, with these two cases having the two highest p16 I.D. values. One 
explanation for the up-regulation of ISGs in vivo in papillary carcinomas may 
be related to the genetic mutations and rearrangements that are only found in 
these cancers, such as RET/PTC rearrangements and the BRAF mutation.
These genetic changes may somehow be linked to the interferon pathway, and 
the de novo expression of interferons may have a specific role to play in 
papillary thyroid tumorigenesis. If this is the case, then this could be an 
explanation for the intense cluster of positively staining cells seen in one 
follicular carcinoma. If these cells harboured a genetic mutation more 
commonly seen in papillary cancers, such as a RET/PTC rearrangement, then 
they would be expected to express HLA-DR, PKR and MxA. However, PKR 
was not expressed in this cluster of cells, and so the function of these ISGs in 
thyroid tumorigenesis remains unclear.
The relationship between HLA-DR expression in papillary cancers and the 
presence of a lymphocytic infiltrate is unclear. One theory is that HLA-DR 
expression is a result of paracrine stimulation by cytokines derived from the 
infiltrating lymphocytes, dendritic cells and other inflammatory cells (Ikeda et 
al., 2002), although several authors have failed to demonstrate a convincing 
spatial relationship (Betterle et al., 1991; Feinmesser et al., 2000), and our in 
vitro data confirms that HLA-DR is up-regulated in the absence of interferon in 
the culture medium. HLA-DR expression can occur in the absence of 
lymphocytes, as seen in distant metastases, which suggests that the 
expression of HLA-DR may be related to a gene associated with the
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development of metastases. This is unlikely to be the case in thyroid 
carcinoma, since follicular carcinomas are able to metastasise but have 
negligible HLA-DR expression.
It has been recently reported that the rearranged RET/PTC oncogene can 
induce the expression of MHC Class II molecules through a STAT-1 (signal 
transducer and activator of transcription-1) mediated mechanism (Hwang et 
al., 2004). Potentially this induction of cytokines by the thyroid tumour cells 
could promote the lymphocytic infiltration seen in papillary thyroid carcinomas. 
These infiltrating lymphocytic immune cells may have a role in tumour 
suppression by expressing co-stimulatory molecules that are not normally 
expressed by thyroid cells, and therefore activating the immune response 
(Lahat et al., 1993). On the other hand, the lymphocytes may produce 
mediators that can enhance tumour growth via a paracrine effect (Marx, 2004). 
However, HLA-DR, PKR and MxA expression were also up-regulated in 
papillary carcinomas that did not have a lymphocytic infiltrate; therefore there 
must be another mechanism involved.
One theory for the differences between our thyrocyte model’s expression of 
ISGs and my in vivo findings is that the ISGs are stimulated in vitro as a 
delayed response to RAS oncogene activation in these thyrocyte colonies. 
This is unlikely because the papillary carcinomas are the tumour group that 
show the greatest up-regulation of ISGs, whilst the follicular carcinomas have a 
much greater prevalence of RAS mutation and a very low incidence of ISG up- 
regulation. Another possibility that must be considered is that our thyrocyte 
tumour model is not a completely accurate representation of the in vivo
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development of thyroid tumours. However, the concurrent up-regulation of 
both p16 and cyclin D1 in both late-stage Ras colonies and in human follicular 
adenomas indicates that the in vitro model must bear some similarities to the in 
vivo neoplastic progression. Finally, as previously discussed, the up-regulation 
of both HLA-DR and PKR has been reported in follicular and papillary 
carcinomas, implying that these genes do have a role to play in thyroid 
tumorigenesis.
The process of malignant transformation is complex, and involves both 
epigenetic and genetic changes in an individual cell, as well as changes in the 
way that cell interacts with its environment. The immune system is 
increasingly thought to have a role to play in this process. Frequently, tumour 
cells express new ‘neo-antigens’ as a result of these multiple genetic changes 
(Little and Stern, 1999). The immunological recognition of these neo-antigens 
is a key event in tumorigenesis (Scanlan et al., 1998). The host’s immune 
cells can potentially recognise these antigens if they are presented by HLA 
molecules, and therefore HLA molecules may have a crucial regulatory role in 
the neoplastic immune response.
The interferons and ISGs produced in response to neoplasia within a tissue 
may elicit anti-tumour effects by affecting tumour cellular proliferation or 
differentiation, and the development of resistance to the effects of interferon 
may be an important reason for the failure of interferon therapy in malignant 
disease (Chawla-Sarkar et al., 2003). The de novo increase in expression of 
MHC class I and II molecules, as seen in many human malignancies, will 
enhance the immunogenicity of a tumour cell and render it more detectable by
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the host’s immune system. However, interferons may have a more indirect 
effect on tumour suppression by affecting the modulation of the immune 
system in response to neoplasia, or by inhibiting angiogenesis of a tumour. 
Interferons are now well accepted as apoptosis-inducing cytokines, although 
the exact pathways though which apoptosis is achieved are still uncertain.
A tumour can potentially evade the immune responses triggered by these neo­
antigens in several ways. This can be done by the physical exclusion of 
immune cells from the growing tumour, the natural disruption of immune cells 
in response to tumorigenesis, or a reduction in a tumour’s immunogenicity, 
either by cells that interfere with antigen-presenting cells, or by blocking the 
production of cytokines needed to instigate the immune response. The 
involvement of the immune system in the neoplastic process is complex. A 
host’s immune system not only protects it against the development of a 
tumour, but can also select for tumours with a low immunogenicity and 
therefore promote tumour growth. Recently, Dunn et al., (2004), developed an 
“immunosurveillance hypothesis of immunoediting”. They envisaged that there 
are “three phases that are collectively denoted the three Es of cancer 
immunoediting: elimination, equilibrium and escape”.
The elimination phase represents the initiation of the immune response when 
immune cells recognise a growing tumour, and Dunn suggests that this occurs 
only after a tumour cell has by-passed its own tumour-suppressor 
mechanisms. A tumour is recognised on the basis of a disruption in the tissue 
stroma, either by invasion or angiogenesis, two of the hallmarks of neoplasia
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stipulated by Hanahan and Weinberg (2000). If this phase is successful, the 
body will successfully eradicate the developing tumour.
If the elimination phase is unsuccessful, then a dynamic equilibrium occurs. 
Lymphocytes and cytokines continue to exert a selection pressure on tumour 
cells but this is not strong enough to destroy the cell population, although many 
of the original malignant cells are destroyed. At the same time, it is proposed 
that new clones of tumour cells are produced with new mutations conferring 
increased resistance to the immune attack, and therefore a lower 
immunogenicity than the original tumour population.
Finally, because of their lower immunogenicity, the new tumour clones escape 
the immune response and the tumour can continue to grow, invade and 
metastasise. They suggest that this only occurs when a tumour cell acquires 
genetic and epigenetic changes which provide the cell with the capability to 
resist detection, and subsequently undergo apoptosis, by the immune system. 
This process of immunoediting has been put forward as the “seventh “hallmark 
of cancer”: the capacity of a malignant cell to evade the extrinsic tumour 
suppressor functions of the immune system” (Dunn et al., 2004).
Our Affymetrix results demonstrated that there was an up-regulation of 
interferon-stimulated genes in late-stage RAS colonies, which resemble in vivo 
follicular adenomas, and this would appear to tie in with Dunn’s hypothesis of 
immunoediting in neoplasia. In vivo, the ISGS were not expressed in the 
follicular adenomas and follicular carcinomas, and were only up-regulated in 
the papillary carcinomas. Follicular adenomas are benign, non-invasive 
tumours that are unable to overcome innate cell-intrinsic tumour suppressor
mechanisms, hence avoiding the need for the extrinsic immune system to 
come into play. However, follicular carcinomas are able to invade and 
metastasise, and these tumours did not appear to have a de novo expression 
of ISGs. It may be that papillary carcinomas have a higher expression of ISGs 
because they commonly have an associated lymphocytic infiltrate, and this 
may be a function of the immunoediting process, although it has been 
demonstrated that HLA-DR expression can occur in papillary carcinomas 
without the presence of this lymphocytic infiltrate.
The picture is still unclear with regards to the exact function of HLA-DR, PKR 
and MxA expression in thyroid cancer. The reduction in PKR staining intensity 
seen in the papillary carcinomas compared to the follicular adenomas suggests 
that PKR may act as a tumour suppressor gene in papillary thyroid 
tumorigenesis. Overall these genes may have a critical role to play in 
tumorigenesis itself, although at a later stage than was first predicted from our 
in vitro work, or their expression may simply be a response to the malignant 
transformation process.
5.5 Conclusions
HLA-DR protein was not expressed in normal thyroid tissue or follicular 
adenomas, was minimally expressed in follicular carcinomas, and was 
up-regulated in 43% papillary carcinomas in cancers both with and 
without a lymphocytic infiltrate.
PKR protein is not expressed in normal thyroid tissue. It was up- 
regulated in 20% follicular adenomas, 12.5% follicular carcinomas and 
57% papillary carcinomas, although there was a decrease in staining 
intensity in the cancers compared to the adenomas. PKR was strongly 
expressed in papillary cancers both with and without lymphocytic 
infiltration.
MxA protein is not expressed in normal thyroid tissue or in follicular 
adenomas, and is minimally expressed in follicular carcinomas. An up- 
regulation of expression was only seen in two (29%) papillary 
carcinomas, one of which had a lymphocytic infiltrate.
One follicular carcinoma had a small cluster of cells that showed intense 
staining of HLA-DR and MxA, but not PKR. This may represent a de 
novo mutation in the RAF/RET/MAPK pathway, normally seen in 
papillary cancers, which induced the expression of these genes.
The absence of expression of all three proteins in the follicular 
adenomas was not in keeping with our original hypothesis, and the up- 
regulation of expression at the carcinoma stage suggests that HLA-DR, 
PKR and MxA may not purely act as tumour suppressors in thyroid 
tumorigenesis.
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5.6 Further work
To provide further data regarding the potential function of these three genes in 
thyroid tumorigenesis, and to investigate the role of PKR as a tumour 
suppressor gene, the immunohistochemical expression of these genes needs 
to be analysed in poorly-differentiated papillary, insular and anaplastic 
carcinomas. Larger numbers of cases for each tumour group are also needed 
to be able to draw more accurate conclusions.
Long-term clinical follow-up of the patients from whom the tissue was taken will 
enable us to correlate the expression of HLA-DR, PKR and MxA with the 
incidence of metastases and survival times, and to speculate whether any of 
these genes are potential markers of malignant or aggressive tumour 
behaviour.
Investigation of the expression of HLA-DR, PKR and MxA expression, together 
with proteins involved in both the Rb and RAF/RET/MAPK pathway in the 
selected follicular and papillary carcinomas, will provide data that may link 
these pathways in thyroid tumorigenesis, and may provide answers for the 
differences in expression of ISGs in follicular and papillary carcinomas.
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CHAPTER 6 
OVERALL CONCLUSIONS
Thyroid carcinoma, as previously discussed in chapter 1, is the commonest 
endocrine malignancy and the disease accounts for 300 deaths per year 
(Mallick e t al., 2000). The initiating events involved in both follicular and 
papillary thyroid carcinogenesis have been widely reviewed in the literature; 
however, the pathways involved in the subsequent malignant transformation 
from follicular adenoma to follicular, insular and anaplastic carcinoma, and 
from papillary carcinoma to poorly-differentiated papillary and anaplastic 
carcinoma are less clearly understood.
In vitro, normal human thyroid follicular cells have a very low proliferative rate, 
and this is dramatically increased in  v itro  by RAS oncogene activation, which 
results in thyrocytes clones that display a phenotype consistent with that of a 
follicular adenoma in  vivo. The eventual cessation of growth of these colonies 
is closely correlated with the increasing expression of the tumour suppressor 
gene p16INK4A, suggesting that p16 may have a role to play in limiting clonal 
expansion in this tumour model. The observed up-regulation of p16 
expression in  v itro  in our thyrocyte tumour model led us to hypothesise that 
p16 expression would be up-regulated in  vivo in follicular adenomas, and 
would subsequently be down-regulated or absent in follicular and papillary 
carcinomas, in accordance with their malignant phenotype and ability to invade 
and metastasise to local and distant tissues.
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I tested this hypothesis using immunohistochemistry, and produced novel 
research regarding p16 protein expression in benign thyroid adenomas and 
well-, poorly- and undifferentiated thyroid carcinomas. The second original 
aspect of this work was the correlation of p16 expression with that of MCM2 
and cyclin A expression (two markers of cellular proliferation).
Although p16 expression was induced in follicular adenomas, there was a 
further increase in both staining intensity and the percentage of positively 
staining cells in both follicular and papillary carcinomas. This was surprising 
and unexpected, and was not consistent with my hypothesis. One explanation 
for the continued expression of p16 in well-differentiated thyroid carcinomas is 
that these cancers are relatively indolent and slow-growing, and therefore 
because they are not rapidly proliferating, the loss of p16-regulated cell cycle 
control is relatively unimportant in this stage of thyroid tumorigenesis. My data 
is also consistent with the few studies reported in the literature that have 
analysed p16 expression in thyroid tumours, as described in chapter 3.
Unfortunately it is impossible to follow the development of a well-differentiated 
carcinoma in  vivo, since thyroid tumours are surgically excised to treat the 
patient. Pathologists have drawn conclusions regarding the natural 
progression of thyroid cancers from the histology of poorly-differentiated 
thyroid cancers that have areas of a well-differentiated tumour adjacent to the 
more aggressive tumour. The incidence of these aggressive anaplastic 
tumours is much lower than that of the well-differentiated follicular and papillary 
tumours. The rarity of anaplastic transformation seen in thyroid cancer is
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consistent with the hypothesis that there are multiple pathways that need to be 
overcome, and that all pathways need to be affected before a tumour gains a 
selection advantage.
Thyroid tumours are generally slow-growing; my data regarding the expression 
of cyclin A, a marker of the S phase of the cell cycle, confirms this. This 
protein was expressed at very low levels (2-6% positively staining cells per 
tumour) in the follicular adenomas, and the follicular and papillary carcinomas. 
I only detected an increase in cyclin A expression in the insular carcinomas, 
and cyclin A was expressed at these high levels in insular carcinomas that 
were both positive and negative for p16 expression. This suggests that those 
poorly-differentiated tumours that continue to express p16 may somehow be 
bypassing the negative regulation of the cell cycle, to allow for an increase in 
the proliferative rate of the cancer. One mechanism for this would be a 
mutation in the Rb pathway downstream from p16, such that p16 would no 
longer have a tumour suppressor effect. Alternatively a newly acquired 
mutation, such as a p53 mutation, could mean that loss of p16 expression no 
longer confers a selective advantage on the cell.
If, as has been suggested by my data, the loss of p16 expression is not 
important for early thyroid tumorigenesis, and the majority of follicular 
adenomas, follicular and papillary carcinomas continue to express p16 protein, 
why does an insular or anaplastic thyroid cancer suppress p16 expression? 
What selective advantage does it give to these tumours? If p16 is no longer
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functional because of a downstream mutation, it would be of no further 
advantage to the cell to stop expressing p16, because these tumours would 
already be capable of achieving uncontrolled proliferation. Mutations in Rb, 
the key downstream effector of p16, however, are rare in thyroid cancer, 
implicating that this is not the primary reason for the increase in proliferation 
seen in p 16-expressing poorly-differentiated tumours.
Well-differentiated follicular and papillary carcinomas are therefore able to 
proliferate and metastasise, albeit at a low rate, despite the expression of p16, 
and the expression of p16 in these tumours reaches a level sufficient to 
severely limit, but not to totally block oncogene-induced proliferation. In a few 
cases, p16 expression is lost, and these tumours show a more rapid and 
aggressive pattern of tumour growth, as reported in the insular and anaplastic 
carcinomas. If p16 was the only rate-limiting step involved in the 
transformation from a well-differentiated to a poorly-differentiated tumour, I 
would expect the incidence of these tumours to be much higher than that 
reported in the literature. Furthermore, loss of p16 expression occurs at a very 
high frequency in many human malignancies and there should therefore be a 
strong selection pressure for this to occur in thyroid tumorigenesis. We 
propose that there is a second pathway that is also involved in cell cycle 
control, which may function independently of the Rb pathway, and that both 
pathways need to be altered prior to uncontrolled proliferation and the 
development of a more aggressive thyroid tumour.
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The results from my immunohistochemical analysis of p16 expression in 
thyroid tumorigenesis were unexpected, and the role of p16 and the Rb 
pathway in early thyroid tumorigenesis is not straightforward. This led me to 
further investigate the role of the Rb pathway in early thyroid tumorigenesis 
through the immunohistochemical expression of the oncogene cyclin D1 and 
the tumour suppressor gene p21. I correlated the expression of these two 
proteins with that of p16 in follicular adenomas, and follicular and papillary 
carcinomas, to produce original research that would further our understanding 
of the Rb pathway and cell cycle control in early thyroid tumorigenesis.
There are several studies that have analysed both cyclin D1 and p21 
expression in thyroid cancers, as previously described in chapter 4. I 
demonstrated an up-regulation of cyclin D1 expression in the follicular 
adenomas, and there was a further up-regulation of this protein in both the 
follicular and papillary carcinomas, consistent with the oncogenic function of 
cyclin D1, and the data in the literature. I observed a positive correlation 
between cyclin D1 and p16 expression in all three tumour groups, and this was 
statistically significant in the papillary carcinoma group.
The follicular adenoma group only showed a minimal up-regulation of p21 
expression, with 90% of the tumours only having 0-3% positively staining cells.
I did demonstrate a small increase in p21 expression in the follicular and 
papillary carcinoma groups, although 25-50% of the cancers did not express 
p21. The induction of p21 expression was not significantly correlated with p16 
expression. These results are also compatible with those stated in the
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literature. The expression of p21 therefore does not appear to have a major 
role to play in early thyroid tumorigenesis.
Taken together, the novel data from chapters 3 and 4 still indicates that there 
is a second pathway that is involved in early thyroid tumorigenesis and cell 
cycle control. Affymetrix microarrays were performed on our late-stage RAS- 
induced thyrocyte colonies to search for potential candidate genes involved in 
such a pathway. This data produced some surprising results. Together with 
p16, there was a significant up-regulation of the interferon-stimulated genes in 
these cells, such as HLA-DR, PKR and MxA. I performed original research to 
investigate the immunohistochemical expression of these three proteins in 
follicular adenomas and follicular and papillary carcinomas, and correlated this 
data with the expression of p16 in the same tumours. I hypothesised that all 
three genes would be up-regulated in the follicular adenomas, in keeping with 
the in  v itro  results.
However, my results did not correlate with the in  vivo findings and therefore my 
hypothesis. Neither HLA-DR nor MxA were expressed in the follicular 
adenomas, and PKR was only expressed in 20% of these tumours. This was 
unexpected. There was obviously no correlation between p16 and ISG 
expression in the adenomas, because the ISGs were as a whole not 
expressed in this tumour group. Similar results were also seen in the follicular 
carcinomas, with the majority of tumours not showing ISG expression. One 
isolated cancer had a small cluster of cells which showed intense staining for
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both HLA-DR and MxA, but not PKR, and this case had the highest p16 I.D. 
score in the group.
An up-regulation of all three ISGs was demonstrated in three out of the seven 
papillary carcinomas, and two of these cancers had an associated lymphocytic 
infiltrate. The two papillary cancers with the highest p16 I.D. scores were 
included in the sub-group with the up-regulation of ISG expression. This novel 
data suggests that although the lymphocytic infiltrate commonly seen in 
papillary cancers may be one mechanism for the induction of ISG expression, 
it cannot be the only mechanism, since HLA-DR, MxA and PKR were 
expressed in a papillary carcinoma and a follicular carcinoma that did not have 
a lymphocytic infiltration. There may also be a positive correlation between the 
induction of p16 and ISG expression in papillary carcinomas. I also observed 
a reduction in PKR staining intensity in the papillary carcinomas compared to 
the follicular adenomas, and together this suggests that PKR may have a role 
to play as a tumour suppressor in thyroid tumorigenesis, although greater 
numbers of both adenomas and carcinomas need to be stained to provide 
convincing evidence for this theory. At present, the exact nature of the 
relationship between HLA-DR, PKR, MxA and p16 expression remains 
unclear.
One theory for the in  v itro  up-regulation of ISG expression is that it is a delayed 
response to the introduction of RAS and subsequent RAS activation into 
normal human thyrocytes. However this cannot be true, because of the
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absence of expression of the ISGs in  vivo in follicular adenomas, and the high 
frequency of RAS mutations in  vivo in follicular adenomas, follicular and 
papillary carcinomas. Therefore, either the in vitro ISG expression must be a 
consequence of another initiating event in thyroid tumorigenesis, or further 
mutations in the RAS/RAF/MAPK pathway are needed in  vivo before these 
proteins are expressed.
I observed that ISG expression was more commonly seen in the papillary 
cancers and therefore their up-regulation could be related to mutations of 
either RET, BRAF or MET, which are specific to papillary carcinomas, and the 
ISGs may somehow function via the RET/RAF/MAPK pathway. Consequently, 
the intense focus of ISG-expressing cells in one particular follicular cancer 
might represent a sub-clone of cells that has selective advantage, and could 
therefore transform into a more aggressive phenotype. The clusters of cells 
that expressed HLA-DR and MxA might have developed a mutation of either 
RET, MET or BRAF, which are more commonly seen in papillary cancer, as 
part of the de-differentiation process. The role of MET expression in papillary 
thyroid tumorigenesis has been previously discussed in chapter 1. RAS 
mutations and RET/PTC rearrangements lead to an up-regulation of MET 
expression in papillary cancers, and this has been shown to recruit 
inflammatory cells to the cancer through the release of cytokines, and has 
been correlated with a poor clinical prognosis in some tumours. The 
recruitment of inflammatory cells to produce a lymphocytic infiltrate in these 
papillary cancers may partly explain the induction of ISGs in these tumours,
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although it cannot be the only mechanism since the ISGs are also expressed 
in the absence of a lymphocytic infiltrate.
Alternatively, as discussed in chapter 5, the expression of ISGs in  vivo could 
be the result of cancer immunoediting and the body’s innate responses to 
tumorigenesis, with the in  vitro  results being an artefact of tissue culture. 
However, several studies have demonstrated that ISGs do have a role to play 
in tumorigenesis, including thyroid tumorigenesis, although this role as yet is 
unclear.
One of the major problems involved in research involving thyroid cancer is the 
relatively small number of tumours that are surgically excised each year, in 
comparison to colorectal carcinoma, for example. Furthermore, the incidence 
of the poorly-differentiated anaplastic thyroid cancers is very low in comparison 
to the well-differentiated thyroid cancers, and therefore it is difficult to get 
access to large numbers of these tumours. This means that the majority of 
papers in the literature, including my own, are analysing small numbers of 
tumours, and therefore caution has to be taken when drawing conclusions. 
One mechanism for increasing the number of cases that are available for 
research is a multi-centre study; however this would increase the potential 
sources of bias, with different techniques used for tissue fixation, slide 
processing, for example.
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In summary, I have produced original research demonstrating that p16 is 
expressed in early thyroid tumorigenesis, and that it continues to be expressed 
at a higher level in well-differentiated thyroid tumours. Furthermore, p16 
expression is only down-regulated or lost in a sub-group of papillary cancers, 
and in the poorly-differentiated insular and anaplastic carcinomas. I also 
demonstrated that the increase in p16 expression seen in the follicular and 
papillary carcinomas was statistically correlated with an increase in cyclin D1 
expression, and that p21 has a minimal role to play in thyroid tumorigenesis. 
In contrast to the Affymetrix data from late-stage RAS-induced thyrocytes 
colonies, ISGS were not up-regulated in the majority of follicular adenomas, 
and there was therefore no correlation between the expression of these genes 
and p16 protein. However, HLA-DR, PKR and MxA were up-regulated in the 
papillary carcinomas, in cancers that either did or did not have a lymphocytic 
infiltrate. Finally, PKR expression seemed to be positively correlated with an 
increase in p16 expression, suggesting that PKR may be partially acting as a 
tumour suppressor in early thyroid tumorigenesis.
So far I have demonstrated that the loss of p16 is a late event in the malignant 
transformation of thyroid cancer from an indolent to a highly aggressive 
tumour, in that this phenomenon is only seen in insular and anaplastic thyroid 
carcinomas. The up-regulation or down-regulation of interferon-stimulated 
genes such as HLA-DR, PKR and MxA may have a role to play a role in this 
neoplastic process, through cancer immunoediting, but there still appears to be 
other pathways involved.
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Thyroid cancer as a whole is unique because both histologically and 
biologically diverse tumours are derived from a single follicular thyroid cell of 
monoclonal origin (Moniz e t al., 2002). It has been suggested that these 
originating follicular cells behave similarly to stem cells, in that they can self- 
renew and give rise to phenotypically-differing daughter cells (Zhang e t al., 
2006). Stem cells have been identified in breast, pancreatic, lung and prostate 
carcinomas and there is evidence to support the theory that the ability of a 
tumour to grow and divide resides in a small population of ‘cancer stem cells’, 
which are responsible for the original tumour initiation (Bonnet and Dick, 1997; 
Pardal e t al., 2003; Hope e t al., 2004; Wicha e t al., 2006). Thyroid cancer 
stem cells may develop de novo  during foetal development, or may be formed 
from mature thyrocytes as part of the de-differentiation process involved in 
tumorigenesis; in which case a benign tumour would only become malignant if 
the lesion were able to produce cancer stem cells to ensure continued 
proliferation and de-differentiation.
Evidence to suggest that the thyroid gland may contain stem cells comes from 
studies of embryological thyroid remnants. The thyroid gland is the first 
endocrine gland to form in a foetus, and persistence of parts of the 
ultimobranchial body, as either thyroglossal cysts or lingual thyroids are 
common in adults, and these are thought to contain stem cells (Beckner e t al., 
1990; Zelmanovitz e t al., 2004). The thyroid gland is thought to have three 
different types of stem cells, which are responsible for the regeneration of 
thyroid follicles during adult life (Zhang e t al., 2006). The three groups 
proposed are follicular progenitor stem cells derived from endoderm, C-cell
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progenitor stem cells derived from neural crest tissue, and a bi-potential 
precursor of both follicular cells and C-cells. However, these three different 
groups may simply represent stem cell differentiation during adult life.
Zhang e t al., (2006) proposed that cancer stem cells continue to slowly divide 
and are kept in check by normal proliferation pathways, just like normal thyroid 
follicular cells. However, if these pathways become altered by genetic 
damage, then the cells would form a neoplastic lesion. Sell e t al., (2004), 
proposed that the developmental stage at which the stem cell is transformed 
will dictate the degree of differentiation of the resulting tumour, thus explaining 
the diversity of thyroid carcinomas. Furthermore, not only does the genetic 
damage need to accumulate in the necessary pathways involved in thyroid 
tumorigenesis, these changes need to occur in the cancer stem cells in order 
to begin the malignant transformation.
If thyroid cancers are derived from a minute stem cell population which can 
give rise to either follicular or papillary tumours, the genetic analysis of such 
tumours would give rise to artificial results, since the research would reflect the 
entire tumour, and not the small (1-2%) number of cancer stem cells in the 
tumour (Nuciforo and Fraggetta, 2004). This may explain why we do not yet 
have a clear understanding of the genetic pathways involved in the 
development of undifferentiated thyroid carcinomas.
238
An alternative theory for the transformation of a thyroid cancer from a well- 
differentiated to a poorly-differentiated phenotype is epithelial-to-mesenchymal 
transition (EMT). This phenomenon involves the “formation of mesenchymal 
cells from epithelia in different embryonic territories” (Thiery, 2003). The 
resulting cells lose their cell-to-cell contact, and develop a phenotype capable 
o f migration and metastasis, which has been implicated in the early stages of 
tumorigenesis (Thiery and Sleeman, 2006).
One of the landmarks of tumorigenesis is tumour invasion and metastasis 
(Hanahan and Weinberg, 2000), and de-differentiation of epithelial cells is 
crucial for this to take place. There is now an accumulation of indirect 
evidence to suggest that EMT occurs in primary cancers (Thiery, 2002). Also, 
the presence of micro-metastatic tumour cells in bone marrow and lymph 
nodes also suggests a role for EMT in cancer progression, and the presence of 
these cells has been associated with a bad prognosis (Pierga e t al., 2003). 
However, are the mesenchymal cells the end result of de-differentiation, or are 
separate genetic pathways involved to create the mesenchymal transition 
process?
Alternatively, both cancer stem cells and EMT may have a role to play in 
thyroid tumorigenesis. Wynford-Thomas and Blaydes (1998) hypothesised 
that the nature of the tumour-initiating cell pre-determined the liability of that 
cell to develop a p53 mutation, and the extent to which that p53 mutation 
would control the proliferative lifespan of the cell. This would relate to different
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stages of differentiation in cancer stem cells in the thyroid gland, which would 
then be affected by a p53 mutation in varying ways, and hence develop 
different phenotypes of thyroid cancer.
Work in our laboratory has identified a sub-population of thyrocytes present in 
human thyroid tissue culture that express the thyroid-specific transcription 
factor PAX8 and yet show a mesenchymal morphology and a dissociated 
pattern of growth. These changes are accompanied by a massive increase in 
cellular proliferation (Bond e t al., 1993). The frequency with which this event 
occurred was so high that it almost certainly had to be an epigenetic event 
rather than a genetic mutation. This data suggests that thyrocytes are capable 
of a spontaneous switch in differentiation to a mesenchymal phenotype.
The activation of the RAS/MAPK pathway has been shown to be important in 
the development of EMT (Janda e t al., 2002; Huber e t al., 2005). If EMT is 
involved in tumorigenesis, thyroid cancer would be an ideal candidate because 
of the frequency of genetic alterations in the RAS/RAF/MAPK pathway. Vasko 
and Saji, (2007), performed micro-arrays on widely invasive thyroid papillary 
carcinoma and poorly-differentiated papillary carcinoma cell lines, and 
demonstrated that the invasion of papillary cancer is associated with EMT 
through the over-expression of vimentin protein, which is critically involved in 
EMT regulation (Shook and Keller, 2003).
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Differentiation switches are common in human neoplasia, and have been 
pathologically described as metaplasia, trans-differentiation and de­
differentiation (Birchmeier and Behrens, 1994; Portella e t al., 1994). The 
thyrocyte model suggests that a cell can side-step cell-cycle control providing 
that both the pRb and p53 pathways have been abrogated, and begin to 
proliferate at an increased rate. Loss of differentiation is a key feature of 
anaplastic thyroid carcinoma, and is accompanied by a more aggressive 
behaviour and a worse prognosis, contrasting with the well-differentiated 
follicular and papillary cancers that have an excellent prognosis. The rare 
occurrence of these anaplastic cancers suggests that a thyroid tumour needs 
both a p53 mutation and a differentiation switch (EMT) before it acquires a 
selective advantage (Wynford-Thomas, 1993a).
I have produced original research investigating some of the molecular 
mechanisms involved in thyroid tumorigenesis. I have demonstrated that p16 
expression is induced in  v ivo  in follicular adenomas, consistent with my original 
hypothesis developed from the expression of p16 in our thyrocyte tumour 
model. However, because p16 expression is still up-regulated in follicular and 
papillary carcinomas, and is only reduced in the more aggressive insular and 
anaplastic carcinomas, there must be another pathway involved in the 
malignant transformation. Furthermore, it is only when a cell has lost the 
function of both the Rb and this second, as yet unknown pathway that it is able 
to develop into a more aggressive phenotype with a worse clinical prognosis. 
The expression of p16 is therefore not a good molecular marker to help 
pathologists differentiate between follicular adenomas and carcinomas.
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However, loss of p16 expression may be a useful indicator of a worse clinical 
prognosis, although a much larger study with long-term clinical follow-up is 
needed to investigate this further.
Secondly, the expression of cyclin D1 is at all stages of thyroid tumorigenesis, 
and this is positively correlated with p16 expression in these cancers, and this 
is in keeping with the oncogenic activity of cyclin D1. When coupled with the 
tumour suppressive effects of p16 expression, these two genes may be acting 
to keep the thyroid tumour cell ‘in check’ until the proposed second pathway is 
altered, prior to the transformation of the tumour to a more malignant 
phenotype. The tumour suppressor gene p21 does not have a major role to 
play in thyroid tumorigenesis, and its expression is not significantly correlated 
with that of p16 in the well-differentiated thyroid cancers. Therefore neither 
cyclin D1 nor p21 are suitable molecular markers to aid in the diagnosis of 
thyroid cancer.
Finally, following on from thyrocyte data, I investigated the 
immunohistochemical expression of HLA-DR, PKR and MxA, to determine 
whether the interferon pathway was the second proposed pathway in thyroid 
tumorigenesis. HLA-DR, PKR and MxA are not over-expressed in follicular 
adenomas and follicular carcinomas, in contrast to the up-regulation seen in 
our thyrocyte tumour model. However, all three genes are expressed in a 
proportion of papillary carcinomas, and this occurs both in the presence and 
absence of a lymphocytic infiltrate in these cancers. The expression of PKR
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was positively correlated with p16 expression, and the intensity of staining in 
the carcinomas was less than that seen in the adenomas, suggesting that PKR 
may function as a tumour suppressor gene in thyroid tumorigenesis. Again, a 
much larger study is needed to compare PKR and p16 expression in well- 
differentiated and poorly-differentiated thyroid cancers, and in other human 
malignancies to investigate this further.
My research has not been able to identify a candidate gene involved in the 
proposed second pathway. There are however two current theories in the 
literature. These are the existence of cancer stem cells that will pre-determine 
the end tumour phenotype, potentially independently of subsequent genetic 
alterations, and epithelial-to-mesenchymal transition.
The thyroid gland is unusual when compared to other human organs, because 
the majority of thyroid cancers are indolent and slow-growing and yet still have 
the potential to be fatal, despite the continued expression of cell cycle 
inhibitory proteins such as p16. One must question why the thyroid gland has 
such a strong defence mechanism to prevent the development of a more 
aggressive phenotype, in contrast to the majority of human malignancies. The 
pathways involved in limiting this aggressive transformation are obviously 
successful in preventing the development of anaplastic carcinoma, as shown 
by the rarity of this tumour. Therefore why don’t organs such as the colon, 
pancreas and prostate also have these pathways in place?
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Clearly further work is needed on both in  v itro  thyrocyte tumour models and on 
early and late in  vivo  thyroid tumours to try and elucidate the exact nature of 
these pathways, which will hopefully lead to increasing our understanding of 
thyroid tumorigenesis, and the development of novel treatment strategies for 
the more aggressive forms of the disease.
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APPENDIX I 
Manufacturers and Suppliers
DAKO
DAKO Ltd, Denmark House, Angel Drove, Ely, Cambs. CB7 4ET 
www.dako.co.uk
Catherine de Micco
Institut National de la Sante et de la Recherche Medicale U555, Laboratory of 
Pathology, Faculty of Medicine, Mediterranean University, Marseille 13385, 
France
Brigitte Franc
Service d'Anatomie et de Cytologie Pathologiques, Hopital A Pare (AP-HP), 
Universite de Versailles, St Quentin en Yvelines, France
George Kochs
Abteilung Virologie, Institut fur Medizinische Mikrobiologie und Hygiene, 
Universitat Freiberg,
D-79008 Freiberg, Germany 
Leica
Leica Microsystems UK Ltd, Davy Avnue, Knowlhill, Milton Keynes MK5 8LB 
www.leica-microsvstems.com/europe
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Novocastra
Novocastra Laboratories Ltd, Balliol Business Park West, Benton Lane, 
Newcastle upon Tyne, NE12 8EW, United Kingdom
www. novocastra .co.uk 
Olympus
Olympus UK Ltd (Head Office), 2-8 Honduras Street, London, EC1Y OTX 
www.olvm pus.co.uk/m icroscopy
Pharmingen
10975 Torreyana Road, San Diego CA 92121-1111, California, USA 
www.pharm inqen.com
Santa Cruz
Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue, Santa Cruz, California 
95060, USA
www.scbt.com
SPSS
SPSS Inc. Headquarters, 233 S. W acker Drive, 11th floor, Chicago, Illinois 
60606
www.spss.com
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Surgipath
Surgipath Europe Limited Venture Park, Stirling W ay, Bretton, Peterborough, 
PE3 8YD
www.suraipath.com  
Thermo Electron Corporation
5344 John Lucas Dr, Burlington, Ontario L7L6A 6 , Canada 
www.thermo.com
Professor GH Williams
Dept o f Pathology, University College London, Gower Street, London, WC1E 
6BT
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APPENDIX II 
Solutions
All solutions were made up with distilled H20.
EDTA (1 litre, 0.01 M)
3.72g EDTA 
0.32g NaOH pearls 
pH 7.0/9.0
Mayer’s Haematoxylin (1 litre)
1g haematoxylin
0.2g sodium iodate
50g potassium aluminium sulphate
50g chloral hydrate
1g citric acid
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APPENDIX III 
DAKO Autostainer Set-up
All computer screen icons that need to be ‘clicked’ with a mouse are highlighted in bold print.
Choosing a template
• Left click on program
• Left click on slides (top left of menu bar)
• Enter number of slides and click OK
• Left click on Protocol Template (bottom of screen)
• Left click on Get Template and select envision from list, which highlights the following
staining protocol -
- Rinse buffer, endogenous enzyme block, rinse buffer,
- Primary antibody, rinse buffer
- Labelled polymer, rinse buffer
- Substrate, rinse water
• Left click on Use Template (bottom of screen)
• Select the desired volume and drop zones for all slides and 200 pi in centre of slide
Assigning slides
• Left click on endogenous enzyme block and select ChemMate HP block, and assign 
to all slides
• Left click on blank box for each slide in primary antibody column
• Select required antibody from the drop down list with left click, or insert by editing 
antibody (e.g. p16) and enter time for incubation (60 minutes)
• Left click on labelled polymer and select Envision+ HRP (mouse or rabbit as required) 
and assign to all slides
• Left click on substrate and select DAB for all slides
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Saving program and printing labels
• Left click on next
• Save program on disk message appears. Left click on yes to save details of this run
• Enter name for run and press enter
• Print slide labels screen appears. Left click all to print labels
• A screen will appear showing a map of reagent volume needed and vial position in the
reagent rack
Loading reagents
• Place reagent vials in the white rack on the Autostainer machine as indicated
• Check volumes of buffer and deionised water for the run - (required volumes are 
stated at the top of the "load Reagents" screen)
• Left click on next
Load and scan slides
• Place slides into slide rack and place 200 pi of DAKO wash buffer on them to prevent 
them drying out before the run starts.
• Left click on scan slides (message appears "is the pathway clear for arm to move?"). 
Check pathway. Left click on yes
• Left click on Prime Pump (Water)
• Left click on Prime Pump (Buffer) 3 times
• Left click on start run
251
APPENDIX IV 
TISSUE SECTION AND TMA RESULTS
Table IV. 1 Immunohistochemistry results for p16, MCM2 and cyclin A expression in 
follicular adenoma tissue sections (FA)
Pathology p16 I.D. score MCM2 L.l. score cyclin A L.l. score
FA 0.2 3 0
FA 0.3 1 0.4
FA 0.5 25 0.3
FA 0. 5 1 0
FA 0.6 15 1.1
FA 0.8 4 0
FA 1 2 0.7
FA 1 8 0.5
FA 1 12 0
FA 1.4 6 0.1
Table IV.2 Immunohistochemistry results for p16, MCM2 and cyclin A expression in 
follicular carcinoma tissue sections (FA)
Pathology p16 I.D. score MCM2 L.l. score cyclin A L.l. score
FC 1 1.2 0
FC 1.1 5 1.8
FC 1.2 1 0
FC 1.5 2.3 0
FC 1.5 0 0.6
FC 1.6 0.6 0
FC 1.8 14 0.2
FC 2.4 3 1.1
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Table IV.3 Immunohistochemistry results for p16, MCM2 and cyclin A expression in
papillary carcinoma tissue sections (FA)
Pathology p16 I.D. score MCM2 L.l. score cyclin A L.l. score
PC 1.1 38 0
PC 1.3 12 0.5
PC 1.7 7 1.2
PC 1.7 11 3
PC 1.8 2 0.7
PC 2 53 1.2
PC 2.7 18 5
Table IV.4 Immunohistochemistry results for p16, MCM2 and cyclin A expression for the 
follicular adenomas on the TMA slides
Case No. p16 I.D. MCM2 L.l. cyclin A L.l.
1 0 1 0
2 0 3.3 0
3 0 1.3 0.7
4 0 5 0
5 0 28.3 1
6 0 41.2 2.3
7 0.4 0 0
8 0.4 11 0.3
9 0.5 1 0
10 1 3.7 0
11 1 11.7 3.7
12 1.2 4.3 1.7
13 1.4 4 1.3
14 1.8 1.7 0
15 1.85 0.7 0
16 1.9 10 2
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Table IV.5 Immunohistochemistry results for p16, MCM2 and cyclin A expression for the
atypical adenomas on the TMA slides
Case No. p16 I.D. MCM2 L.l. cyclin A L.l.
1 0.05 7.3 0
2 0.25 3 1.7
3 0.9 3.3 0
4 1.05 7.3 0
5 1.3 5 0
6 1.9 0.7 0
7 1.9 4.3 0
8 2.2 32.3 3.3
9 2.7 3 0
10 2.95 5.3 0
Table IV.6 Immunohistochemistry results for p16, MCM2 and cyclin A expression for the 
follicular carcinomas on the TMA slides
Case No. p16 I.D. MCM2 L.l. cyclin A L.l.
1 0.1 0.7 20
2 0.9 1 0
3 0.9 2.6 0
4 1 0 0
5 1 1.7 1.7
6 1 3 0
7 1.2 29.7 1
8 1.95 0.3 0.3
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Table IV.7 Immunohistochemistry results for p16, MCM2 and cyclin A expression for the
papillary carcinomas on the TMA slides
Case No. p16 I.D. MCM2 L.l. cyclin A L.l.
1 0 0 0.7
2 0 4 0
3 0 21.3 0
4 0 63 0
5 0.04 58 0
6 0.05 6 0.7
7 0.05 43.3 0
8 0.1 1.7 0
9 0.1 2.3 0
10 0.3 2.3 0
11 0.3 5.3 No tissue
12 0.4 23.5 0.5
13 0.5 9 0.3
14 0.5 No tissue 1.3
15 0.6 36 6.7
16 0.9 1 1
17 0.95 3 2
18 1 1.7 2.5
19 1.4 6.7 0.7
20 1.5 5.7 No tissue
21 2.2 8 5.3
22 2.25 26.3 0
23 2.4 31.7 0
24 No tissue 15 4.3
25 No tissue 37.7 No tissue
26 No tissue No tissue 1
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Table IV .8 Immunohistochemistry results for p16, MCM2 and cyclin A expression scores
for the insular carcinomas on the TMA slides
Case No. p16 I.D. MCM2 L.l. cyclin A L.l.
1 0 0 0
2 0 0 21.7
3 0.02 4.3 1
4 0.14 8.3 0.7
5 0.4 2.7 0.2
6 0.85 6.7 2.7
7 0.95 5 3.3
8 1 0 0
9 1 3.3 2.5
10 1 15 6.7
11 1.05 3.7 1
12 1.25 6.7 3
13 1.45 8.3 1.7
14 1.9 20 13.3
15 2 0 0.3
16 2.3 10 1
17 2.7 6.7 3
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